0001682149--12-312024Q2falsehttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent00000000000022238049214340.010.00670.010.00670.010.00670.00670.01P2YP5Y2024-01-01http://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilities0001682149wisa:MaximGroupLlcMember2022-11-212022-11-210001682149wisa:MaximGroupLlcMember2022-08-152022-08-150001682149us-gaap:SeriesAPreferredStockMember2024-01-012024-06-300001682149wisa:SeriesBPreferredStockWarrantsMember2024-01-012024-06-300001682149us-gaap:RestrictedStockUnitsRSUMemberwisa:September2021InducementGrantMember2021-09-132021-09-130001682149wisa:SeriesBPreferredStockWarrantsMemberwisa:January2024PromissoryNotesMemberwisa:January2024ShortTermLoanMemberwisa:SeriesBConvertibleRedeemablePreferredStockMember2024-01-262024-02-290001682149wisa:NewCommonStockWarrantsMember2024-01-012024-06-300001682149wisa:NewCommonStockWarrantsMemberwisa:SeriesBConvertibleRedeemablePreferredStockMemberwisa:InducementAgreementMember2023-12-052023-12-050001682149wisa:SeriesBPreferredStockWarrantsMemberwisa:SeriesBConvertibleRedeemablePreferredStockMemberwisa:OctoberPublicOfferingMember2023-01-012023-12-310001682149wisa:LongTermStockIncentivePlanMember2023-01-240001682149wisa:LongTermStockIncentivePlanMember2023-01-230001682149wisa:LongTermStockIncentivePlanMember2024-03-150001682149wisa:LongTermStockIncentivePlanMember2024-03-140001682149wisa:January2024PromissoryNotesMemberwisa:January2024ShortTermLoanMember2024-01-262024-02-290001682149wisa:SeriesBPreferredStockWarrantsMemberus-gaap:PreferredStockMember2024-01-012024-03-310001682149us-gaap:ConvertiblePreferredStockMemberus-gaap:PreferredStockMember2024-01-012024-03-310001682149wisa:RegisteredDirectOfferingFebruary2023Member2023-01-310001682149wisa:JulyInducementWarrantsMemberus-gaap:CommonStockMember2023-07-260001682149wisa:SeriesWarrantsMemberus-gaap:InvestorMember2022-12-010001682149wisa:SeriesBWarrantsMemberus-gaap:InvestorMember2022-12-010001682149wisa:CommonStockWarrantsMemberwisa:UnitsMember2024-02-132024-02-130001682149wisa:SeriesBConvertibleRedeemablePreferredStockMemberwisa:OctoberPublicOfferingMember2023-10-162023-10-160001682149us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2024-04-012024-06-300001682149us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-06-300001682149us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-06-300001682149us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2023-04-012023-06-300001682149us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-310001682149us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-06-300001682149us-gaap:ConvertibleDebtMember2022-08-152022-08-150001682149us-gaap:WarrantMemberwisa:HelgeKristensenMember2024-06-300001682149us-gaap:WarrantMemberwisa:HelgeKristensenMember2023-12-310001682149us-gaap:ConvertibleDebtMemberus-gaap:InvestorMember2022-08-240001682149us-gaap:ConvertibleDebtMember2022-08-150001682149us-gaap:ConvertibleDebtMember2022-08-152022-08-150001682149wisa:MajorCustomerNumberTwoMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2024-04-012024-06-300001682149wisa:MajorCustomerNumberThreeMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2024-04-012024-06-300001682149wisa:MajorCustomerNumberOneMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2024-04-012024-06-300001682149wisa:MajorCustomerNumberFourMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2024-04-012024-06-300001682149wisa:MajorCustomerNumberTwoMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-06-300001682149wisa:MajorCustomerNumberTwoMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-06-300001682149wisa:MajorCustomerNumberThreeMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-06-300001682149wisa:MajorCustomerNumberThreeMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-06-300001682149wisa:MajorCustomerNumberOneMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-06-300001682149wisa:MajorCustomerNumberOneMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-06-300001682149wisa:MajorCustomerNumberFourMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-06-300001682149wisa:MajorCustomerNumberFourMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-06-300001682149wisa:MajorCustomerNumberTwoMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2023-04-012023-06-300001682149wisa:MajorCustomerNumberThreeMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2023-04-012023-06-300001682149wisa:MajorCustomerNumberOneMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2023-04-012023-06-300001682149wisa:MajorCustomerNumberFourMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2023-04-012023-06-300001682149wisa:MajorCustomerNumberTwoMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-310001682149wisa:MajorCustomerNumberOneMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-310001682149wisa:MajorCustomerNumberTwoMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-06-300001682149wisa:MajorCustomerNumberOneMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-06-300001682149wisa:MayInducementWarrantsMember2023-05-152023-05-1500016821492024-01-192024-01-190001682149wisa:SeriesBPreferredStockWarrantsMember2024-02-132024-02-1300016821492024-04-012024-04-300001682149us-gaap:CommonStockMember2024-01-012024-03-310001682149wisa:PrefundedWarrantsMemberus-gaap:CommonStockMemberwisa:March2024OfferingMember2024-03-260001682149wisa:CommonStockWarrantsMemberwisa:March2024OfferingMember2024-03-260001682149wisa:PrefundedWarrantsMemberus-gaap:CommonStockMemberwisa:PublicOfferingFebruary2024Member2024-02-130001682149srt:MinimumMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExpectedTermMember2024-06-300001682149srt:MaximumMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExpectedTermMember2024-06-300001682149srt:MinimumMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRiskFreeInterestRateMember2024-06-300001682149us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputPriceVolatilityMember2024-06-300001682149us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExpectedDividendRateMember2024-06-300001682149us-gaap:WarrantMemberus-gaap:MeasurementInputSharePriceMemberwisa:SecondMay2024RegisteredDirectOfferingAndConcurrentPrivatePlacementMember2024-05-150001682149us-gaap:WarrantMemberus-gaap:MeasurementInputRiskFreeInterestRateMemberwisa:SecondMay2024RegisteredDirectOfferingAndConcurrentPrivatePlacementMember2024-05-150001682149us-gaap:WarrantMemberus-gaap:MeasurementInputPriceVolatilityMemberwisa:SecondMay2024RegisteredDirectOfferingAndConcurrentPrivatePlacementMember2024-05-150001682149us-gaap:WarrantMemberus-gaap:MeasurementInputExpectedTermMemberwisa:SecondMay2024RegisteredDirectOfferingAndConcurrentPrivatePlacementMember2024-05-150001682149us-gaap:WarrantMemberus-gaap:MeasurementInputExpectedDividendRateMemberwisa:SecondMay2024RegisteredDirectOfferingAndConcurrentPrivatePlacementMember2024-05-150001682149us-gaap:WarrantMemberus-gaap:MeasurementInputSharePriceMemberwisa:May2024RegisteredDirectOfferingAndConcurrentPrivatePlacementMember2024-05-130001682149us-gaap:WarrantMemberus-gaap:MeasurementInputRiskFreeInterestRateMemberwisa:May2024RegisteredDirectOfferingAndConcurrentPrivatePlacementMember2024-05-130001682149us-gaap:WarrantMemberus-gaap:MeasurementInputPriceVolatilityMemberwisa:May2024RegisteredDirectOfferingAndConcurrentPrivatePlacementMember2024-05-130001682149us-gaap:WarrantMemberus-gaap:MeasurementInputExpectedTermMemberwisa:May2024RegisteredDirectOfferingAndConcurrentPrivatePlacementMember2024-05-130001682149us-gaap:WarrantMemberus-gaap:MeasurementInputExpectedDividendRateMemberwisa:May2024RegisteredDirectOfferingAndConcurrentPrivatePlacementMember2024-05-130001682149us-gaap:WarrantMemberus-gaap:MeasurementInputSharePriceMemberwisa:ThirdApril2024RegisteredDirectOfferingAndConcurrentPrivatePlacementMember2024-04-260001682149us-gaap:WarrantMemberus-gaap:MeasurementInputRiskFreeInterestRateMemberwisa:ThirdApril2024RegisteredDirectOfferingAndConcurrentPrivatePlacementMember2024-04-260001682149us-gaap:WarrantMemberus-gaap:MeasurementInputPriceVolatilityMemberwisa:ThirdApril2024RegisteredDirectOfferingAndConcurrentPrivatePlacementMember2024-04-260001682149us-gaap:WarrantMemberus-gaap:MeasurementInputExpectedTermMemberwisa:ThirdApril2024RegisteredDirectOfferingAndConcurrentPrivatePlacementMember2024-04-260001682149us-gaap:WarrantMemberus-gaap:MeasurementInputExpectedDividendRateMemberwisa:ThirdApril2024RegisteredDirectOfferingAndConcurrentPrivatePlacementMember2024-04-260001682149us-gaap:WarrantMemberus-gaap:MeasurementInputSharePriceMemberwisa:SecondApril2024RegisteredDirectOfferingAndConcurrentPrivatePlacementMember2024-04-190001682149us-gaap:WarrantMemberus-gaap:MeasurementInputRiskFreeInterestRateMemberwisa:SecondApril2024RegisteredDirectOfferingAndConcurrentPrivatePlacementMember2024-04-190001682149us-gaap:WarrantMemberus-gaap:MeasurementInputPriceVolatilityMemberwisa:SecondApril2024RegisteredDirectOfferingAndConcurrentPrivatePlacementMember2024-04-190001682149us-gaap:WarrantMemberus-gaap:MeasurementInputExpectedTermMemberwisa:SecondApril2024RegisteredDirectOfferingAndConcurrentPrivatePlacementMember2024-04-190001682149us-gaap:WarrantMemberus-gaap:MeasurementInputExpectedDividendRateMemberwisa:SecondApril2024RegisteredDirectOfferingAndConcurrentPrivatePlacementMember2024-04-190001682149us-gaap:WarrantMemberus-gaap:MeasurementInputSharePriceMemberwisa:InitialApril2024RegisteredDirectOfferingAndConcurrentPrivatePlacementMember2024-04-170001682149us-gaap:WarrantMemberus-gaap:MeasurementInputRiskFreeInterestRateMemberwisa:InitialApril2024RegisteredDirectOfferingAndConcurrentPrivatePlacementMember2024-04-170001682149us-gaap:WarrantMemberus-gaap:MeasurementInputPriceVolatilityMemberwisa:InitialApril2024RegisteredDirectOfferingAndConcurrentPrivatePlacementMember2024-04-170001682149us-gaap:WarrantMemberus-gaap:MeasurementInputExpectedTermMemberwisa:InitialApril2024RegisteredDirectOfferingAndConcurrentPrivatePlacementMember2024-04-170001682149us-gaap:WarrantMemberus-gaap:MeasurementInputExpectedDividendRateMemberwisa:InitialApril2024RegisteredDirectOfferingAndConcurrentPrivatePlacementMember2024-04-170001682149us-gaap:WarrantMemberus-gaap:MeasurementInputSharePriceMemberwisa:March2024OfferingMember2024-03-260001682149us-gaap:WarrantMemberus-gaap:MeasurementInputRiskFreeInterestRateMemberwisa:March2024OfferingMember2024-03-260001682149us-gaap:WarrantMemberus-gaap:MeasurementInputPriceVolatilityMemberwisa:March2024OfferingMember2024-03-260001682149us-gaap:WarrantMemberus-gaap:MeasurementInputExpectedTermMemberwisa:March2024OfferingMember2024-03-260001682149us-gaap:WarrantMemberus-gaap:MeasurementInputExpectedDividendRateMemberwisa:March2024OfferingMember2024-03-260001682149us-gaap:WarrantMemberus-gaap:MeasurementInputSharePriceMemberwisa:PublicOfferingFebruary2024Member2024-02-130001682149us-gaap:WarrantMemberus-gaap:MeasurementInputRiskFreeInterestRateMemberwisa:PublicOfferingFebruary2024Member2024-02-130001682149us-gaap:WarrantMemberus-gaap:MeasurementInputPriceVolatilityMemberwisa:PublicOfferingFebruary2024Member2024-02-130001682149us-gaap:WarrantMemberus-gaap:MeasurementInputExpectedTermMemberwisa:PublicOfferingFebruary2024Member2024-02-130001682149us-gaap:WarrantMemberus-gaap:MeasurementInputExpectedDividendRateMemberwisa:PublicOfferingFebruary2024Member2024-02-130001682149us-gaap:WarrantMemberus-gaap:MeasurementInputSharePriceMemberwisa:January2024PromissoryNotesMember2024-01-190001682149us-gaap:WarrantMemberus-gaap:MeasurementInputRiskFreeInterestRateMemberwisa:January2024PromissoryNotesMember2024-01-190001682149us-gaap:WarrantMemberus-gaap:MeasurementInputPriceVolatilityMemberwisa:January2024PromissoryNotesMember2024-01-190001682149us-gaap:WarrantMemberus-gaap:MeasurementInputExpectedTermMemberwisa:January2024PromissoryNotesMember2024-01-190001682149us-gaap:WarrantMemberus-gaap:MeasurementInputExpectedDividendRateMemberwisa:January2024PromissoryNotesMember2024-01-190001682149us-gaap:WarrantMemberus-gaap:MeasurementInputSharePriceMemberwisa:March2023OfferingMember2023-03-270001682149us-gaap:WarrantMemberus-gaap:MeasurementInputRiskFreeInterestRateMemberwisa:March2023OfferingMember2023-03-270001682149us-gaap:WarrantMemberus-gaap:MeasurementInputPriceVolatilityMemberwisa:March2023OfferingMember2023-03-270001682149us-gaap:WarrantMemberus-gaap:MeasurementInputExpectedTermMemberwisa:March2023OfferingMember2023-03-270001682149us-gaap:WarrantMemberus-gaap:MeasurementInputExpectedDividendRateMemberwisa:March2023OfferingMember2023-03-270001682149us-gaap:WarrantMemberus-gaap:MeasurementInputSharePriceMemberwisa:February2023OfferingMember2023-01-310001682149us-gaap:WarrantMemberus-gaap:MeasurementInputRiskFreeInterestRateMemberwisa:February2023OfferingMember2023-01-310001682149us-gaap:WarrantMemberus-gaap:MeasurementInputPriceVolatilityMemberwisa:February2023OfferingMember2023-01-310001682149us-gaap:WarrantMemberus-gaap:MeasurementInputExpectedTermMemberwisa:February2023OfferingMember2023-01-310001682149us-gaap:WarrantMemberus-gaap:MeasurementInputExpectedDividendRateMemberwisa:February2023OfferingMember2023-01-310001682149us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001682149us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001682149us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001682149wisa:SeriesBPreferredStockWarrantsMember2024-06-300001682149wisa:PreferredStockWarrantLiabilityMemberwisa:SeriesBConvertibleRedeemablePreferredStockMember2023-12-310001682149wisa:CommonStockWarrantLiabilityMemberwisa:SeriesBConvertibleRedeemablePreferredStockMember2023-12-310001682149us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001682149us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001682149us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001682149us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExercisePriceMember2024-01-012024-06-3000016821492023-01-012023-12-310001682149wisa:January2024ShortTermLoanMemberwisa:SeriesBConvertibleRedeemablePreferredStockMember2024-01-190001682149wisa:SeriesBConvertibleRedeemablePreferredStockMember2024-02-132024-02-130001682149wisa:SeriesBPreferredStockWarrantsMemberus-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001682149wisa:SeriesBPreferredStockWarrantsMember2024-01-012024-03-310001682149us-gaap:ConvertibleDebtMemberus-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001682149us-gaap:ConvertibleDebtMember2023-01-012023-03-310001682149wisa:SecondMay2024RegisteredDirectOfferingMember2024-05-152024-05-150001682149wisa:May2024RegisteredDirectOfferingMember2024-05-132024-05-130001682149wisa:ThirdApril2024RegisteredDirectOfferingMember2024-04-262024-04-260001682149wisa:SecondApril2024RegisteredDirectOfferingMember2024-04-192024-04-190001682149wisa:InitialApril2024RegisteredDirectOfferingMember2024-04-172024-04-170001682149us-gaap:CommonStockMember2024-04-012024-06-300001682149wisa:PrefundedWarrantsMemberwisa:March2024OfferingMember2024-03-262024-03-260001682149us-gaap:CommonStockMemberwisa:March2024OfferingMember2024-03-262024-03-260001682149wisa:UnitsMemberwisa:PublicOfferingFebruary2024Member2024-02-132024-02-130001682149wisa:PreFundedUnitsMemberwisa:PublicOfferingFebruary2024Member2024-02-132024-02-130001682149wisa:RegisteredDirectOfferingApril2023Member2023-04-072023-04-070001682149us-gaap:CommonStockMember2023-04-012023-06-300001682149wisa:RegisteredDirectOfferingFebruary2023Member2023-01-312023-01-310001682149us-gaap:CommonStockMember2023-01-012023-03-310001682149wisa:SeriesBPreferredStockWarrantsMemberus-gaap:CommonStockMember2024-01-012024-03-310001682149us-gaap:ConvertibleDebtMemberus-gaap:CommonStockMember2023-01-012023-03-3100016821492024-04-042024-04-0400016821492023-01-242023-01-240001682149srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AccountingStandardsUpdate202006Memberus-gaap:AdditionalPaidInCapitalMember2024-06-300001682149us-gaap:RetainedEarningsMember2024-06-300001682149us-gaap:AdditionalPaidInCapitalMember2024-06-300001682149us-gaap:AccountingStandardsUpdate202006Memberus-gaap:ConvertiblePreferredStockMemberus-gaap:PreferredStockMember2024-03-310001682149us-gaap:AccountingStandardsUpdate202006Memberus-gaap:AdditionalPaidInCapitalMember2024-03-310001682149us-gaap:RetainedEarningsMember2024-03-310001682149us-gaap:AdditionalPaidInCapitalMember2024-03-310001682149us-gaap:AccountingStandardsUpdate202006Member2024-03-310001682149us-gaap:RetainedEarningsMember2023-12-310001682149us-gaap:AdditionalPaidInCapitalMember2023-12-310001682149us-gaap:RetainedEarningsMember2023-06-300001682149us-gaap:AdditionalPaidInCapitalMember2023-06-300001682149us-gaap:RetainedEarningsMember2023-03-310001682149us-gaap:AdditionalPaidInCapitalMember2023-03-310001682149us-gaap:RetainedEarningsMember2022-12-310001682149us-gaap:AdditionalPaidInCapitalMember2022-12-310001682149us-gaap:InvestorMember2022-11-282022-11-280001682149us-gaap:CommonStockMember2024-06-300001682149us-gaap:CommonStockMember2024-03-310001682149us-gaap:ConvertiblePreferredStockMemberus-gaap:PreferredStockMember2023-12-310001682149us-gaap:CommonStockMember2023-12-310001682149us-gaap:CommonStockMember2023-06-300001682149us-gaap:CommonStockMember2023-03-310001682149us-gaap:CommonStockMember2022-12-310001682149wisa:SecondMay2024RegisteredDirectOfferingMember2024-05-150001682149wisa:May2024RegisteredDirectOfferingMember2024-05-130001682149wisa:ThirdApril2024RegisteredDirectOfferingMember2024-04-260001682149wisa:SecondApril2024RegisteredDirectOfferingMember2024-04-190001682149wisa:InitialApril2024RegisteredDirectOfferingMember2024-04-170001682149wisa:UnitsMemberwisa:PublicOfferingFebruary2024Member2024-02-130001682149wisa:SeriesBPreferredStockWarrantsMemberwisa:SeriesBConvertibleRedeemablePreferredStockMemberwisa:OctoberPublicOfferingMember2023-10-160001682149us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Member2024-06-300001682149us-gaap:WarrantMemberwisa:ExercisePriceRangeTwoMember2024-01-012024-06-300001682149us-gaap:WarrantMemberwisa:ExercisePriceRangeThreeMember2024-01-012024-06-300001682149us-gaap:WarrantMemberwisa:ExercisePriceRangeOneMember2024-01-012024-06-300001682149us-gaap:WarrantMemberwisa:ExercisePriceRangeFourMember2024-01-012024-06-300001682149us-gaap:WarrantMemberwisa:ExercisePriceRangeFiveMemberMember2024-01-012024-06-300001682149us-gaap:WarrantMember2024-01-012024-06-300001682149us-gaap:WarrantMemberwisa:ExercisePriceRangeTwoMember2023-01-012023-12-310001682149us-gaap:WarrantMemberwisa:ExercisePriceRangeThreeMember2023-01-012023-12-310001682149us-gaap:WarrantMemberwisa:ExercisePriceRangeOneMember2023-01-012023-12-310001682149us-gaap:WarrantMemberwisa:ExercisePriceRangeFourMember2023-01-012023-12-310001682149us-gaap:WarrantMemberwisa:ExercisePriceRangeFiveMemberMember2023-01-012023-12-310001682149us-gaap:WarrantMember2023-01-012023-12-310001682149srt:MinimumMemberus-gaap:WarrantMemberwisa:ExercisePriceRangeTwoMember2024-06-300001682149srt:MinimumMemberus-gaap:WarrantMemberwisa:ExercisePriceRangeOneMember2024-06-300001682149srt:MinimumMemberus-gaap:WarrantMemberwisa:ExercisePriceRangeFiveMemberMember2024-06-300001682149srt:MaximumMemberus-gaap:WarrantMemberwisa:ExercisePriceRangeTwoMember2024-06-300001682149srt:MaximumMemberus-gaap:WarrantMemberwisa:ExercisePriceRangeOneMember2024-06-300001682149srt:MaximumMemberus-gaap:WarrantMemberwisa:ExercisePriceRangeFiveMemberMember2024-06-300001682149srt:MinimumMemberus-gaap:WarrantMemberwisa:ExercisePriceRangeFiveMemberMember2023-12-310001682149srt:MaximumMemberus-gaap:WarrantMemberwisa:ExercisePriceRangeFiveMemberMember2023-12-310001682149us-gaap:WarrantMemberwisa:ExercisePriceRangeTwoMember2024-06-300001682149us-gaap:WarrantMemberwisa:ExercisePriceRangeThreeMember2024-06-300001682149us-gaap:WarrantMemberwisa:ExercisePriceRangeOneMember2024-06-300001682149us-gaap:WarrantMemberwisa:ExercisePriceRangeFourMember2024-06-300001682149us-gaap:WarrantMemberwisa:ExercisePriceRangeFiveMemberMember2024-06-300001682149us-gaap:WarrantMember2024-06-300001682149us-gaap:WarrantMemberwisa:ExercisePriceRangeTwoMember2023-12-310001682149us-gaap:WarrantMemberwisa:ExercisePriceRangeThreeMember2023-12-310001682149us-gaap:WarrantMemberwisa:ExercisePriceRangeOneMember2023-12-310001682149us-gaap:WarrantMemberwisa:ExercisePriceRangeFourMember2023-12-310001682149us-gaap:WarrantMemberwisa:ExercisePriceRangeFiveMemberMember2023-12-310001682149wisa:LongTermStockIncentivePlanMember2024-06-300001682149us-gaap:RestrictedStockUnitsRSUMemberwisa:TwentyTwentyStockIncentivePlanMember2024-01-012024-06-300001682149us-gaap:RestrictedStockUnitsRSUMemberwisa:TechnicalTeamRetentionPlan2022Member2024-01-012024-06-300001682149us-gaap:RestrictedStockUnitsRSUMemberwisa:LongTermStockIncentivePlanMember2024-01-012024-06-300001682149us-gaap:RestrictedStockMemberwisa:TwentyTwentyStockIncentivePlanMember2024-01-012024-06-300001682149us-gaap:RestrictedStockUnitsRSUMemberwisa:TechnicalTeamRetentionPlan2022Member2023-01-012023-06-300001682149us-gaap:RestrictedStockUnitsRSUMemberwisa:LongTermStockIncentivePlanMember2023-01-012023-06-300001682149us-gaap:RestrictedStockMemberwisa:TwentyTwentyStockIncentivePlanMember2023-01-012023-06-300001682149us-gaap:RestrictedStockUnitsRSUMemberwisa:TechnicalTeamRetentionPlan2022Member2024-06-300001682149us-gaap:RestrictedStockUnitsRSUMemberwisa:TwentyTwentyStockIncentivePlanMember2023-12-310001682149us-gaap:RestrictedStockUnitsRSUMemberwisa:TechnicalTeamRetentionPlan2022Member2023-12-310001682149us-gaap:RestrictedStockMember2023-12-310001682149us-gaap:RestrictedStockMemberwisa:TwentyTwentyTwoPlanMember2024-01-012024-06-300001682149us-gaap:RestrictedStockMemberwisa:September2021InducementGrantMember2024-01-012024-06-300001682149wisa:September2021InducementGrantMember2024-01-012024-06-300001682149wisa:RegisteredDirectOfferingMarch2023Member2023-03-272023-03-270001682149wisa:SecondMay2024RegisteredDirectOfferingAndConcurrentPrivatePlacementMember2024-05-172024-05-170001682149wisa:May2024RegisteredDirectOfferingAndConcurrentPrivatePlacementMember2024-05-152024-05-150001682149wisa:ThirdApril2024RegisteredDirectOfferingAndConcurrentPrivatePlacementMember2024-04-302024-04-300001682149wisa:SecondApril2024RegisteredDirectOfferingAndConcurrentPrivatePlacementMember2024-04-232024-04-230001682149wisa:InitialApril2024RegisteredDirectOfferingAndConcurrentPrivatePlacementMember2024-04-192024-04-190001682149wisa:JulyInducementWarrantsMember2023-07-262023-07-260001682149wisa:RegisteredDirectOfferingApril2023Member2023-04-122023-04-120001682149wisa:RegisteredDirectOfferingMarch2023Member2023-03-292023-03-290001682149wisa:RegisteredDirectOfferingFebruary2023Member2023-02-032023-02-030001682149wisa:SalesToRelatedPartyMemberwisa:HansongTechnologyMember2024-04-012024-06-300001682149wisa:ConsumerAudioProductsMember2024-04-012024-06-300001682149wisa:ComponentsMember2024-04-012024-06-300001682149srt:NorthAmericaMember2024-04-012024-06-300001682149srt:EuropeMember2024-04-012024-06-300001682149srt:AsiaPacificMember2024-04-012024-06-300001682149wisa:SalesToRelatedPartyMemberwisa:HansongTechnologyMember2024-01-012024-06-300001682149wisa:ConsumerAudioProductsMember2024-01-012024-06-300001682149wisa:ComponentsMember2024-01-012024-06-300001682149srt:NorthAmericaMember2024-01-012024-06-300001682149srt:EuropeMember2024-01-012024-06-300001682149srt:AsiaPacificMember2024-01-012024-06-300001682149wisa:SalesToRelatedPartyMemberwisa:HansongTechnologyMember2023-04-012023-06-300001682149wisa:ConsumerAudioProductsMember2023-04-012023-06-300001682149wisa:ComponentsMember2023-04-012023-06-300001682149srt:NorthAmericaMember2023-04-012023-06-300001682149srt:EuropeMember2023-04-012023-06-300001682149srt:AsiaPacificMember2023-04-012023-06-300001682149wisa:SalesToRelatedPartyMemberwisa:HansongTechnologyMember2023-01-012023-06-300001682149wisa:ConsumerAudioProductsMember2023-01-012023-06-300001682149wisa:ComponentsMember2023-01-012023-06-300001682149srt:NorthAmericaMember2023-01-012023-06-300001682149srt:EuropeMember2023-01-012023-06-300001682149srt:AsiaPacificMember2023-01-012023-06-300001682149us-gaap:ConvertibleDebtMember2023-04-112023-04-110001682149wisa:PurchaseOfSpeakerProductsFromRelatedPartyMemberwisa:HansongTechnologyMember2024-04-012024-06-300001682149wisa:PurchaseOfSpeakerProductsFromRelatedPartyMemberwisa:HansongTechnologyMember2024-01-012024-06-300001682149wisa:PurchaseOfSpeakerProductsFromRelatedPartyMemberwisa:HansongTechnologyMember2023-04-012023-06-300001682149wisa:PurchaseOfSpeakerProductsFromRelatedPartyMemberwisa:HansongTechnologyMember2023-01-012023-06-300001682149srt:MinimumMember2024-06-300001682149srt:MaximumMember2024-06-300001682149us-gaap:ToolsDiesAndMoldsMember2024-06-300001682149us-gaap:MachineryAndEquipmentMember2024-06-300001682149us-gaap:ToolsDiesAndMoldsMember2023-12-310001682149us-gaap:MachineryAndEquipmentMember2023-12-310001682149wisa:SeriesBPreferredStockWarrantsMemberwisa:SeriesBConvertibleRedeemablePreferredStockMember2024-01-012024-06-300001682149wisa:January2024PromissoryNotesMemberwisa:January2024ShortTermLoanMember2024-01-192024-01-190001682149wisa:SeriesBPreferredStockWarrantsMemberwisa:SeriesBConvertibleRedeemablePreferredStockMemberwisa:InducementAgreementMember2023-01-012023-12-310001682149wisa:SeriesBConvertibleRedeemablePreferredStockMemberwisa:InducementAgreementMember2023-01-012023-12-310001682149wisa:MaximGroupLlcMemberus-gaap:ConvertibleDebtMember2022-08-152022-08-150001682149wisa:SeriesBConvertibleRedeemablePreferredStockMember2024-06-300001682149wisa:SeriesBConvertibleRedeemablePreferredStockMemberwisa:OctoberPublicOfferingMember2023-12-310001682149wisa:SeriesBPreferredStockWarrantsMemberwisa:SeriesBConvertibleRedeemablePreferredStockMemberwisa:OctoberPublicOfferingMember2023-10-162023-10-160001682149wisa:SeriesBConvertibleRedeemablePreferredStockMember2023-01-012023-12-310001682149wisa:PrefundedWarrantsMemberus-gaap:CommonStockMemberwisa:March2024OfferingMember2024-03-262024-03-260001682149wisa:CommonStockWarrantsMemberwisa:March2024OfferingMember2024-03-262024-03-260001682149wisa:March2024OfferingMember2024-03-262024-03-260001682149wisa:PrefundedWarrantsMemberus-gaap:CommonStockMemberwisa:PublicOfferingFebruary2024Member2024-02-132024-02-130001682149wisa:CommonStockWarrantsMemberwisa:PublicOfferingFebruary2024Member2024-02-132024-02-130001682149wisa:PublicOfferingFebruary2024Member2024-02-132024-02-130001682149wisa:SeriesBUnitsMemberwisa:OctoberPublicOfferingMember2023-10-162023-10-1600016821492024-02-132024-02-130001682149wisa:SalesToRelatedPartyMemberwisa:HansongTechnologyMember2024-06-300001682149wisa:PurchaseOfSpeakerProductsFromRelatedPartyMemberwisa:HansongTechnologyMember2024-06-300001682149wisa:SalesToRelatedPartyMemberwisa:HansongTechnologyMember2023-06-300001682149wisa:PurchaseOfSpeakerProductsFromRelatedPartyMemberwisa:HansongTechnologyMember2023-06-300001682149srt:OfficeBuildingMember2024-06-300001682149srt:OfficeBuildingMember2023-12-310001682149us-gaap:OtherNoncurrentAssetsMember2023-12-310001682149wisa:TwoThousandTwentyTwoStockIncentivePlanMember2024-01-012024-06-300001682149wisa:TwentyTwentyStockIncentivePlanMember2024-01-012024-06-300001682149us-gaap:RetainedEarningsMember2024-04-012024-06-300001682149us-gaap:RetainedEarningsMember2024-01-012024-03-310001682149us-gaap:RetainedEarningsMember2023-04-012023-06-300001682149us-gaap:RetainedEarningsMember2023-01-012023-03-310001682149wisa:MeriwetherGroupCapitalHeroFundLpMemberus-gaap:ShortTermDebtMember2023-10-102023-10-100001682149wisa:MeriwetherGroupCapitalHeroFundLpMemberwisa:MeriwetherGroupCapitalHeroFundLpMemberwisa:HowittMember2024-01-012024-06-3000016821492024-06-1300016821492023-09-082023-09-080001682149us-gaap:ConvertibleDebtMember2023-04-112023-04-110001682149us-gaap:WarrantMember2024-06-300001682149us-gaap:WarrantMember2023-12-310001682149us-gaap:WarrantMember2023-06-300001682149us-gaap:WarrantMember2022-12-310001682149us-gaap:WarrantMember2024-01-012024-06-300001682149us-gaap:WarrantMember2023-01-012023-06-300001682149wisa:SeriesBConvertibleRedeemablePreferredStockMember2024-01-012024-06-300001682149us-gaap:RestrictedStockUnitsRSUMemberwisa:TwentyTwentyTwoPlanMember2024-06-300001682149us-gaap:RestrictedStockMemberwisa:TwentyTwentyStockIncentivePlanMember2024-06-300001682149us-gaap:RestrictedStockMember2024-06-300001682149us-gaap:RestrictedStockUnitsRSUMemberwisa:TwentyTwentyTwoPlanMember2024-01-012024-06-300001682149us-gaap:RestrictedStockMember2024-01-012024-06-300001682149us-gaap:ConvertibleDebtMember2024-06-300001682149us-gaap:ConvertibleDebtMember2024-06-300001682149us-gaap:ConvertibleDebtMember2024-01-190001682149wisa:MeriwetherGroupCapitalHeroFundLpMemberus-gaap:ShortTermDebtMember2023-09-082023-09-080001682149wisa:MeriwetherGroupCapitalHeroFundLpMemberus-gaap:ShortTermDebtMember2023-09-080001682149wisa:January2024PromissoryNotesMemberwisa:January2024ShortTermLoanMember2024-01-190001682149wisa:MeriwetherGroupCapitalHeroFundLpMemberwisa:LoanAndSecurityAgreementMemberus-gaap:ShortTermDebtMember2023-09-080001682149us-gaap:ConvertibleDebtMemberus-gaap:InvestorMember2022-08-150001682149us-gaap:ConvertibleDebtMember2022-08-150001682149us-gaap:ConvertibleDebtMember2023-02-012023-02-010001682149wisa:SeriesBConvertibleRedeemablePreferredStockMember2023-12-310001682149wisa:SeriesBConvertibleRedeemablePreferredStockMemberwisa:OctoberPublicOfferingMember2023-10-1600016821492024-03-310001682149wisa:NewCommonStockWarrantsMemberwisa:SeriesBConvertibleRedeemablePreferredStockMemberwisa:InducementAgreementMember2023-12-310001682149wisa:EquityWarrantsMember2024-04-300001682149wisa:SeriesBPreferredStockWarrantsMemberwisa:January2024PromissoryNotesMemberwisa:January2024ShortTermLoanMemberwisa:SeriesBConvertibleRedeemablePreferredStockMember2024-02-020001682149wisa:SeriesBPreferredStockWarrantsMemberwisa:January2024PromissoryNotesMemberwisa:January2024ShortTermLoanMemberwisa:SeriesBConvertibleRedeemablePreferredStockMember2024-01-260001682149wisa:SeriesBPreferredStockWarrantsMemberwisa:January2024PromissoryNotesMemberwisa:January2024ShortTermLoanMemberwisa:SeriesBConvertibleRedeemablePreferredStockMember2024-01-190001682149us-gaap:WarrantMember2023-12-310001682149wisa:CommonStockWarrantsMember2023-10-160001682149wisa:CommonStockPurchaseWarrantsInPrivatePlacementMemberwisa:RegisteredDirectOfferingApril2023Member2023-04-0700016821492023-03-310001682149wisa:MaximGroupLlcMember2022-08-150001682149wisa:PrefundedCommonStockWarrantsMemberwisa:PublicOfferingFebruary2024Member2024-02-130001682149wisa:CommonStockWarrantsMemberwisa:PublicOfferingFebruary2024Member2024-02-130001682149wisa:SeriesBPreferredStockWarrantsMemberwisa:OctoberPublicOfferingMember2023-10-160001682149wisa:OctoberPublicOfferingMember2023-10-160001682149wisa:SeriesBPreferredStockWarrantsMemberwisa:SeriesBConvertibleRedeemablePreferredStockMember2024-06-300001682149wisa:NewCommonStockWarrantsMember2024-06-300001682149us-gaap:WarrantMemberwisa:SecondMay2024RegisteredDirectOfferingAndConcurrentPrivatePlacementMember2024-05-150001682149wisa:SecondMay2024ConcurrentPrivatePlacementMember2024-05-150001682149us-gaap:WarrantMemberwisa:May2024RegisteredDirectOfferingAndConcurrentPrivatePlacementMember2024-05-130001682149wisa:May2024ConcurrentPrivatePlacementMember2024-05-130001682149us-gaap:WarrantMemberwisa:ThirdApril2024RegisteredDirectOfferingAndConcurrentPrivatePlacementMember2024-04-260001682149wisa:ThirdApril2024ConcurrentPrivatePlacementMember2024-04-260001682149us-gaap:WarrantMemberwisa:SecondApril2024RegisteredDirectOfferingAndConcurrentPrivatePlacementMember2024-04-190001682149wisa:SecondApril2024ConcurrentPrivatePlacementMember2024-04-190001682149us-gaap:WarrantMemberwisa:InitialApril2024RegisteredDirectOfferingAndConcurrentPrivatePlacementMember2024-04-170001682149wisa:InitialApril2024ConcurrentPrivatePlacementMember2024-04-170001682149us-gaap:WarrantMemberwisa:March2024OfferingMember2024-03-260001682149wisa:CommonStockWarrantsMemberwisa:UnitsMemberwisa:PublicOfferingFebruary2024Member2024-02-130001682149wisa:PreFundedUnitsMemberwisa:PublicOfferingFebruary2024Member2024-02-130001682149us-gaap:WarrantMemberwisa:PublicOfferingFebruary2024Member2024-02-130001682149wisa:January2024WarrantSharesMemberwisa:January2024ShortTermLoanMember2024-01-190001682149us-gaap:WarrantMemberwisa:January2024PromissoryNotesMember2024-01-190001682149wisa:SeriesBPreferredStockWarrantsMemberwisa:SeriesBConvertibleRedeemablePreferredStockMemberwisa:InducementAgreementMember2023-12-310001682149wisa:SeriesBPreferredStockWarrantsMemberwisa:SeriesBConvertibleRedeemablePreferredStockMemberwisa:InducementAgreementMember2023-12-050001682149wisa:NewCommonStockWarrantsMemberwisa:SeriesBConvertibleRedeemablePreferredStockMemberwisa:InducementAgreementMember2023-12-050001682149srt:MinimumMemberwisa:CommonStockWarrantsMember2023-10-160001682149srt:MaximumMemberwisa:CommonStockWarrantsMember2023-10-160001682149wisa:JulyInducementWarrantsMember2023-07-260001682149wisa:MayInducementWarrantsMember2023-05-150001682149wisa:RegisteredDirectOfferingApril2023Member2023-04-070001682149wisa:CommonStockPurchaseWarrantsInPrivatePlacementMemberwisa:RegisteredDirectOfferingMarch2023Member2023-03-270001682149us-gaap:WarrantMemberwisa:March2023OfferingMember2023-03-270001682149wisa:PrefundedWarrantsMemberwisa:RegisteredDirectOfferingFebruary2023Member2023-01-310001682149wisa:CommonStockPurchaseWarrantsInPrivatePlacementMemberwisa:RegisteredDirectOfferingFebruary2023Member2023-01-310001682149us-gaap:WarrantMemberwisa:February2023OfferingMember2023-01-310001682149us-gaap:ConvertibleDebtMemberus-gaap:InvestorMember2022-08-150001682149wisa:MaximGroupLlcMember2022-08-1500016821492023-06-3000016821492022-12-310001682149us-gaap:WarrantMember2024-01-012024-06-300001682149us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-06-300001682149us-gaap:RestrictedStockMember2024-01-012024-06-300001682149us-gaap:ConvertiblePreferredStockMember2024-01-012024-06-300001682149us-gaap:WarrantMember2023-01-012023-06-300001682149us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-06-300001682149us-gaap:RestrictedStockMember2023-01-012023-06-300001682149us-gaap:ConvertiblePreferredStockMember2023-01-012023-06-300001682149us-gaap:ConvertibleDebtMember2024-01-012024-06-300001682149us-gaap:ConvertibleDebtMember2023-01-012023-12-3100016821492023-01-012023-06-300001682149us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001682149us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-3100016821492024-01-012024-03-310001682149us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-3000016821492023-04-012023-06-300001682149us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-3100016821492023-01-012023-03-3100016821492024-06-3000016821492023-12-3100016821492024-04-012024-06-3000016821492024-08-1300016821492024-01-012024-06-30xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:purewisa:segmentwisa:Ywisa:itemwisa:Dwisa:customer

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2024

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______________to _______________.

Commission File Number: 001-38608

WISA Technologies, Inc.

(Exact name of registrant as specified in its charter)

Delaware

    

30-1135279

(State or other jurisdiction of incorporation or organization) 

(I.R.S. Employer Identification No.)

15268 NW Greenbrier Pkwy

Beaverton, OR 97006

(Address of principal executive offices) (Zip Code)

(408) 627-4716

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

    

Trading symbol(s)

    

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

WISA

The Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer  

Accelerated filer  

Non-accelerated filer  

Smaller reporting company  

 

Emerging growth company  

If an emerging growth company, indicate by check-mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes      No  

The number of shares of the registrant’s common stock outstanding as of   August 13, 2024 is 5,620,610.

WISA TECHNOLOGIES, INC.

QUARTERLY REPORT ON FORM 10-Q

For the quarter ended June 30, 2024

Page 
Number 

PART I: FINANCIAL INFORMATION

 

Item 1. Financial Statements (unaudited)

 

Condensed Consolidated Balance Sheets

3

Condensed Consolidated Statements of Operations

4

Condensed Consolidated Statements of Stockholders’ Equity (Deficit)

5

Condensed Consolidated Statements of Cash Flows

6

Notes to Condensed Consolidated Financial Statements

7

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

35

Item 3. Quantitative and Qualitative Disclosures About Market Risk

38

Item 4. Controls and Procedures

38

PART II. OTHER INFORMATION

 

Item 1. Legal Proceedings

39

Item 1A. Risk Factors

39

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

39

Item 3. Defaults Upon Senior Securities

39

Item 4. Mine Safety Disclosures

39

Item 5. Other Information

39

Item 6. Exhibits

40

SIGNATURES

41

2

PART I: FINANCIAL INFORMATION

Item 1. Financial Statements

WISA TECHNOLOGIES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)

    

June 30, 2024

    

December 31, 2023

  

(unaudited)

  

(1)

Assets

 

  

 

  

Current Assets:

 

  

 

  

Cash and cash equivalents

$

6,113

$

411

Accounts receivable

 

117

 

294

Inventories

 

2,330

 

2,737

Prepaid expenses and other current assets

 

1,413

 

641

Total current assets

 

9,973

 

4,083

Property and equipment, net

 

65

 

93

Other assets

 

594

 

647

Total assets

$

10,632

$

4,823

Liabilities, Convertible Redeemable Preferred Stock and Stockholders’ Equity / (Deficit)

 

 

Current Liabilities:

 

 

Accounts payable

$

2,191

$

2,320

Accrued liabilities

 

1,379

 

1,317

Total current liabilities

 

3,570

 

3,637

Warrant liabilities

25

5,460

Other liabilities

607

636

Total liabilities

 

4,202

 

9,733

Commitments and contingencies (Note 8)

 

  

 

  

Series B Convertible Redeemable Preferred Stock, par value $0.0001; 375,000 shares authorized; 0 and 38,335 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively

247

Stockholders’ Equity / (Deficit):

 

  

 

  

Common stock, par value $0.0001; 300,000,000 shares authorized; 4,921,434 and 222,380 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively

 

1

 

1

Additional paid-in capital

 

293,429

 

241,884

Accumulated deficit

 

(287,000)

 

(247,042)

Total stockholders’ equity / (deficit)

 

6,430

 

(5,157)

Total liabilities, convertible preferred stock and stockholders’ equity / (deficit)

$

10,632

$

4,823

(1)The condensed consolidated balance sheet as of December 31, 2023 was derived from the audited consolidated balance sheet as of that date.

Note: Share and per share amounts have been retroactively adjusted to reflect the impact of a 1-for-100 reverse stock split effected in January 2023 as well as a 1-for-150 reverse stock split effected in April 2024, as discussed in Note 1.

The accompanying notes are an integral part of these condensed consolidated financial statements

3

WISA TECHNOLOGIES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

For the three and six months ended June 30, 2024 and 2023

(in thousands, except share and per share data)

(unaudited)

Three Months Ended June 30, 

Six Months Ended June 30, 

    

2024

    

2023

    

2024

    

2023

Revenue, net

$

345

 

$

425

$

600

 

$

894

Cost of revenue

 

334

 

 

626

 

672

 

 

2,348

Gross profit (deficit)

 

11

 

 

(201)

 

(72)

 

 

(1,454)

Operating Expenses:

 

 

 

 

 

 

Research and development

 

1,789

 

 

1,933

 

3,504

 

 

3,826

Sales and marketing

 

865

 

 

1,089

 

1,794

 

 

2,383

General and administrative

 

2,762

 

 

1,470

 

4,193

 

 

2,832

Total operating expenses

 

5,416

 

 

4,492

 

9,491

 

 

9,041

Loss from operations

 

(5,405)

 

 

(4,693)

 

(9,563)

 

 

(10,495)

Interest expense, net

 

(4)

 

 

(37)

 

(1,269)

 

 

(760)

Change in fair value of warrant liabilities

 

(37,255)

 

 

246

 

(29,126)

 

 

5,850

Loss on debt extinguishment

(837)

(837)

Other expense, net

 

(1)

 

 

(3)

 

 

 

(3)

Loss before provision for income taxes

 

(42,665)

 

 

(5,324)

 

(39,958)

 

 

(6,245)

Provision for income taxes

 

 

 

2

 

 

 

2

Net loss

(42,665)

 

(5,326)

(39,958)

 

(6,247)

Deemed dividend on conversion of Series B preferred for common stock and repurchase of Series B preferred stock

(5,842)

Net loss attributable to common stockholders

$

(42,665)

$

(5,326)

$

(45,800)

$

(6,247)

Net loss per common share - basic and diluted

$

(11.89)

 

$

(180.18)

$

(21.95)

 

$

(303.28)

Weighted average number of common shares used in computing net loss per common share

 

3,587,122

 

 

29,560

 

2,086,312

 

 

20,598

Note: Share and per share amounts have been retroactively adjusted to reflect the impact of a 1-for-100 reverse stock split effected in January 2023 as well as a 1-for-150 reverse stock split effected in April 2024, as discussed in Note 1.

The accompanying notes are an integral part of these condensed consolidated financial statements.

4

WISA TECHNOLOGIES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

For the three and six months ended June 30, 2024 and 2023

(in thousands, except share and per share data)

(unaudited)

Total

Convertible Preferred Stock

Common Shares

Additional

Accumulated

Stockholders’

    

Shares

    

Amount

  

  

Shares

    

Amount

    

Paid-in Capital

    

Deficit

    

Equity (Deficit)

Balance as of December 31, 2023

 

38,335

$

247

 

222,380

$

1

$

241,884

$

(247,042)

$

(5,157)

Stock-based compensation

4

380

380

Cumulative effect of ASU 2020-06 adoption

 

 

116

 

 

 

(116)

 

 

(116)

Issuance of Series B preferred stock in connection with warrant exercise, net of discounts

29,322

386

Issuance of common stock in connection with conversion of Series B preferred stock

 

(5,000)

 

(325)

 

8,038

 

 

325

 

 

325

Deemed dividend on conversion of Series B preferred for common stock and repurchase of Series B preferred stock

 

 

5,842

 

 

 

(5,842)

 

 

(5,842)

Repurchase of Series B preferred stock and Series B preferred stock warrants

(62,657)

(6,266)

824

824

Issuance of common stock, pre-funded units and warrants, net of offering costs

1,442,518

4,210

4,210

Issuance of common stock in connection with reverse split rounding-up for fractional shares

84,255

Net income

2,707

2,707

Balance as of March 31, 2024

1,757,195

1

241,665

(244,335)

(2,669)

Stock-based compensation

255,915

241

241

Issuance of common stock in connection with warrant exercise

441,822

556

556

Issuance of common stock and warrants, net of offering costs

2,466,583

8,756

8,756

Issuance of common stock to vendors

360

360

Restricted stock awards cancelled

(82)

Release of vested restricted common stock

1

Conversion of liability warrants to equity warrants

41,851

41,851

Net loss

(42,665)

(42,665)

Balance as of June 30, 2024

 

 

4,921,434

$

1

$

293,429

$

(287,000)

$

6,430

Total

Convertible Preferred Stock

Common Shares

Additional

Accumulated

Stockholders’

    

Shares

    

Amount

  

  

Shares

    

Amount

    

Paid-in Capital

    

Deficit

    

Equity

Balance as of December 31, 2022

4,750

$

1

$

226,324

$

(228,321)

$

(1,996)

Stock-based compensation

499

499

Restricted stock awards cancelled

(0)

Issuance of common stock in connection with convertible promissory note

450

708

708

Issuance of common stock in connection with warrant exercise

5,723

8,202

8,202

Issuance of common stock and warrants, net of offering costs

9,470

1,271

1,271

Net loss

(921)

(921)

Balance as of March 31, 2023

20,393

1

237,004

(229,242)

7,763

Stock-based compensation

481

481

Release of vested restricted common stock

1

Restricted stock awards cancelled

(1)

Issuance of common stock and warrants, net of offering costs

5,040

1,048

1,048

Issuance of common stock in connection with warrant exercise

9,908

1,894

1,895

Net loss

(5,326)

(5,326)

Balance as of June 30, 2023

35,341

$

1

$

240,427

$

(234,568)

$

5,861

Note: Share and per share amounts have been retroactively adjusted to reflect the impact of a 1-for-100 reverse stock split effected in January 2023 as well as a 1-for-150 reverse stock split effected in April 2024, as discussed in Note 1.

The accompanying notes are an integral part of these condensed consolidated financial statements.

5

WISA TECHNOLOGIES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

For the six months ended June 30, 2024 and 2023

(in thousands)

(unaudited)

Six Months Ended June 30, 

    

2024

    

2023

Cash flows from operating activities:

 

  

 

  

Net loss

$

(39,958)

$

(6,247)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

  

Stock-based compensation

777

980

Depreciation and amortization

48

65

Amortization of debt discounts

1,260

738

Change in fair value of warrant liability

29,126

(5,850)

Loss on extinguishment of convertible note payable

837

Changes in operating assets and liabilities:

 

 

Accounts receivable

 

177

 

172

Inventories

 

407

 

1,595

Prepaid expenses and other current assets

 

(418)

 

225

Other assets

53

47

Accounts payable

 

(534)

 

(1,105)

Accrued liabilities

 

46

 

(544)

Other liabilities

 

(29)

 

(39)

Net cash used in operating activities

 

(9,045)

 

(9,126)

Cash flows from investing activities:

 

  

 

  

Issuance of note receivable

(150)

Purchases of property and equipment

 

(20)

 

(16)

Net cash used in investing activities

 

(170)

 

(16)

Cash flows from financing activities:

 

  

 

  

Proceeds from issuance of common stock in connection with warrant exercise

556

Proceeds from issuance of common stock and warrants, net of offering costs

19,980

1,927

Proceeds from issuance of short-term loan, net of issuance costs

600

7,995

Proceeds from exercise of warrants

714

Repurchase of Series B preferred stock warrants

(6,266)

Repayment of short-term loan

(667)

Repayment of convertible note payable

(1,657)

Repayment of finance lease

(13)

Net cash provided by financing activities

 

14,917

 

8,252

Net decrease in cash and cash equivalents

 

5,702

 

(890)

Cash and cash equivalents as of beginning of period

 

411

 

2,897

Cash and cash equivalents as of end of period

$

6,113

$

2,007

Supplemental disclosure of cash flow information:

Cash paid for interest

$

276

$

20

Cash paid for income taxes

$

$

2

Noncash Investing and Financing Activities:

 

  

 

  

Conversion of liability warrants to equity warrants

$

41,851

$

Issuance of warrant liability in connection with financing

$

8,701

$

Deemed dividend on conversion of Series B preferred stock and repurchase of Series B preferred stock

$

5,842

$

Unpaid financings issuance costs

$

421

$

Cashless exercise of warrants

$

587

$

8,191

Issuance of common stock to vendors

$

360

$

warrant exercise in connection with loan settlement

$

333

$

Issuance of common stock in connection with Series B preferred stock

$

325

$

Issuance of warrant liability in connection with February 2023 offering

$

$

5,600

Issuance of common stock in connection with convertible promissory note

$

$

708

Record Right-of-Use Assets obtained in exchange for modified operating lease liabilities

$

$

554

Deferred offering costs reclassed from prepaid expenses

$

$

(97)

The accompanying notes are an integral part of these condensed consolidated financial statements.

6

WISA TECHNOLOGIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Three and Six Months Ended June 30, 2024 and 2023

(unaudited)

1.

Business and Summary of Significant Accounting Policies

WiSA Technologies, Inc. formerly known as Summit Wireless Technologies, Inc. (together with its subsidiaries also referred to herein as “we”, “us”, “our”, or the “Company”), was originally formed as a limited liability company in Delaware on July 23, 2010. Our business is to deliver the best-in-class immersive wireless sound technology for intelligent devices and next generation home entertainment systems through the sale of module components to audio companies as well as audio products to resellers and consumers.

Nasdaq Compliance

The Company is currently in compliance with the listing rules of The Nasdaq Stock Market LLC (“Nasdaq”), subject to the monitorings described below.

On April 29, 2024, Nasdaq notified the Company in a letter that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550 (a)(2) (the “Minimum Bid Price Requirement”) as required by a hearing panel’s decision on April 5, 2024. The Company is subject to monitoring for a period of one year from the date of the letter. If, within that one-year monitoring period, Nasdaq’s Listing Qualifications staff (the “Staff”) finds the Company again out of compliance with the Minimum Bid Price Requirement, the Company will not be permitted to provide the Staff with a plan of compliance with respect to such deficiency and the Staff will not be permitted to grant additional time for the Company to regain compliance with respect to such deficiency, nor will the Company be afforded an applicable cure or compliance period. Instead, the Staff will issue a delist determination letter and the Company will have an opportunity to request a new hearing with a hearings panel. The Company will have the opportunity to respond and present to the panel.    

On July 3, 2024, Nasdaq notified the Company in a letter that the Company has regained compliance with the equity requirement under Nasdaq Listing Rule 5550(b)(1) (the “Equity Rule”) as required by the panel’s April 5, 2024 decision. The Company is subject to monitoring for a period of one year from the date of the letter. If, within that one-year monitoring period, the Staff finds the Company again out of compliance with the Equity Rule, the Company will not be permitted to provide the Staff with a plan of compliance with respect to such deficiency and the Staff will not be permitted to grant additional time for the Company to regain compliance with respect to such deficiency, nor will the Company be afforded an applicable cure or compliance period. Instead, the Staff will issue a delist determination letter and the Company will have an opportunity to request a new hearing with a hearings panel. The Company will have the opportunity to respond and present to the panel.

7

Table of Contents

WISA TECHNOLOGIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Three and Six Months Ended June 30, 2024 and 2023

(unaudited)

1.

Business and Summary of Significant Accounting Policies, continued

Reverse Stock Splits

April 2024 Reverse Stock Split

On April 4, 2024, the Board approved a 1-for-150 reverse stock split (the “April 2024 Reverse Stock Split”) of our outstanding shares of common stock and authorized the filing of a certificate of amendment to our certificate of incorporation, as amended, with the Secretary of State of the State of Delaware to effect the April 2024 Reverse Stock Split. On April 12, 2024, the April 2024 Reverse Stock Split was effected and the condensed consolidated financial statements have been retroactively adjusted. All common stock share numbers, warrants to purchase common stock, prices and exercise prices have been retroactively adjusted to reflect the April 2024 Reverse Stock Split. The common stock began trading on a split-adjusted basis at the start of trading on April 15, 2024. Unless otherwise indicated, the information presented in this Quarterly Report on Form 10-Q (this “Report”) gives effect to the April 2024 Reverse Stock Split.

January 2023 Reverse Stock Split

On January 24, 2023, the Board approved a 1-for-100 reverse stock split (the “January 2023 Reverse Stock Split”) of our outstanding shares of common stock and authorized the filing of a certificate of amendment to our certificate of incorporation, as amended, with the Secretary of State of the State of Delaware to effect the January 2023 Reverse Stock Split. On January 26, 2023, the January 2023 Reverse Stock Split was effected and the condensed consolidated financial statements have been retroactively adjusted. All common stock share numbers, warrants to purchase common stock, prices and exercise prices have been retroactively adjusted to reflect the January 2023 Reverse Stock Split. The common stock began trading on a split-adjusted basis at the start of trading on January 27, 2023. Unless otherwise indicated, the information presented in this Report gives effect to the January 2023 Reverse Stock Split.

Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and include all adjustments necessary for the fair presentation of the Company’s financial position, results of operations and cash flows for the periods presented. The condensed consolidated financial statements reflect the accounts of WISA Technologies, Inc. and its wholly-owned subsidiaries, WISA Technologies Korea, LTD, a Korean limited company, which was established in September 2022, and WiSA, LLC, a Delaware limited liability company. All intercompany balances and transactions are eliminated.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

Reclassification

Certain reclassifications have been made to prior periods’ condensed consolidated financial statements to conform to the current period presentation. These reclassifications did not result in any change in previously reported net income (loss), total assets or stockholders’ deficit.

8

Table of Contents

WISA TECHNOLOGIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Three and Six Months Ended June 30, 2024 and 2023

(unaudited)

1.Business and Summary of Significant Accounting Policies, continued

Concentration of Credit Risk and Other Risks and Uncertainties

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Cash and cash equivalents are deposited in demand and money market accounts at one financial institution. At times, such deposits may be in excess of insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.

The Company’s accounts receivable are derived from revenue earned from customers located throughout the world. The Company performs credit evaluations of its customers’ financial condition and may, in certain circumstances, require full or partial payment in advance of shipping. As of June 30, 2024 and December 31, 2023, there was no allowance for credit losses. As of June 30, 2024, the Company had four customers accounting for 43%, 33%, 12%and 11% of accounts receivable. As of December 31, 2023, the Company had two customers accounting for 71% and 20% of accounts receivable.

The Company had four customers accounting for 33%, 27%, 20% and 11% of its net revenue for the three months ended June 30, 2024. The Company had four customers accounting for 28%, 27%, 19% and 10% of its net revenue for the six months ended June 30, 2024. The Company had four customers accounting for 35%, 13%, 12% and 11% of its net revenue for the three months ended June 30, 2023. The Company had two customers accounting for 29% and 17% of its net revenue for the six months ended June 30, 2023.

The Company’s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, continued acceptance of the Company’s products, competition from substitute products and larger companies, protection of proprietary technology, strategic relationships and dependence on key individuals.

The Company relies on sole-source suppliers to manufacture some of the components used in its product. The Company’s manufacturers and suppliers may encounter problems during manufacturing due to a variety of reasons, any of which could delay or impede their ability to meet demand. The Company is heavily dependent on a single contractor in China for assembly and testing of its products, a single contractor in Japan for the production of its transmit semiconductor chip and a single contractor in China for the production of its receive semiconductor chip.

Cash and Cash Equivalents

The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents.

Accounts Receivable and Allowance for Credit Losses

Accounts receivable are recorded at the invoice amount and are generally not interest bearing. The Company reviews its trade receivables aging to identify specific customers with known disputes or collection issues. The Company exercises judgment when determining the adequacy of these reserves as it evaluates historical bad debt trends and changes to customers’ financial conditions.

Fair Value of Financial Instruments

Carrying amounts of certain of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities. The carrying value of the Company’s borrowings and capital lease liabilities approximates fair value based upon borrowing rates currently available to the Company for loans and capital leases with similar terms. The Company’s Warrant liabilities are the only financial instrument that is adjusted to fair value on a recurring basis.

9

Table of Contents

WISA TECHNOLOGIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Three and Six Months Ended June 30, 2024 and 2023

(unaudited)

1.

Business and Summary of Significant Accounting Policies, continued

Inventories

Inventories, principally purchased components, are stated at the lower of cost or net realizable value. Cost is determined using an average cost, which approximates actual cost on a first-in, first-out basis. Inventory in excess of salable amounts and inventory which is considered obsolete based upon changes in existing technology is written off. At the point of loss recognition, a new lower cost basis for that inventory is established and subsequent changes in facts and circumstances do not result in the restoration or increase in the new cost basis.

Property and Equipment, Net

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over their estimated useful lives of two to five years. Leasehold improvements and assets acquired under capital lease are amortized on a straight-line basis over the shorter of the useful life or term of the lease. Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred.

Convertible Financial Instruments

The Company bifurcates conversion options and warrants from their host instruments and accounts for them as freestanding derivative financial instruments if certain criteria are met. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. An exception to this rule is when the host instrument is deemed to be conventional, as that term is described under applicable U.S. GAAP.

When the Company has determined that the embedded conversion options and warrants should be bifurcated from their host instruments, discounts are recorded for the intrinsic value of conversion options embedded in the instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the instrument.

Debt discounts under these arrangements are amortized to interest expense using the interest method over the earlier of the term of the related debt or their earliest date of redemption.

Warrants for Common Shares, Convertible Redeemable Preferred Shares, and Derivative Financial Instruments

Warrants for our common shares, convertible redeemable preferred shares, and derivative financial instruments are classified as equity if the contracts (1) require physical settlement or net-share settlement or (2) give the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). Contracts which (1) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the control of the Company), (2) give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement), or (3) contain reset provisions that do not qualify for the scope exception are classified as equity or liabilities. The Company assesses classification of its warrants for shares of common stock and other derivatives at each reporting date to determine whether a change in classification between equity and liabilities is required.

10

Table of Contents

WISA TECHNOLOGIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Three and Six Months Ended June 30, 2024 and 2023

(unaudited)

1.

Business and Summary of Significant Accounting Policies, continued

Product Warranty

The Company’s products are generally subject to a one-year warranty, which provides for the repair, rework, or replacement of products (at the Company’s option) that fail to perform within the stated specification. The Company has assessed its historical claims and, to date, product warranty claims have not been significant. The Company will continue to assess if there should be a warranty accrual going forward.

Revenue Recognition

The Company generates revenue primarily from two product categories which include the sale of Consumer Audio Products as well as the sale of Components. The Company applies the following five steps: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when a performance obligation is satisfied. The Company considers customer purchase orders to be the contracts with a customer. Revenues, net of expected discounts, are recognized when the performance obligations of the contract with the customer are satisfied and when control of the promised goods are transferred to the customer, typically when products, which have been determined to be the only distinct performance obligations, are shipped to the customer. Expected costs of assurance warranties and claims are recognized as expense.

Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by us from a customer and deposited with the relevant government authority, are excluded from revenue. Our revenue arrangements do not contain significant financing components.

Sales to certain distributors are made under arrangements which provide the distributors with price adjustments, price protection, stock rotation and other allowances under certain circumstances. The Company does not provide its customers with a contractual right of return. However, the Company accepts limited returns on a case-by-case basis. These returns, adjustments and other allowances are accounted for as variable consideration. We estimate these amounts based on the expected amount to be provided to customers and reduce revenue recognized. We believe that there will not be significant changes to our estimates of variable consideration.

If a customer pays consideration, or the Company has a right to an amount of consideration that is unconditional before we transfer a good or service to the customer, those amounts are classified as contract liabilities which are included in other current liabilities when the payment is made or it is due, whichever is earlier.

Practical Expedients and Exemptions

In accordance with Accounting Standards Codification Topic 606, Revenue from Contracts with Customers, we use the following practical expedients: (i) not to adjust the promised amount of consideration for the effects of a significant financing component when we expect, at contract inception, that the period between our transfer of a promised product or service to a customer and when the customer pays for that product or service will be one year or less; (ii) to expense costs as incurred for costs to obtain a contract when the amortization period would have been one year or less; (iii) not to assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract with the customer. In addition, we do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less.

11

Table of Contents

WISA TECHNOLOGIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Three and Six Months Ended June 30, 2024 and 2023

(unaudited)

1.

Business and Summary of Significant Accounting Policies, continued

During the three months ended June 30, 2024 and 2023, net revenue consisted of the following:

    

For the Three Months Ended June 30,

    

For the Six Months Ended June 30, 

(in thousands)

2024

    

2023

2024

    

2023

Components

$

314

$

313

$

473

$

640

Consumer Audio Products

 

31

 

112

 

127

 

254

Total

$

345

$

425

$

600

$

894

Contract Balances

The Company receives payments from customers based on a billing schedule as established in our contracts to partially offset prepayments required by our vendors on long lead time materials. Amounts collected prior to the fulfillment of the performance obligation are considered contract liabilities and classified as customer advances within accrued liabilities on the consolidated balance sheets. Contract assets are recorded when the Company has a conditional right to consideration for our completed performance under the contracts. Accounts receivables are recorded when the right to this consideration becomes unconditional. The Company does not have any material contract assets as of June 30, 2024 and December 31, 2023. During the six month ended June 30, 2024, the Company did not recognize any revenue that was included in the contract liabilities balance as of December 31, 2023.

June 30, 

December 31, 

(in thousands)

    

2024

    

2023

Contract Liabilities

$

150

$

19

Revenue by Geographic Area

In general, revenue disaggregated by geography (See Note 10) is aligned according to the nature and economic characteristics of our business and provides meaningful disaggregation of our results of operations. Since we operate in one segment, all financial segment and product line information can be found in the condensed consolidated financial statements.

Stock-Based Compensation

The Company measures and recognizes the compensation expense for restricted stock units and restricted stock awards granted to employees and directors based on the fair value of the award on the grant date.

Restricted stock units give an employee an interest in Company stock but they have no tangible value until vesting is complete. Restricted stock units and restricted stock awards are equity classified and measured at the fair market value of the underlying stock at the grant date and recognized as expense over the related service or performance period. The Company elected to account for forfeitures as they occur. The fair value of stock awards is based on the quoted price of our common stock on the grant date. Compensation cost for restricted stock units and restricted stock awards is recognized using the straight-line method over the requisite service period.

12

Table of Contents

WISA TECHNOLOGIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Three and Six Months Ended June 30, 2024 and 2023

(unaudited)

1.

Business and Summary of Significant Accounting Policies, continued

Research and Development

Research and development costs are charged to operations as incurred and includes salaries, consulting expenses and an allocation of facility costs.

Advertising Costs

Advertising costs are charged to sales and marketing expenses as incurred. Advertising costs for the three and six months ended June 30, 2024 were $117,000 and $264,000, respectively. Advertising costs for the three and six months ended June 30,  2023 were $118,000 and $273,000, respectively.

Comprehensive Loss

Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may include certain changes in equity that are excluded from net loss. For the three and six months ended June 30, 2024 and 2023, the Company’s comprehensive loss is the same as its net loss.

Foreign Currency

The financial position and results of operations of the Company’s foreign operations are measured using currencies other than the U.S. dollar as their functional currencies. Accordingly, for these operations all assets and liabilities are translated into U.S. dollars at the current exchange rates as of the respective balance sheet date. Expense items are translated using the weighted average exchange rates prevailing during the period. Cumulative gains and losses from the translation of these operations’ financial statements are reported as a separate component of stockholders’ equity, while foreign currency transaction gains or losses, resulting from re-measuring local currency to the U.S. dollar are recorded in the condensed consolidated statement of operations in other income (expense), net and were not material for the three and six months ended June 30, 2024 and 2023.

Net Loss per Common Share

Basic and diluted net loss per common share is presented in conformity with the two-class method required for participating securities. The Company considers all series of convertible preferred stock to be participating securities. Under the two-class method, the net loss attributable to common stockholders is not allocated to the convertible preferred stock as the holders of the convertible preferred stock do not have a contractual obligation to share in the losses of the Company. Under the two-class method, net income would be attributed to common stockholders and participating securities based on their participation rights.

Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares and potentially dilutive common share equivalents outstanding for the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per common share calculation, Series A 8% Senior Convertible Preferred Stock (“Series A Preferred Stock”), warrants exercisable for common stock, restricted stock units and shares issuable upon the conversion of convertible notes payable are considered to be potentially dilutive securities. Net loss is adjusted for any deemed dividends to preferred stockholders to compute income available to common stockholders.

As of June 30, 2024, warrants to purchase 9,793,531 shares of common stock, 260,441 shares of restricted stock, 16 shares of restricted stock issued under an inducement grant and 14 shares underlying restricted stock units, have been excluded from the calculation of net loss per common share because the inclusion would be antidilutive.

As of June 30, 2023, warrants to purchase 37,572 shares of common stock, 69 shares of restricted stock, 18 shares of restricted stock issued under an inducement grant and 36 shares underlying restricted stock units have been excluded from the calculation of net loss per common share because the inclusion would be antidilutive.

13

Table of Contents

WISA TECHNOLOGIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Three and Six Months Ended June 30, 2024 and 2023

(unaudited)

1.Business and Summary of Significant Accounting Policies, continued

Income Taxes

Deferred taxes are provided on the liability method whereby deferred tax assets are recognized for deductible temporary differences, and operating loss and tax credit carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is “more-likely-than-not” that some portion or all of the deferred tax assets will not be realized. The Company has recognized valuation allowances against its deferred tax assets as of June 30, 2024 and December 31, 2023. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

The Company uses a comprehensive model for recognizing, measuring, presenting, and disclosing in the condensed consolidated financial statements tax positions taken or expected to be taken on a tax return. A tax position is recognized as a benefit only if it is “more-likely-than-not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more-likely-than-not” test, no tax benefit is recorded. The Company recognizes interest accrued and penalties related to unrecognized tax benefits in tax expense. As of June 30, 2024 and December 31, 2023, the Company recognized no interest and penalties.

Recently Adopted Accounting Pronouncements

In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06 “Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity.” This ASU simplifies accounting for convertible instruments by removing major separation models required under current U.S. GAAP. The Company adopted this standard on January 1, 2024 using the modified retrospective method by applying the ASU to financial instruments outstanding as of January 1, 2024, with the cumulative effect of adoption recognized at that date through an adjustment to the opening balance of retained earnings. As such, the Company adopted the standard by eliminating any unamortized discount to the Series B Preferred Stock for the beneficial conversion feature. The cumulative effect of ASU 2020-06 adoption adjusted against additional paid-in-capital due to the absence of retained earnings on January 1, 2024 amounted to $116,000.

Recently Issued and Not Yet Adopted Accounting Pronouncements

In December 2023, the FASB issued ASU 2023-09 – Income Taxes (Topic 740): Improvements to Income Tax Disclosures” to help investors better understand an entity’s exposure to potential changes in jurisdictional tax legislation and the ensuing risks and opportunities. Furthermore, the Update improves disclosures used to assess income tax information that affects cash flow forecasts and capital allocation decisions. The Update is effective for public business entities for annual periods beginning after December 15, 2024, on a prospective basis. The Company is currently evaluating the impact of the adoption of this standard on our condensed consolidated financial statements.

In November 2023, the FASB issued ASU 2023-07 “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,” aiming to enhance the transparency and relevance of segment information provided in financial statements. The amendments in this Update require that a public entity disclose significant segment expenses, profit or loss and assets, etc. for each reportable segment, on an annual and interim basis. The Update is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact of the adoption of this standard on our condensed consolidated financial statements.

We have reviewed other recent accounting pronouncements and concluded they are either not applicable to the business, or no material effect is expected on the condensed consolidated financial statements as a result of future adoption.

14

Table of Contents

WISA TECHNOLOGIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Three and Six Months Ended June 30, 2024 and 2023

(unaudited)

2.

Going Concern

The condensed consolidated financial statements of the Company have been prepared on a going concern basis, which contemplates the realization of assets and the discharge of liabilities in the normal course of business. As of June 30, 2024, the Company had cash and cash equivalents of $6.1 million and reported net cash used in operations of $9.0 million during the six months ended June 30, 2024. The Company expects operating losses to continue in the foreseeable future because of additional costs and expenses related to research and development activities, plans to expand its product portfolio, and increase its market share. The Company’s ability to attain profitable operations is dependent upon achieving a level of revenues adequate to support its cost structure.

Based on current operating levels, the Company will need to raise additional funds in the next 12 months by selling additional equity or incurring debt. To date, the Company has funded its operations primarily through sales of its securities in public and private markets, proceeds from the exercise of warrants to purchase common stock and the sale of convertible notes. Additionally, future capital requirements will depend on many factors, including the rate of revenue growth, the selling price of the Company’s products, the expansion of sales and marketing activities, the timing and extent of spending on research and development efforts and the continuing market acceptance of the Company’s products. These factors raise substantial doubt about the Company’s ability to continue as a going concern for the twelve months from the date of this Report.

Management of the Company intends to raise additional funds through the issuance of equity securities or debt. There can be no assurance that, in the event the Company requires additional financing, such financing will be available at terms acceptable to the Company, if at all. Failure to generate sufficient cash flows from operations, raise additional capital and reduce discretionary spending could have a material adverse effect on the Company’s ability to achieve its intended business objectives. As a result, the substantial doubt about the Company’s ability to continue as a going concern has not been alleviated. The accompanying condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

3.

Balance Sheet Components

Inventories (in thousands):

June 30, 

December 31, 

    

2024

    

2023

Raw materials

$

648

$

621

Work in progress

22

Finished goods

 

1,660

 

2,116

Total inventories

$

2,330

$

2,737

Note receivable:

On June 13, 2024, the Company entered into a Senior Secured Promissory Note and Security Agreement (“Promissory Note and Security Agreement”) with an unaffiliated third-party company (“the Borrower”). Pursuant to the Promissory Note and Security Agreement, the Company agreed to provide the Borrower with a term loan in the principal amount of $150,000 (“June 2024 Note”). The June 2024 Note matures on October 11, 2024. Borrowings under the June 2024 Note bear interest at a rate per annum equal to 5.12%. On the maturity date, subject to any extension, the Borrower will be obligated to make a payment equal to all unpaid principal and accrued interest. Note receivable is included in other assets on the condensed consolidated balance sheets. There was no note receivable at December 31, 2023.

15

Table of Contents

WISA TECHNOLOGIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Three and Six Months Ended June 30, 2024 and 2023

(unaudited)

3.Balance Sheet Components, continued

Property and equipment, net (in thousands):

June 30, 

December 31, 

    

2024

    

2023

Machinery and equipment

$

758

$

741

Tooling

 

14

 

11

 

772

 

752

Less: Accumulated depreciation and amortization

 

(707)

 

(659)

Property and equipment, net

$

65

$

93

Depreciation and amortization expense for the three months ended June 30, 2024 and 2023 were approximately of $28,000 and $32,000, respectively. Depreciation and amortization expense for the six months ended June 30, 2024 and 2023 were approximately  $48,000 and $65,000, respectively.

Accrued liabilities (in thousands):

June 30, 

December 31, 

    

2024

    

2023

Accrued vacation

$

448

$

418

Accrued audit fees

161

211

Accrued legal fees

158

Accrued rebate

151

215

Customer advance

150

19

Accrued compensation

 

130

 

127

Accrued lease liability, current portion

67

Accrued other

114

327

Total accrued liabilities

$

1,379

$

1,317

4.

Borrowings

Convertible Promissory Note

On August 15, 2022, the Company entered into a Securities Purchase Agreement (the “August Purchase Agreement”), by and between the Company and an institutional investor (the “Convertible Note Investor”), pursuant to which the Company agreed to issue to the Investor a senior secured convertible note in the principal amount of $3,600,000 (the “Convertible Note”) and a warrant to purchase up to 140 shares of the Company’s common stock, at an initial exercise price of $14,955.00 per share, in consideration for $3,000,000. Pursuant to the August Purchase Agreement, upon the closing of the private placement, pursuant to which Maxim Group LLC (“Maxim”) acted as placement agent (the “Private Placement”), the Company received gross proceeds of $3,000,000. After the deduction of banker fees, commitment fees and other expenses associated with the transaction, the Company received net proceeds of $2,483,000. The Company used the net proceeds primarily for working capital and general corporate purposes.

16

Table of Contents

WISA TECHNOLOGIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Three and Six Months Ended June 30, 2024 and 2023

(unaudited)

4.

Borrowings, continued

The Convertible Note matured on August 15, 2024, does not bear interest and ranks senior to the Company’s existing and future indebtedness and is secured to the extent and as provided in the Security Agreements. The Convertible Note is convertible in whole or in part at the option of the Convertible Note Investor into shares of Common stock (the “Conversion Shares”) at the Conversion Price (as defined below) at any time following the date of issuance of the Convertible Note. The Convertible Note defines “Conversion Price” as equal to the lesser of (a) 90% of the average of the five lowest daily VWAPs (as defined in the Convertible Note) during the previous twenty trading days prior to delivery to the Company of the Convertible Note Investor’s applicable notice of conversion and (b) $13,890.00 (the “Base Conversion Price”). The Base Conversion Price is subject to full ratchet antidilution protection, subject to a floor conversion price of $75.00 per share (the “Floor Price”).

In connection with the Private Placement, the Company issued warrants to the Convertible Note Investor and Maxim to purchase common shares of 140 and 13, respectively (see Note 5 – Fair Value Measurements). The sum of the fair value of the warrants, the original issue discount for interest, issuance costs and the derivative liability for the embedded conversion feature for the Convertible Note were recorded as debt discounts totaling $2,509,000 to be amortized to interest expense over the respective term using the effective interest method. During the year ended December 31, 2023, the Company recognized $737,000 of interest expense from the amortization of debt discounts and repayment of the convertible note payable in April 2023.

In connection with the Private Placement, the Company entered into a placement agency agreement with Maxim (the “Placement Agency Agreement”), and agreed to issue to Maxim, a warrant to purchase up to an aggregate of 13 shares of Common Stock (the “Maxim Warrant”) at an initial exercise price of $14,955.00 per share, which is exercisable at any time on or after the six-month anniversary of the closing date of the Private Placement and will expire on the fifth (5th) anniversary of its date of issuance.

Effective August 24, 2022, the Company and the Investor agreed to amend Section 3.1(b) of the Convertible Note to provide that the Conversion Price could not be lower than the Floor Price until stockholder approval has been obtained, after which stockholder approval the Floor Price may be reduced to no lower than $37.50, subject to adjustment pursuant to the terms of the Convertible Note. The changes were effected by cancellation of the Convertible Note and the issuance of a replacement senior secured convertible note (the “New Convertible Note”) to the Investor. The New Convertible Note contains identical terms as the Convertible Note, except for the amendment to the Section 3.1(b).

On November 21, 2022, the Company and Maxim entered into an agreement to amend the Maxim Warrant (the “Maxim Warrant Amendment”). Specifically, the Maxim Warrant Amendment sets forth certain circumstances in which the lock up restrictions to which the Maxim Warrant is subject would not apply. The Maxim Warrant Amendment also clarifies certain limitations with respect to demand registration rights and provides that Maxim’s piggy-back registration rights expire on the fifth (5th) anniversary of the Maxim Warrant’s date of issuance.

The New Convertible Note contained several embedded conversion features. The Company concluded that those conversion features require bifurcation from the New Convertible Note and subsequent accounting in the same manner as a freestanding derivative. The Company recognized a derivative liability of $286,000 upon execution of the note agreement and such amount was included in the $2,509,000 of debt discounts noted above. Subsequent changes in the fair value of these conversion features are measured at each reporting period and recognized in the consolidated statement of operations.

On November 28, 2022, the Company entered into a waiver of rights (the “Waiver”) with the New Convertible Note Investor, pursuant to which the New Convertible Note Investor agreed to waive certain prohibitions under the August Purchase Agreement with respect to the offering of units in December 2022 in exchange for the issuance by the Company, on the closing date of such offering, of an additional number of Series A warrants to purchase shares of Common Stock (“Series A Warrants”) and an additional number of Series B warrants to purchase shares of Common Stock (“Series B Warrants”) equal to the quotient obtained by dividing $750,000 by the public offering price for the units sold in the offering (such Warrants, the “Waiver Warrants”).

17

Table of Contents

WISA TECHNOLOGIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Three and Six Months Ended June 30, 2024 and 2023

(unaudited)

4.

Borrowings, continued

In connection with the public offering the Company consummated on December 1, 2022 (the “December 2022 Offering”), the Company issued 357 Series A Warrants and 357 Series B Warrants to the New Convertible Note Investor (See Note 6). The Company’s obligation to issue shares of common stock underlying the Waiver Warrants is expressly conditioned upon stockholder approval of all of the transactions contemplated by the August Purchase Agreement. At a Special Meeting of Stockholders held on January 24, 2023, the Company received stockholder approval of the transactions contemplated by the August Purchase Agreement. Additionally, as a result of the December 2022 Offering, the Base Conversion Price was adjusted to the Floor Price.

On February 1, 2023, the holder of the New Convertible Note converted approximately $708,000, a portion of the outstanding principal amount into 450 shares of the Company’s common stock.

On April 11, 2023, the Company paid $1,656,744 to the holder of the New Convertible Note which repaid the entirety of the outstanding balance and included the unpaid principal, interest through the payoff date, and a pre-payment premium of $276,000 which was recorded as a component of loss on debt extinguishment.

September 2023 Short-Term Loan Agreement

On September 8, 2023, the Company entered into that certain Loan and Security Agreement with the Meriwether Group Capital Hero Fund LP (“Meriwether Hero Fund”). Pursuant to the Loan and Security Agreement, the Meriwether Hero Fund agreed to provide the Company with bridge financing in the form of a term loan in the original principal amount of $650,000, which term loan will be senior in priority to the Company’s present and future indebtedness (“Meriwether Loan”). The Meriwether Loan was to mature on November 7, 2023, subject to further extension. In addition, the Company had the right to request additional funding under the Loan and Security Agreement.

Borrowings under the Meriwether Loan bore interest at a rate per annum equal to 18%. On the maturity date, subject to any extension, the Company was obligated to make a payment equal to all unpaid principal and accrued interest. Pursuant to Meriwether Loan, the Company was required to pay to the Meriwether Hero Fund a fully earned, non-refundable, origination fee in the amount of$50,000. The Company was also required to pay to the Meriwether Hero Fund a fully earned, non-refundable, exit fee in the amount of $50,000 due and payable on the maturity date.

The Meriwether Loan also provided that all present and future indebtedness and the obligations of the Company to the Meriwether Hero Fund shall be secured by a first priority security interest in all real and personal property collateral of the Company.

The Meriwether Loan contained customary representations, warranties and affirmative and negative covenants. In addition, the Meriwether Loan contained customary events of default that entitle the Meriwether Hero Fund to cause the Company’s indebtedness under the Meriwether Loan to become immediately due and payable, and to exercise remedies against the Company and the collateral securing the term loan.

On October 10, 2023, the Meriwether Hero Fund, agreed to extend the Meriwether Loan maturity date from November 7, 2023 to December 7, 2023, for a fee of $20,000.

On December 7, 2023, the Company repaid the full amount of the Meriwether Loan, including all fees and accrued interest.

January 2024 Short-Term Loan Agreement

On January 19, 2024, the Company issued promissory notes in the aggregate principal amount of $1,000,000 (the “January 2024 Promissory Notes”) and common stock purchase warrants to purchase up to an aggregate of 66,665 shares (the “January 2024 Warrant Shares”) of the Company’s common stock, at an initial exercise price of $22.23 per share with four accredited investors (each an “Investor” and together the “Investors”). In connection with the January 2024 Promissory Notes, the Company received gross proceeds of $600,000, before fees and other expenses associated with the transaction. 

18

Table of Contents

WISA TECHNOLOGIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Three and Six Months Ended June 30, 2024 and 2023

(unaudited)

4.

Borrowings, continued

The January 2024 Promissory Note was to mature on the earlier to occur of: (i) July 17, 2024 and (ii) the full or partial exercise of certain Series B Preferred Stock purchase warrants currently held by the Investor, issuable for at least 9,322 shares of the Company’s Series B Convertible Preferred Stock, par value $0.0001 per share (“Series B Preferred Stock”), upon such full or partial exercise. The January 2024 Promissory Notes did not bear interest except upon the occurrence of an Event of Default (as defined in the January 2024 Promissory Notes). The January 2024 Promissory Notes were not convertible into shares of Common Stock or Series B Preferred Stock.  

Between the dates of January 26, 2024 and February 2, 2024, the January 2024 Promissory Notes were repaid in full following the exercise of certain of the Company’s Series B Preferred Stock purchase warrants for a total of 29,322 shares of Series B Preferred Stock. The 2024 Promissory Notes were settled via the payment of $667,000 in cash and a $333,000 offset to the amount due by one of the investors from the exercise of 9,322 Series B Preferred Stock purchase warrants.

In connection with the issuance of the January 2024 Warrant Shares (see Note 5 – Fair Value Measurements), the fair value of the warrants and the original issue discount for interest were recorded as debt discounts totaling $1,260,000. The debt discounts were to be amortized to interest expense over the respective term using the effective interest method. In connection with the full repayment of the January 2024 Promissory Notes, the Company recognized $1,260,000 of interest expense in the six months ended June 30, 2024.

5.

Fair Value Measurements

The Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. Each level of input has different levels of subjectivity and difficulty involved in determining fair value.

Level 1 – Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date. Therefore, determining fair value for Level 1 investments generally does not require significant judgment, and the estimation is not difficult.
Level 2 – Pricing is provided by third-party sources of market information obtained through investment advisors. The Company does not adjust for or apply any additional assumptions or estimates to the pricing information received from its advisors.
Level 3 – Inputs used to measure fair value are unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions. The determination of fair value for Level 3 instruments involves the most management judgment and subjectivity. The Company’s financial assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2024 and December 31, 2023 by level within the fair value hierarchy, are as follows:

(in thousands)

June 30, 2024

Significant

Quoted prices

other

Significant

in active

observable

unobservable

markets

inputs

inputs

    

(Level 1)

    

(Level 2)

    

(Level 3)

Liabilities:

  

  

  

Warrant liabilities

$

$

$

25

19

Table of Contents

WISA TECHNOLOGIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Three and Six Months Ended June 30, 2024 and 2023

(unaudited)

5.Fair Value Measurements, continued

(in thousands)

December 31, 2023

Significant

Quoted prices

other

Significant

in active

observable

unobservable

markets

inputs

inputs

    

(Level 1)

    

(Level 2)

    

(Level 3)

Liabilities:

Warrant liabilities

$

$

$

5,460

There were no transfers between Level 1, 2 or 3 during the three and six months ended June 30, 2024 or 2023.

Warrant Liabilities

The following table includes a summary of changes in fair value of the Company’s warrant liabilities measured at fair value using significant unobservable inputs (Level 3) as of June 30, 2024 and 2023. For June 30, 2024, the fair value of the common warrants was determined using the Black-Scholes Model based on the following key inputs and assumptions: common stock price of $2.57; exercise prices between $3.196 and $1,574.00; expected yield of 0.0%; expected volatility of 143%; risk-free interest rate of 4.52% and expected life between 3.1 and 3.6 years.

During the three months ended June 30, 2024, the Company amended the terms of certain warrant agreements to remove certain exercise price reset, right to reprice and/or share adjustment provisions (“Reset Provisions”) following a reverse split, in addition to other revisions to the warrants. In April 2024, the Company effected the April 2024 Reverse Stock Split thereby removing the Reset Provisions (“Reset Amendment Effective Date”) and in accordance with provisions in certain of the warrants issued warrants to purchase an additional 5,602,693 shares of common stock. Accordingly, the Company remeasured the warrant liability for each of the amended warrants following the Reset Amendment Effective Date and recorded that amount to change in fair value of warrant liabilities with a corresponding increase to warrant liabilities. Following the Reset Amendment Effective Date, such warrants were no longer deemed to be liability warrants but were now classified as equity warrants. In connection with this reclassification the Company reclassed approximately $41.9 million from warrant liabilities to additional paid in capital.

For the six months ended June 30,

(in thousands)

    

2024

2023

Beginning balance

$

5,460

    

$

8,945

Additions

 

8,701

 

5,600

Change in fair value

 

29,126

 

(5,850)

Exercise of warrant liabilities

 

(587)

 

(8,191)

Repurchase

(824)

Conversion of liability warrants to equity warrants

(41,851)

Ending balance

$

25

$

504

The changes in fair value of the warrant liabilities are recorded in change in fair value of warrant liabilities in the condensed consolidated statements of operations.

20

Table of Contents

WISA TECHNOLOGIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Three and Six Months Ended June 30, 2024 and 2023

(unaudited)

6.

Convertible Redeemable Preferred Stock and Stockholders’ Equity

Series B Preferred Stock, Series B Preferred Stock Warrants

On October 16, 2023, the Company consummated a public offering for an aggregate of 87,000 Series B Units (“Series B Units”). Each Series B Unit consists of one share of the Company’s Series B Preferred Stock and two warrants, each to purchase one share of Series B Preferred Stock (“Series B Preferred Stock Warrant”). Each share of Series B Preferred Stock is convertible at the holder’s option at any time, through a two-year period, into the number of shares of the Company’s common stock determined by dividing the $100 stated value per share of the Series B Preferred Stock by a conversion price of $62.205 per share. Each share of Series B Preferred Stock is convertible into 1 share of common stock, and each Series B Preferred Stock Warrant entitles the holder to purchase one share of Series B Preferred Stock at an initial exercise price of $55 per share. Dividends are paid in additional fully paid and nonassessable Series B Preferred Stock, at a 20% dividend rate, non-cumulative. If any shares of Series B Preferred Stock are outstanding at the end of the two-year period, the holder would be entitled to a cash redemption value equal to the $100 stated value per share. The gross proceeds from the sale of Series B Units were $4,785,000, before broker fees and related expenses of approximately $830,000.

Exercise of Series B Preferred Stock Warrants

On December 5, 2023, the Company executed an Inducement Agreement (the “Inducement Agreement”) with the holders of Series B Preferred Stock Warrants, reducing the exercise price to $35.72 per share of Series B Preferred Stock. Any holder that exercised Series B Preferred Stock Warrants under the Inducement Agreement received a new Common Stock Warrant (“New Common Stock Warrants”) for each Series B Preferred Stock Warrant exercised. Each New Common Stock Warrant entitles the holder to purchase 2 shares of common stock at an initial exercise price of $22.23 per share.

Due to certain price protections included with the New Common Stock Warrants, the warrants did not meet the criteria for equity classification and thus are subject to liability treatment. Total proceeds from the exercise of 61,613 Series B Preferred Stock Warrants of $2,264,000 through December 31, 2023, and the remaining fair value of the Series B Preferred Stock Warrant liability immediately prior to the exercise of $1,628,000 resulted in a total of $3,892,000 recorded for the new 61,613 shares of Series B Preferred Stock, of which $3,322,000 was allocated to the Common Stock Warrants liability based on their fair value and $569,000 was allocated to the Series B Preferred Stock using the residual method of allocation. In connection with this new issuance, the Company has recorded additional discounts to the Series B Preferred Stock for a beneficial conversion feature of $196,000, the Common Stock Warrants of $3,322,000 and issuance costs of $146,000. The Company also accretes to Series B Preferred Stock, against additional paid in capital as a deemed dividend, for the difference between the total proceeds of $35.72 per share of Series B Preferred Stock and the full redemption price of $100 per share. The Company uses the effective interest method to calculate the accretion amount for each period. All 61,613 New Common Stock Warrants issued as a result of the exercise of Series B Preferred Stock Warrants were outstanding as of December 31, 2023.

Issuance costs of $429,000 and $125,000 were expensed on the date of issuance of the Series B Preferred Stock Warrants and the New Common Stock Warrants, respectively as such warrants were recorded at fair value. Total issuance costs expensed from the issuances were charged to Change in fair value of warrant liabilities and amounted to $554,000.

21

Table of Contents

WISA TECHNOLOGIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Three and Six Months Ended June 30, 2024 and 2023

(unaudited)

6.

Convertible Redeemable Preferred Stock and Stockholders’ Equity, continued

Through various dates from issuance to December 31, 2023, the holders of 110,278 shares of Series B Preferred Stock converted their shares into 177,282 shares of Common Stock. Unamortized discounts to the Series B Preferred Stock of $6,063,000 were immediately recorded as a deemed dividend as of conversion date. Amortization and accretion of discounts from issuance date through December 31, 2023 amounted to $297,000, which were also recorded as a deemed dividend to the holders of Series B Preferred Stock. The total such deemed dividends amounted to $6,360,000 for the year ended December 31, 2023 and was recorded as a net loss available to common stockholders on the Company’s consolidated statement of operations.

The 38,335 shares of Series B Preferred Stock outstanding as of December 31, 2023, were to become mandatorily redeemable on October 15, 2025 in the amount of $3,833,500.

Through various dates during the six months ended June 30, 2024, holders of Series B Preferred Stock Warrants exercised their warrants into 29,332 shares of Series B Preferred Stock at an exercise price of $35.72 per share. For each exercised Series B Preferred Stock Warrant, the holder received one share of Series B Preferred Stock and one New Common Stock Warrant. Each New Common Stock Warrant entitles the holder to purchase 2 shares of Common Stock at an initial exercise price of $22.23 per share. Due to certain price protections included with the New Common Stock Warrants, the warrants did not meet the criteria for equity classification and thus are subject to liability treatment. Total proceeds from the exercise of the 29,332 Series B Preferred Stock Warrants amounted to $1,047,000, and the remaining fair value of the Series B Preferred Stock Warrant Liability immediately prior to the exercise of $587,000 resulted in a total of $1,634,000 recorded for the new 29,332 shares of Series B Preferred Stock, of which $1,188,000 was allocated to the New Common Stock Warrants liability based on their fair value and $446,000 was allocated to the Series B Preferred Stock using the residual method of allocation. In connection with this new issuance, the Company recorded additional discounts to the Series B Preferred Stock for the New Common Stock Warrants of $1,188,000 and issuance costs of $61,000. The Company also accretes to Series B Preferred Stock, against additional paid-in-capital as a deemed dividend, for the difference between the total proceeds of $35.72 per share of Series B Preferred Stock and the full redemption price of $100 per share. The Company uses the effective interest method to calculate the accretion amount for each period.

Issuance costs of $44,000 were expensed on the date of issuance of the New Common Stock Warrants, as such warrants were recorded at fair value.

Conversion of Series B Preferred Stock

Through various dates during the six months ended June 30, 2024, the holders of 5,000 shares of Series B Preferred Stock converted their shares into 8,038 shares of Common Stock. Unamortized discounts to the Series B Preferred Stock of $269,000 were immediately recorded as a deemed dividend as of conversion date.

February 2024 Series B Preferred Stock and Series B Preferred Stock Warrants Repurchase

On February 13, 2024, the Company and its Series B Preferred Stock and Series B Preferred Stock Warrants holders entered into an arrangement where the Company agreed to repurchase 62,657 Series B Preferred Stock shares and 81,315 Series B Preferred Stock warrants for a total of $6,266,000. Unamortized discounts to the Series B Preferred Stock of $5,381,000 were immediately recorded as a deemed dividend as of repurchase date. The remaining fair value of the Series B Preferred Stock Warrant Liability of $824,000 was adjusted against additional paid-in-capital on repurchase date.

Other Deemed Dividends

Amortization and accretion of discounts for all Series B Preferred Stock during the six months ended June 30, 2024 amounted to $192,000, which were also recorded as a deemed dividend to the holders of Series B Preferred Stock.

The total of deemed dividends (as discussed in this section, the Conversion of Series B Preferred Stock and February 2024 Series B Preferred Stock and Series B Preferred Stock Warrants Repurchase sections above) amounted to $5,842,000 for the six months ended June 30, 2024 and was recorded as an adjustment to net loss available to common stockholders on the Company’s condensed consolidated statement of operations.

22

Table of Contents

WISA TECHNOLOGIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Three and Six Months Ended June 30, 2024 and 2023

(unaudited)

6.

Convertible Redeemable Preferred Stock and Stockholders’ Equity, continued

Common Stock

2018 Long Term Stock Incentive Plan

On January 30, 2018, the Company’s board of directors approved the establishment of the Company’s 2018 Long-Term Stock Incentive Plan (the “LTIP”) and termination of its Carve-Out Plan. Under the LTIP, the aggregate maximum number of shares of common stock (including shares underlying options) that may be issued under the LTIP pursuant to awards of Restricted Shares or Options will be limited to 15% of the outstanding shares of common stock, which calculation shall be made on the first trading day of each new fiscal year; provided that, in any year no more than 8% of the common stock or derivative securitization with common stock underlying 8% of the common stock may be issued in any fiscal year. At a Special Meeting of Stockholders on January 24, 2023, the Company’s stockholders approved certain amendments to the LTIP to: (i) increase the annual share limit of Common Stock that may be issued in any single fiscal year only for the 2023 fiscal year under the LTIP from 8% of the shares of Common Stock outstanding to 15% of the shares of Common Stock outstanding (which amount equates to the maximum amount that may be issued in the aggregate under the LTIP), and (ii) permit immediately quarterly calculations based on the number of shares of Common Stock outstanding as of the first trading day of each fiscal quarter, rather than solely as of the first trading day of the fiscal year. At a Special Meeting of Stockholders on March 15, 2024, the Company’s stockholders further approved an amendment to the LTIP to increase the annual share limit of Common Stock that may be issued only for the 2024 fiscal year under the LTIP from 8% of the shares of Common Stock outstanding to 15% of the shares of Common Stock outstanding (which amount equates to the maximum amount that may be issued in the aggregate under the LTIP). As of June 30, 2024, up to 477,774 shares of common stock are available for grants to participants under the LTIP.

A summary of activity related to restricted stock awards for the six months ended June 30, 2024 is presented below:

    

    

Weighted-Average 

Stock Awards

Shares

Grant Date Fair Value

Non-vested as of January 1, 2024

5,382

$

374.00

Granted

 

255,915

$

2.64

Vested

 

(774)

$

674.09

Forfeited

 

(82)

$

681.69

Non-vested as of June 30, 2024

 

260,441

$

9.22

As of June 30, 2024, the unamortized compensation costs related to the unvested restricted stock awards was approximately $1,620,000 which is to be amortized on a straight-line basis over a weighted-average period of approximately 2 years.

For the six months ended June 30, 2024, 774 shares of common stock were issued upon vesting of outstanding restricted stock, pursuant to the LTIP with an intrinsic value of less than $2,000. For the six months ended June 30, 2023, 24 shares of common stock were issued upon vesting of outstanding restricted stock, pursuant to the LTIP with an intrinsic value of less than $5,000.

23

Table of Contents

WISA TECHNOLOGIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Three and Six Months Ended June 30, 2024 and 2023

(unaudited)

6.

Convertible Redeemable Preferred Stock and Stockholders’ Equity, continued

2020 Stock Incentive Plan

A summary June 30, 2024 is presented below:

Weighted-Average 

Stock Units

    

Shares

    

Grant Date Fair Value

Non-vested as of January 1, 2024

 

1

$

56,430.00

Granted

 

$

Vested

 

(1)

$

56,430.00

Forfeited

 

$

Non-vested as of June 30, 2024

 

$

As of June 30, 2024, there was no unamortized compensation costs.

For the six months ended June 30, 2024, 1 share of common stock was issued upon vesting of outstanding restricted stock units pursuant to the 2020 Stock Incentive Plan with an intrinsic value of less than $1,000. For the six months ended June 30, 2023, no shares of common stock, issued under the 2020 Stock Incentive Plan, were released.

Inducement Grant

On September 13, 2021, the Company issued 21 shares of restricted common stock to Eric Almgren, the Company’s Chief Strategist, as an inducement grant (“September 2021 Inducement Grant”). As of June 30, 2024, the unamortized compensation cost related to the unvested September 2021 Inducement Grant was approximately $57,000 which is being amortized on a straight-line basis over a period of approximately 0.2 years. The Company recorded stock-based compensation of $64,000 and $128,000 related to this grant for three and six months ended June 30, 2024. As of June 30, 2024, 16 shares are unvested.

For the six months ended June 30, 2024, no shares of restricted stock were released under the September 2021 Inducement Grant.

2022 Plan

A summary of activity related to restricted stock units under the Company’s Technical Team Retention Plan of 2022 (the “2022 Plan”) for the six months ended June 30, 2024 is presented below:

Weighted-Average

Stock Units

    

Shares

    

Grant Date Fair Value

Non-vested as of January 1, 2024

 

17

$

7,800.00

Granted

 

$

Vested

 

(3)

$

7,800.00

Forfeited

 

$

Non-vested as of June 30, 2024

 

14

$

7,800.00

As of June 30, 2024, the unamortized compensation cost related to the unvested restricted stock units was approximately $94,000 which is to be amortized on a straight-line basis over a weighted-average period of approximately 2 years.

For the six months ended June 30, 2024, 3 shares of common stock were issued upon vesting of outstanding restricted stock units pursuant to the 2022 Plan with an intrinsic value of less than $1,000. For the six months ended June 30, 2023, no shares of common stock, issued under the 2022 Plan, were released.

24

Table of Contents

WISA TECHNOLOGIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Three and Six Months Ended June 30, 2024 and 2023

(unaudited)

6.

Convertible Redeemable Preferred Stock and Stockholders’ Equity, continued

February 2023 Offering

On January 31, 2023, the Company entered into a securities purchase agreement with certain institutional investors, pursuant to which the Company agreed to issue and sell to such investors (i) in a registered direct offering, 1,344 shares of common stock and pre-funded warrants (the “February 2023 Pre-Funded Warrants”) to purchase up to 2,545 shares of common stock, at an exercise price of $0.015 per share of common stock, and (ii) in a concurrent private placement, common stock purchase warrants, exercisable for an aggregate of up to 5,833 shares of common stock, at an initial exercise price of $1,573.50 per share of common stock (the “February 2023 Offering”). In February and March of 2023, all the February 2023 Pre-Funded Warrants were exercised for cash.

On February 3, 2023, the Company closed the February 2023 Offering, and received net proceeds of approximately $5.3 million after deducting placement agent fees and other offering expenses payable by the Company.

Also, in connection with the February 2023 Offering, on January 31, 2023, the Company entered into a placement agency agreement with Maxim, pursuant to which Maxim agreed to act as placement agent on a “best efforts” basis in connection with the offering and (ii) the Company agreed to pay Maxim an aggregate fee equal to 8.0% of the gross proceeds raised in the offering.

March 2023 Offering

On March 27, 2023, the Company entered into a securities purchase agreement with certain institutional investors, pursuant to which the Company agreed to issue and sell to such investors (i) in a registered direct offering, 5,581 shares of common stock of the Company and (ii) in a concurrent private placement, common stock purchase warrants, exercisable for an aggregate of up to 11,163 shares of common stock, at an initial exercise price of $286.50 per share (the “March 2023 Offering”).

On March 29, 2023, the Company closed the March 2023 Offering and received net proceeds of approximately $1.6 million, after deducting fees payable to the financial advisor and other offering expenses.

April 2023 Offering

On April 7, 2023, the Company entered into a securities purchase agreement with certain institutional investors, pursuant to which the Company issued and sold to such investors (i) in a registered direct offering, 4,954 shares of common stock of the Company and (ii) in a concurrent private placement, common stock purchase warrants exercisable for an aggregate of up to 9,908 shares of Common Stock, at an initial exercise price of $211.50 per share of Common Stock (the “April 2023 Offering”).

On April 12, 2023, the Company closed the April 2023 Offering and received net proceeds of approximately $1.0 million, after deducting fees payable to the financial advisor and other offering expenses.

October 2023 Warrant Repurchase

On October 16, 2023, the Company and certain of its common stock warrants holders entered into an arrangement where the Company agreed to repurchase outstanding common stock purchase warrants exercisable for an aggregate of up to 30,978 shares of Common Stock, at an exercise prices ranging from $193.50 to $286.50 per share of Common Stock for a total of $2,323,000. The repurchased warrants were previously classified as equity warrants and at the date of repurchase a charge was recorded to additional paid-in capital.

25

Table of Contents

WISA TECHNOLOGIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Three and Six Months Ended June 30, 2024 and 2023

(unaudited)

6.

Convertible Redeemable Preferred Stock and Stockholders’ Equity, continued

February 2024 Issuance of Common Stock and Pre-Funded Common Stock Warrants

On February 13, 2024, the Company consummated a public offering (the “February Public Offering”) of 158,227 units (the “February Units”) and 867,373 pre-funded units (the “February Pre-Funded Units”). Each February Unit was issued at $9.75 per unit and included one share of common stock and one common stock warrant (the “February Common Warrants”) exercisable for one share of common stock at a $9.75 exercise price. Each February Pre-Funded Unit was issued at $9.735 per unit and included one pre-funded common stock warrant (the “February Pre-Funded Warrants”), exercisable for one share of common stock at an initial exercise price of $0.015 and one February Common Warrant. The gross proceeds from the issuance of the February Units and the February Pre-Funded Units were $1,543,000 and $8,444,000, respectively, for total aggregate proceeds of $9,987,000 before broker fees and related expenses of approximately $998,000. As a result of certain price protection clauses, the February Common Warrants did not meet the criteria for equity classification and thus are subject to liability treatment. Accordingly, of the $9,987,000 gross proceeds from the February public offering, an amount of $6,308,000, representing the fair value of the February Common Warrants as of the issuance date was allocated to the February Common Warrants liability, with the residual proceeds of $3,679,000 allocated to the Common Stock and February Pre-Funded Warrants, which met the criteria for equity classification.

Of the gross broker fees and related expenses of approximately $998,000, the Company allocated $368,000 to the issued Common Stock and February Pre-Funded Warrants, which were recorded as a reduction of additional paid-in-capital. The remaining issuance cost of $630,000 was allocated to the February Common Warrants and was expensed on the date of issuance as such warrants were recorded at fair value.

March 2024 Issuance of Common Stock, Prefunded Common Stock Warrants and Common Stock Warrants

On March 26, 2024, the Company entered into a Securities Purchase Agreement with certain purchasers where the Company issued 417,833 shares of common stock, 93,342 pre-funded common stock warrants (the “March Pre-Funded Warrants”) and common stock warrants (the “March Common Warrants”) to purchase up to 511,175 shares of common stock at an initial exercise price of $6.00 per share (known in aggregate as the “March 2024 Offering”). Total proceeds per the Securities Purchase Agreement amounted to $2,299,000 before broker fees and other related expenses of approximately $388,000. As a result of certain price protection clauses, the March Common Warrants did not meet the criteria for equity classification and thus are subject to liability treatment. Accordingly, of the $2,299,000 gross proceeds from the March public offering, an amount of $1,227,000, representing the fair value of the March Common Warrants as of the issuance date was allocated to the March Common Warrants liability, with the residual proceeds of $1,072,000 allocated to the Common Stock and March Pre-Funded Warrants, which met the criteria for equity classification.

Of the gross broker fees and related expenses of approximately $388,000, the Company allocated $181,000 to the issued Common Stock and the March Pre-Funded Warrants, which were recorded as a reduction of additional paid-in-capital. The remaining issuance cost of $207,000 was allocated to the March Common Warrants and was expensed on the date of issuance as such warrants were recorded at fair value.

April 2024 Issuances of Common Stock and Common Stock Warrants

On April 17, 2024, the Company entered into a securities purchase agreement with certain accredited investors, pursuant to which the Company agreed to issue and sell to such investors (i) in a registered direct offering, 225,834 shares of common stock at $3.321 per share, and (ii) in a concurrent private placement, common stock purchase warrants exercisable for an aggregate of up to 225,834 shares of common stock, at an initial exercise price of $3.196 per share (the “Initial April 2024 Registered Direct Offering and Concurrent Private Placement”). The Initial 2024 Registered Direct Offering and Concurrent Private Placement closed on April 19, 2024 and the Company received gross proceeds of approximately $750,000 before deducting placement agent fees and other offering expenses of approximately $159,000.

26

Table of Contents

WISA TECHNOLOGIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Three and Six Months Ended June 30, 2024 and 2023

(unaudited)

6.

Convertible Redeemable Preferred Stock and Stockholders’ Equity, continued

On April 19, 2024, the Company entered into a securities purchase agreement with certain accredited investors, pursuant to which the Company agreed to issue and sell to such investors (i) in a registered direct offering, 361,904 shares of common stock at $5.25 per share, and (ii) in a concurrent private placement, common stock purchase warrants exercisable for an aggregate of up to 542,856 shares of common stock, at an initial exercise price of $5.06 per share (the “Second April 2024 Registered Direct Offering and Concurrent Private Placement”). The Second 2024 Registered Direct Offering and Concurrent Private Placement closed on April 23, 2024 and the Company received gross proceeds of approximately $1.9 million before deducting placement agent fees and other offering expenses of approximately $268,000.

On April 26, 2024, the Company entered into a securities purchase agreement with certain accredited investors, pursuant to which the Company agreed to issue and sell to such investors (i) in a registered direct offering, 418,845 shares of common stock at $5.73 per share, and (ii) in a concurrent private placement, common stock purchase warrants exercisable for an aggregate of up to 418,845 shares of common stock, at an initial exercise price of $5.60 per share (the “Third April 2024 Registered Direct Offering and Concurrent Private Placement”). The Third 2024 Registered Direct Offering and Concurrent Private Placement closed on April 30, 2024 and the Company received gross proceeds of approximately $2.4 million before deducting placement agent fees and other offering expenses of approximately $298,000.

May 2024 Issuances of Common Stock and Common Stock Warrants

On May 13, 2024, the Company entered into a securities purchase agreement with certain accredited investors, pursuant to which the Company agreed to issue and sell to such investors (i) in a registered direct offering, 785,000 shares of common stock at $3.31 per share, and (ii) in a concurrent private placement, common stock purchase warrants exercisable for an aggregate of up to 785,000 shares of common stock, at an initial exercise price of $3.18 per share (the “Initial May 2024 Registered Direct Offering and Concurrent Private Placement”). The Initial May 2024 Registered Direct Offering and Concurrent Private Placement closed on May 15, 2024 and the Company received gross proceeds of approximately $2.6 million before deducting placement agent fees and other offering expenses of approximately $314,000.

On May 15, 2024, the Company entered into a securities purchase agreement with certain accredited investors, pursuant to which the Company agreed to issue and sell to such investors (i) in a registered direct offering, 675,000 shares of common stock at $3.61 per share, and (ii) in a concurrent private placement, common stock purchase warrants exercisable for an aggregate of up to 675,000 shares of common stock, at an initial exercise price of $3.48 per share (the “Second May 2024 Registered Direct Offering and Concurrent Private Placement”). The Second May 2024 Registered Direct Offering and Concurrent Private Placement closed on May 17, 2024 and the Company received gross proceeds of approximately $2.4 million before deducting placement agent fees and other offering expenses of approximately $290,000.

For the three months ended June 30, 2024, the Company’s board of directors approved the issuance of a total of 136,203 shares of common stock to two vendors for investor relations services. The fair value of such common shares was calculated to be $360,000 and was recorded to other assets and additional paid in capital. The fair value of such shares will be amortized over the service period of each agreement which ranged from 6 months to 12 months. The shares of common stock will be issued in July 2024.

Warrants for Shares of Common Stock

A summary of the warrant activity and related information for the six months ended June 30, 2024 and the year ended 2023 is provided as follows.

In connection with February 2023 Offering, the Company issued common stock purchase warrants to investors to purchase up to 5,833 shares of the Company’s common stock, at an initial exercise price of $1,573.50 per share. The grant date fair value of such warrants was $5,600,000, which was recorded as a liability with the offset recorded to additional paid-in capital on the condensed consolidated balance sheets. The fair value of such warrants was determined using the Black-Scholes Model based on the following weighted average assumption: common stock price on the date of grant of $1,335.00; expected yield of 0.0%; expected volatility of 96%; risk-free interest rate of 3.67% and expected life of 5 years.

27

Table of Contents

WISA TECHNOLOGIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Three and Six Months Ended June 30, 2024 and 2023

(unaudited)

6.

Convertible Redeemable Preferred Stock and Stockholders’ Equity, continued

In connection with March 2023 Offering, the Company issued common stock purchase warrants to investors to purchase up to 11,163 shares of the Company’s common stock, at an initial exercise price of $286.50 per share. The grant date fair value of such warrant was $2,113,000, which was recorded as equity. The fair value of such warrants was determined using the Black-Scholes Model based on the following weighted average assumption: common stock price on the date of grant of $249.00; expected yield of 0.0%; expected volatility of 104%; risk-free interest rate of 3.67% and expected life of 5 years.

May 2023 Warrant Inducement

On May 15, 2023, the Company entered into warrant exercise inducement offer letters with the holders of common stock purchase warrants exercisable for an aggregate of up to 9,907 shares of common stock at an initial exercise price of $211.50 per share issued on April 12, 2023 (the “April Warrants”). The April Warrant holders agreed to exercise for cash April Warrants to purchase up to 9,907 shares of common stock in exchange for the Company’s agreement to issue 19,815 new warrants (the “May Inducement Warrants”) on substantially the same terms as the April Warrants. The Company received net proceeds of approximately $1.9 million from the exercise of the April Warrants. Each May Inducement Warrant is exercisable at a price per share of common stock of $199.50, which was equal to the Minimum Price (as defined by the Nasdaq Listing Rules).

Each May Inducement Warrant is immediately exercisable upon issuance and will expire on the fifth anniversary of its issuance. The exercise price of the May Inducement Warrants is subject to appropriate adjustment in the event of recapitalization events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting the Company’s common stock. The May Inducement Warrants are callable by the Company at a redemption price of $75.00 per May Inducement Warrant, provided that the resale of the shares of common stock underlying the May Inducement Warrants are then registered or may be resold under Rule 144 under the Securities Act.

July 2023 Warrant Inducement

On July 26, 2023, the Company entered into warrant exercise inducement offer letters (the “July Inducement Letters”) with holders of the May Inducement Warrants pursuant to which the Company agreed to issue new inducement warrants (the “July Inducement Warrants”) to purchase a number of shares of Common Stock equal to 100% of the number of shares of Common Stock received upon exercise of the May Inducement Warrants during the period provided for in the July Inducement Letters, with such July Inducement Warrants to be issued on substantially the same terms as the May Inducement Warrants. The holders exercised 3,400 May Inducement Warrants pursuant to certain of the July Inducement Letters, and the Company received aggregate gross proceeds of approximately $678,000 from such exercises. In exchange for the exercises of the May Inducement Warrants, the Company issued July Inducement Warrants exercisable for an aggregate of up to 3,400 shares of common stock at an initial exercise price of $193.50 per share. The inducement offering period closed at 5:00 p.m. EDT on August 8, 2023.

28

Table of Contents

WISA TECHNOLOGIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Three and Six Months Ended June 30, 2024 and 2023

(unaudited)

6.

Convertible Redeemable Preferred Stock and Stockholders’ Equity, continued

Each July Inducement Warrant was immediately exercisable upon issuance and will expire on the fifth anniversary of its issuance. The exercise price of the July Inducement Warrants is subject to appropriate adjustment in the event of recapitalization events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting the Company’s common stock. The July Inducement Warrants are callable by the Company at a redemption price of $75.00 per July Inducement Warrant, provided that the resale of the shares of common stock underlying the July Inducement Warrants are then registered or may be resold under Rule 144 under the Securities Act.

During the three months ended March 31, 2023, 18 warrants to purchase common stock were exercised for cash, resulting in proceeds of approximately $32,000. In addition, during the three months ended March 31, 2023, 7,454 warrants were exercised using an alternative cashless exercise provision, resulting in the issuance 5,705 shares of common stock.

In connection with the January 2024 Promissory Notes, the Company issued common stock purchase warrants to investors to purchase up to 66,665 shares of the Company’s common stock, at an initial exercise price of $22.23 per share. The grant date fair value of such warrant was $860,000, which was recorded as a liability with the offset recorded to additional paid-in capital on the condensed consolidated balance sheets. The fair value of such warrants was determined using the Black-Scholes Model based on the following weighted average assumption: common stock price on the date of grant of $15.99; expected yield of 0.0%; expected volatility of 119%; risk-free interest rate of 4.31% and expected life of 5 years.

In connection with February Public Offering, the Company issued common stock purchase warrants to investors to purchase up to 1,025,600 shares of the Company’s common stock, at an initial exercise price of $9.75 per share. The grant date fair value of such warrant was $6,308,000, which was recorded as a liability with the offset recorded to additional paid-in capital on the condensed consolidated balance sheets. The fair value of such warrants was determined using the Black-Scholes Model based on the following weighted average assumption: common stock price on the date of grant of $7.62; expected yield of 0.0%; expected volatility of 119%; risk-free interest rate of 4.31% and expected life of 5 years.

In connection with March 2024 Offering, the Company issued common stock purchase warrants to investors to purchase up to 511,175 shares of the Company’s common stock, at an initial exercise price of $6.00 per share. The grant date fair value of such warrant was $1,227,000, which was recorded as a liability with the offset recorded to additional paid-in capital on the condensed consolidated balance sheets. The fair value of such warrants was determined using the Black-Scholes Model based on the following weighted average assumption: common stock price on the date of grant of $3.18; expected yield of 0.0%; expected volatility of 119%; risk-free interest rate of 4.21% and expected life of 5 years.

On March 26, 2024, the Company entered into a warrant amendment agreement (the “Warrant Amendment Agreement”) with certain holders of (i) the New Common Stock Warrants, (ii) the common stock purchase warrants dated January 23, 2024 (the “January 2024 Warrants”), and (iii) the February Common Warrants (together with the New Common Stock Warrants and the January 2024 Warrants, the “Original Warrants”), whereby the holders agreed to (i) amend the New Common Stock Warrants and the January 2024 Warrants so such warrants shall not be exercisable until one or more certificates of amendment to the Company’s certificate of incorporation, as amended, are filed with the Secretary of State of the State of Delaware to effectuate an increase in authorized shares of capital stock of the Company and a reverse stock split of the Company’s outstanding shares of common stock; and (ii) remove certain exercise price reset, right to reprice and/or share adjustment provisions in the Original Warrants, to be effective following the first adjustments following the April 2024 Reverse Stock Split.

In connection with the Initial April 2024 Registered Direct Offering and Concurrent Private Placement, the Company issued Common Stock Purchase Warrants to investors to purchase up to 225,834 shares of the Company’s common stock, at an initial exercise price of $3.196 per share. The grant date fair value of such warrant was $1,255,000, which was recorded as equity. The fair value of such warrants was determined using the Black-Scholes Model based on the following weighted average assumption: common stock price on the date of grant of $6.06; expected yield of 0.0%; expected volatility of 135%; risk-free interest rate of 4.63% and expected life of 5 years.

29

Table of Contents

WISA TECHNOLOGIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Three and Six Months Ended June 30, 2024 and 2023

(unaudited)

6.

Convertible Redeemable Preferred Stock and Stockholders’ Equity, continued

In connection with the Second April 2024 Registered Direct Offering and Concurrent Private Placement, the Company issued Common Stock Purchase Warrants to investors to purchase up to 542,856 shares of the Company’s common stock, at an initial exercise price of $5.06 per share. The grant date fair value of such warrant was $2,595,000, which was recorded as equity. The fair value of such warrants was determined using the Black-Scholes Model based on the following weighted average assumption: common stock price on the date of grant of $5.39; expected yield of 0.0%; expected volatility of 135%; risk-free interest rate of 4.63% and expected life of 5 years.

In connection with the Third April 2024 Registered Direct Offering and Concurrent Private Placement, the Company issued Common Stock Purchase Warrants to investors to purchase up to 418,845 shares of the Company’s common stock, at an initial exercise price of $5.60 per share. The grant date fair value of such warrant was $2,048,000, which was recorded as equity. The fair value of such warrants was determined using the Black-Scholes Model based on the following weighted average assumption: common stock price on the date of grant of $5.54; expected yield of 0.0%; expected volatility of 135%; risk-free interest rate of 4.63% and expected life of 5 years.

In connection with the Initial May 2024 Registered Direct Offering and Concurrent Private Placement, the Company issued Common Stock Purchase Warrants to investors to purchase up to 785,000 shares of the Company’s common stock, at an initial exercise price of $3.18 per share. The grant date fair value of such warrant was $2,453,000, which was recorded as equity. The fair value of such warrants was determined using the Black-Scholes Model based on the following weighted average assumption: common stock price on the date of grant of $3.50; expected yield of 0.0%; expected volatility of 137%; risk-free interest rate of 4.35% and expected life of 5 years.

In connection with the Second May 2024 Registered Direct Offering and Concurrent Private Placement, the Company issued Common Stock Purchase Warrants to investors to purchase up to 675,000 shares of the Company’s common stock, at an initial exercise price of $3.48 per share. The grant date fair value of such warrant was $1,944,000, which was recorded as equity. The fair value of such warrants was determined using the Black-Scholes Model based on the following weighted average assumption: common stock price on the date of grant of $3.26; expected yield of 0%; expected volatility of 137%; risk-free interest rate of 4.35% and expected life of 5 years.

During the three months ended June 30, 2024, 438,611 warrants, including pre-funded warrants, to purchase common stock were exercised for cash, resulting in net proceeds of approximately $556,000. In addition, during the three months ended June 30, 2024, 3,225 warrants were exercised using an alternative cashless exercise provision, resulting in the issuance 3,211 shares of common stock. During the three months ended June 30, 2023, 1,486,132 warrants to purchase common stock were exercised for cash, resulting in net proceeds of approximately $1,895,000. In addition, during the three months ended June 30, 2023, 17,143 warrants were exercised using an alternative cashless exercise provision, resulting in the issuance 12,856 shares of common stock.

Information regarding warrants for common stock outstanding and exercisable as of June 30, 2024 is as follows:

Warrants

Weighted Average

Warrants

Exercise

Outstanding as of

Remaining

Exercisable as of

Price

    

June 30, 2024

    

Life (years)

    

June 30, 2024

$0.015 - $3.48

 

8,832,641

 

4.9

 

1,693,173

$5.06 - $6.00

 

954,827

 

4.8

 

954,827

$1,574.00

 

5,831

 

3.6

 

5,831

$14,995.00

 

12

 

3.1

 

12

$22,800 - $393,000

 

220

 

1.1

 

219

$4.45 *

 

9,793,531

 

4.9

 

2,654,062

*Weighted average

30

Table of Contents

WISA TECHNOLOGIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Three and Six Months Ended June 30, 2024 and 2023

(unaudited)

6.Convertible Redeemable Preferred Stock and Stockholders’ Equity, continued

Warrants exercisable as of June 30, 2024 exclude warrants to purchase 7,139,469 shares of common stock issued to investors that participated in the February Public Offering and March 2024 Offering that require shareholder approval prior to the warrants being exercisable.

Information regarding warrants for common stock outstanding and exercisable as of December 31, 2023 is as follows:

    

Warrants

    

Weighted Average

    

Warrants

Exercise

Outstanding as of

Remaining

Exercisable as of

Price

December 31, 2023

Life (years)

December 31, 2023

$22.50

 

188,025

 

4.9

 

467

$1,573.50

 

5,833

 

4.1

 

5,833

$14,955.00

 

13

 

3.6

 

13

$22,800.00

 

3

 

3.0

 

3

$30,000- $654,000

 

239

 

1.6

 

239

$135.00 *

 

194,113

 

4.9

 

6,555

*Weighted Average

Warrants exercisable as of December 31, 2023 exclude warrants to purchase 1 shares of common stock issued to a marketing firm, which vest upon the achievement of certain milestones and warrants to purchase 187,557 shares of common stock issued to investors that participated in the Inducement Agreement that requires shareholder approval prior to the warrants being exercisable.

7.

Income Taxes

The Company recorded no provision for income taxes for the three and six months ended June 30, 2024. The Company recorded a provision for income taxes of $2,000 and $2,000 for the three and six months ended June 30, 2023, respectively.

The Company’s effective tax rate was 0.0% for the three and six months ended June 30, 2024 and 2023. The difference between the effective tax rate and the federal statutory tax rate for the three and six months ended June 30, 2024 and 2023 primarily relates to the valuation allowance on the Company’s deferred tax assets.

For interim periods, the Company estimates its annual effective income tax rate and applies the estimated rate to the year-to-date income or loss before income taxes. The Company also computes the tax provision or benefit related to items reported separately and recognizes the items net of their related tax effect in the interim periods in which they occur. The Company also recognizes the effect of changes in enacted tax laws or rates in the interim periods in which the changes occur.

As of June 30, 2024 and December 31, 2023, the Company retains a full valuation allowance on its deferred tax assets. The realization of the Company’s deferred tax assets depends primarily on its ability to generate taxable income in future periods. The amount of deferred tax assets considered realizable in future periods may change as management continues to reassess the underlying factors it uses in estimating future taxable income.

The provision for income taxes for the three and six months ended June 30, 2024 and 2023 was calculated on a jurisdiction basis.

31

Table of Contents

WISA TECHNOLOGIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Three and Six Months Ended June 30, 2024 and 2023

(unaudited)

8.

Commitments and Contingencies

Operating Leases

The Company leases office space under a non-cancellable operating lease that expires in January 2024 and has an option to renew this lease, with renewal rates to be negotiated. Operating lease rentals are expensed on a straight-line basis over the life of the lease beginning on the date we take possession of the property. At lease inception, we determine the lease term by assuming the exercise of those renewal options that are reasonably assured. The exercise of lease renewal options is at our sole discretion. The lease term is used to determine whether a lease is financing or operating and is used to calculate straight-line rent expense. Additionally, the depreciable life of leasehold improvements is limited by the expected lease term. Leases with an initial term of 12 months or less are not recorded on the condensed consolidated balance sheet; we recognize lease expense for these leases on a straight-line basis over the lease term.

The following table reflects our lease assets and our lease liabilities at June 30, 2024 and December 31, 2023 (in thousands):

    

June 30, 

    

December 31,

2024

2023

Assets:

Operating lease right-of-use assets

$

575

$

616

Liabilities:

 

  

 

  

Operating lease liabilities, current

$

67

$

Operating lease liabilities, non-current

$

607

$

636

Operating lease right-of-use assets are included in other assets. Operating lease liabilities, current, are included in accrued liabilities and Operating lease liabilities, non-current, are include in other liabilities on the condensed consolidated balance sheets.

Lease Costs:

The components of lease costs were as follows (in thousands):

    

Three Months Ended

    

Six Months Ended

June 30, 2024

June 30, 2024

Operating lease cost

$

42

$

95

Short term lease cost

$

7

15

Total lease cost

$

49

$

110

As of June 30, 2024, the maturity of operating lease liabilities was as follows (in thousands):

Payments due in:

 

Year ending December 31, 2024 (6 months remaining)

 

$

59

Year ending December 31, 2025

 

185

Year ending December 31, 2026

191

Year ending December 31, 2027

197

Year ending December 31, 2028

203

Thereafter

93

Total minimum lease payments

928

Less: Amounts representing interest

 

(254)

Present value of capital lease obligations

$

674

32

Table of Contents

WISA TECHNOLOGIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Three and Six Months Ended June 30, 2024 and 2023

(unaudited)

8.

Commitments and Contingencies, continued

Lease Term and Discount Rate:

    

June 30, 2024

Weighted-average remaining lease term (in years)

 

5.00

Weighted-average discount rate

 

13.0

%

The discount rate was calculated by using the Company’s estimated incremental borrowing rate.

Other Information:

Supplemental cash flow information related to leases was as follows (in thousands):

    

Three Months Ended

    

Six Months Ended

June 30, 2024

June 30, 2024

Operating cash outflows from operating leases

$

$

3

Contingencies

In the normal course of business, the Company may become involved in legal proceedings. The Company will accrue a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When only a range of a possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. The accrual for a litigation loss contingency might include, for example, estimates of potential damages, outside legal fees and other directly related costs expected to be incurred.

The Company’s management does not believe that any such matters, individually or in the aggregate, will have a materially adverse effect on the Company’s condensed consolidated financial statements.

9.

Related Parties

Helge Kristensen

Mr. Kristensen has served as a member of the Company’s board of directors since 2010. Mr. Kristensen serves as vice president of Hansong Technology, an original device manufacturer of audio products based in China, president of Platin Gate Aps, a company with focus on service-branding in lifestyle products as well as pro line products based in Denmark and co-founder and director of Inizio Capital, an investment company based in the Cayman Islands.

For the three months ended June 30, 2024 and 2023, Hansong Technology purchased modules from the Company of approximately $10,000 and $24,000, respectively, and made payments to the Company of approximately $0 and $189,000, respectively. At June 30, 2024 and 2023, Hansong Technology owed the Company approximately $39,000 and $29,000, respectively. For the three months ended June 30, 2024 and 2023, Hansong Technology sold speaker products to the Company of approximately $1,000 and $21,000, respectively, and the Company made payments to Hansong Technology of approximately $63,000 and $794,000 respectively. At June 30, 2024 and 2023, the Company owed Hansong Technology approximately $163,000 and $350,000, respectively.

For the six months ended June 30, 2024 and 2023, Hansong Technology purchased modules from the Company of approximately $35,000 and $48,000, respectively, and made payments to the Company of approximately $0 and $189,000, respectively. For the six months ended June 30, 2024 and 2023, Hansong Technology sold speaker products to the Company of approximately $1,000 and $59,000, respectively, and the Company made payments to Hansong Technology of approximately $88,000 and $1,053,000, respectively.

33

Table of Contents

WISA TECHNOLOGIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Three and Six Months Ended June 30, 2024 and 2023

(unaudited)

9.

Related Parties, continued

As of June 30, 2024 and December 31, 2023, Mr. Kristensen owned less than 1.0% of the outstanding shares of the Company’s common stock.

David Howitt

Mr. Howitt has served as a member of the Company’s board of directors since December 2021. Mr. Howitt is founder and CEO of Meriwether Group LLC, (“Meriwether”), a strategic consulting firm that works with disruptive consumer brands by integrating their visions, developing growth strategies, scaling their brands, and increasing revenue in order to build enterprise value. Meriwether is the manager of Meriwether Accelerators LLC. Meriwether which is also majority-owned by Mr. Howitt, owns a 25% general partner interest in Meriwether Hero Fund.

On September 8, 2023, the Company entered into a Loan and Security Agreement with Meriwether Hero Fund. Pursuant to the Loan and Security Agreement, Meriwether Hero Fund provided the Company with a term loan in the principal amount of $650,000 that was scheduled to mature on November 7, 2023, subject to further extension. The Company repaid the loan in full on December 7, 2023. See Note 4 Short-Term Loan for additional information.

As of June 30, 2024 and December 31, 2023, Mr. Howitt owned less than 1.0% of the outstanding shares of the Company’s common stock.

10.

Segment Information

The Company operates in one business segment. Our chief decision-maker, the President and Chief Executive Officer, evaluates our performance based on company-wide consolidated results.

Net revenue from customers is designated based on the geographic region to which the product is delivered. Net revenue by geographic region for the three and six months ended June 30, 2024 and 2023 was as follows:

For the Three Months Ended

For the Six Months Ended

June 30, 

June 30, 

(in thousands)

    

2024

    

2023

    

2024

    

2023

Asia Pacific

$

264

$

301

$

351

$

598

North America

26

112

115

265

Europe

 

55

 

12

 

134

 

31

Total

$

345

$

425

$

600

$

894

Substantially all of our long-lived assets are located in the United States.

34

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Cautionary Notice Regarding Forward Looking Statements

This Report contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements discuss matters that are not historical facts. Because they discuss future events or conditions, forward-looking statements may include words such as “anticipate,” “believe,” “estimate,” “intend,” “could,” “should,” “would,” “may,” “seek,” “plan,” “might,” “will,” “expect,” “predict,” “project,” “forecast,” “potential,” “continue,” negatives thereof or similar expressions. These forward-looking statements are found at various places throughout this Report and include information concerning possible or assumed future results of WiSA Technologies, Inc.’s (“WiSA”, the “Company”, “our”, “us” or “we”) operations; business strategies; future cash flows; financing plans; plans and objectives of management; any other statements regarding future operations, future cash needs, business plans and future financial results, and any other statements that are not historical facts.

From time to time, forward-looking statements also are included in our other periodic reports on Form 10-K, 10-Q and 8-K, in our press releases, in our presentations, on our website and in other materials released to the public. Any or all of the forward-looking statements included in this Report and in any other reports or public statements made by us are not guarantees of future performance and may turn out to be inaccurate. These forward-looking statements represent our intentions, plans, expectations, assumptions and beliefs about future events and are subject to risks, uncertainties and other factors, including risks related to market, economic and other conditions; WiSA’s ability to continue as a going concern; WiSA’s ability to maintain the listing of its common stock on Nasdaq; WiSA’s ability to manage costs and execute on its operational and budget plans; and, WiSA’s ability to achieve its financial goals. Many of those factors are outside of our control and could cause actual results to differ materially from the results expressed or implied by those forward-looking statements. In light of these risks, uncertainties and assumptions, the events described in the forward-looking statements might not occur or might occur to a different extent or at a different time than we have described. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this Report. All subsequent written and oral forward-looking statements concerning other matters addressed in this Report and attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this Report.

Except to the extent required by law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, a change in events, conditions, circumstances or assumptions underlying such statements, or otherwise.

Overview

We are an emerging technology company and our primary business focus is to enable immersive, wireless sound technology for intelligent devices and next-generation home entertainment systems. Our first generation product, which we continue to sell to consumer electronics companies, is based on our proprietary wireless modules. In 2023 we introduced our second generation technology, WiSA E. WiSA E is a proprietary technology that delivers seamless integration across platforms and devices, allowing for interoperable high-quality audio. WiSA E is System-on-Chip (“SoC”) agnostic, compatible with a wide range of SoCs and Wi-Fi agnostic, functioning efficiently across Wi-Fi compliant chips. Designed to be embedded into various devices, including TVs, mobile devices, set-top boxes, and projectors it provides interoperability between WiSA E audio source devices and playback equipment such as speakers, soundbars, subwoofers, smart speakers, and headphones, ensuring cost-effectiveness without compromising quality or performance.

To date, our operations have been funded through sales of our common and preferred equity, proceeds from the exercise of warrants to purchase common stock, sale of debt instruments, and revenue from the sale of our products. Our condensed consolidated financial statements contemplate the continuation of our business as a going concern. However, we are subject to the risks and uncertainties associated with an emerging business, as noted above we have no established source of capital, and we have incurred recurring losses from operations since inception.

Comparison of the Three and Six Months Ended June 30, 2024 and 2023

Revenue

Revenue for the three months ended June 30, 2024 was $345,000 a decrease of $80,000 or 19% compared to the revenue for the three months ended June 30, 2023 of $425,000. The decrease was a result of lower Consumer Audio Product sales which decreased by $81,000 compared to the three months ended June 30, 2023. The decrease in sales is primarily related to fewer products sold (due in part to a slowdown in spending on consumer electronics.)

35

Revenue for the six months ended June 30, 2024 was $600,000 a decrease of $294,000 or 33% compared to the revenue for the six months ended June 30, 2023 of $894,000. The decrease was a result of lower Component revenue which decreased by $167,000 compared to the six months ended June 30, 2023, and lower Consumer Audio Product sales, which decreased by $127,000, compared to the six months ended June 30, 2023. The decrease in overall sales is primarily related to fewer products sold (due in part to a slowdown in spending on consumer electronics.)

Gross Profit and Operating Expenses

Gross Profit (Deficit)

Gross profit for the three months ended June 30, 2024 was $11,000 compared to a gross deficit of ($201,000) for the three months ended June 30, 2023. The gross margin as a percent of sales was 3% for the three months ended June 30, 2024, compared to (47%) for the three months ended June 30, 2023. The improvement in gross profit and gross margin as a percent of sales compared to the prior period is mainly attributable to the fact that the three months ended June 30, 2023 included a $169,000 increase in inventory reserves as a result of certain excess raw materials, primarily attributable to the out of balance inventory associated with longer lead time semiconductor chips, whereas the three months ended June 30, 2024 did not have any increases to inventory reserves.

Gross deficit for the six months ended June 30, 2024 was ($72,000), compared to a gross deficit of ($1,454,000) for the six months ended June 30, 2023. The improvement in gross deficit between periods is mainly attributable to lower cost of revenue of sales. The gross margin as a percent of sales was (12%) for the six months ended June 30, 2024, compared to (163%) for the six months ended June 30, 2023. The improvement in gross deficit and gross margin as a percent of sales compared to the prior period is mainly attributable to the fact that the six months ended June 30, 2023 included a $1.4 million increase in inventory reserves as a result of certain excess raw materials, primarily attributable to the out of balance inventory associated with longer lead time semiconductor chips, whereas the six months ended June 30, 2024 did not have any increases to inventory reserves.

Research and Development

Research and development expenses for the three months ended June 30, 2024 were $1,789,000, a decrease of $144,000, compared to the research and development expenses for the three months ended June 30, 2023 of $1,933,000. The decrease in research and development expenses is primarily related to decreased legal fees and consulting expenses of $77,000 and $68,000, respectively.

Research and development expenses for the six months ended June 30, 2024 were $3,504,000, a decrease of $322,000 compared to the research and development expenses for the six months ended June 30, 2023 of $3,826,000. The decrease in research and development expenses is primarily related to decreased consulting expenses, which includes outside engineering, reduced legal fees and reduced stock based compensation of $165,000, $82,000 and $69,000, respectively.

Sales and Marketing

Sales and marketing expenses for the three months ended June 30, 2024 were $865,000, a decrease of $224,000 compared to the sales and marketing expenses for the three months ended June 30, 2023 of $1,089,000. The decrease in sales and marketing expenses is primarily related to decreased salary and benefit expense of $134,000 and decreased website expenses of $66,000.

Sales and marketing expenses for the six months ended June 30, 2024 were $1,794,000, a decrease of $589,000 compared to the sales and marketing expenses for the six months ended June 30, 2023 of $2,383,000. The decrease in sales and marketing expenses is primarily related to decreased salary and benefit expense of $308,000 and decreased website expenses, consulting expenses and public relations expenses of $138,000, $56,000 and $42,000, respectively.

General and Administrative

General and administrative expenses for the three months ended June 30, 2024 were $2,762,000, an increase of $1,292,000 compared to the general and administrative expenses for the three months ended June 30, 2023 of $1,470,000. The increase in general and administrative expenses is primarily related to increased investor relations expenses of $1,015,000, which includes stock-based compensation charges of $156,000, and increased legal fees and shareholder expenses of $244,000 and $103,000, respectively, offset partially by decreased stock-based compensation expense of $165,000.

36

General and administrative expenses for the six months ended June 30, 2024 were $4,193,000, an increase of $1,361,000, compared to the general and administrative expenses for the three months ended June 30, 2023 of $2,832,000. The increase in general and administrative expenses is primarily related to increased investor relations expenses of $1,304,000, which includes stock-based compensation charges of $156,000, and increased legal fees and shareholder expenses of $134,000 and $131,000, respectively, offset partially by decreased stock-based compensation expense of $253,000.

Interest Expense, net

Interest expense, net for the three months ended June 30, 2024 was $4,000, a decrease of $33,000 compared to the interest expense for the three months ended June 30, 2023 of $37,000. Interest expense, net for the six months ended June 30, 2024 was $1,269,000, an increase of $509,000 compared to the interest expense for the six months ended June 30, 2023 of $760,000.

The increase in interest expense, net for the six months ended June 30, 2024, was primarily due to the amortization of debt discounts associated with the January 2024 Promissory Note in the principal amount of $1,000,000 that the Company incurred in January 2024 and repaid in full in January 2024.

Change in Fair Value of Warrant Liability

Change in fair value of warrant liability for the three months ended June 30, 2024 was a loss of $37,255,000, compared to a gain of $246,000 for the three months ended June 30, 2023. The change in fair value of the warrant liability for the three months ended June 30, 2024 was due to the issuance of additional warrants to purchase 5,602,693 shares of common stock and the subsequent valuing of such warrants. The additional warrants were issued as a result of provision in certain of the warrant agreements that was triggered following the Company’s reverse stock split that occurred in April 2024.

Change in fair value of warrant liability for the six months ended June 30, 2024 was a loss of $29,126,000 compared to a gain of $5,850,000 for the six months ended June 30, 2023. The change in fair value of the warrant liability for the six months ended June 30, 2024 was due to the issuance of additional warrants to purchase 5,602,693 shares of common stock and the subsequent valuing of such warrants. The additional warrants were issued as a result of provision in certain of the warrant agreements that was triggered following the Company’s reverse stock split that occurred in April 2024.

Liquidity and Capital Resources

Cash and cash equivalents as of June 30, 2024 were $6,113,000 compared to $411,000, as of December 31, 2023.

We recorded a net loss of $39,958,000 for the six months ended June 30, 2024 and used net cash in operating activities of $9,045,000. We incurred a net loss of $6,247,000 for the six months ended June 30, 2023 and used net cash in operating activities of $9,126,000. Excluding non-cash adjustments, the primary reasons for the increase in the use of net cash from operating activities during the six months ended June 30, 2024, was related to an increase in prepaid expenses and decrease in accounts payable, partially offset by a decrease in inventories.

We have financed our operations to date primarily through the issuance of equity securities, proceeds from the exercise of warrants to purchase common stock and sale of debt instruments. In January 2024, we received gross proceeds of $600,000 from the issuance of promissory notes and common stock purchase warrants to certain accredited investors. In February 2024, we received gross proceeds of approximately $10.0 million from the public offering of 1,025,600 units, with each unit consisting of one share of common stock (or pre-funded warrant in lieu thereof) and one warrant, each to purchase one (1) share of common stock. In March 2024 we received net proceeds of approximately $2.3 million from the issuance of 417,833 shares of common stock, 93,342 pre-funded common stock warrants and the issuance of 511,175 warrants to purchase common stock. On April 19, 2024, we received net proceeds of approximately $591,000 from the issuance of 225,834 shares of common stock and the issuance of 225,834 warrants to purchase common stock. On April 23, 2024, we received net proceeds of approximately $1.6 million from the issuance of 361,904 shares of common stock and the issuance of 542,856 warrants to purchase common stock. On April 30, 2024, we received net proceeds of approximately $2.1 million from the issuance of 418,845 shares of common stock and the issuance of 418,845 warrants to purchase common stock. On May 15, 2024, we received net proceeds of approximately $2.3 million from the issuance of 785,000 shares of common stock and the issuance of 785,000 warrants to purchase common stock. On May 17, 2024, we received net proceeds of approximately $2.1 million from the issuance of 675,000 shares of common stock and the issuance of 675,000 warrants to purchase common stock. We will need to raise additional proceeds via the issuance of equity securities and/or the sale of debt instruments in the fourth quarter of 2024 to fund operations for fiscal year 2025.

37

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

As a smaller reporting company, as defined in Rule 12b-2 of the Exchange Act, we are not required to provide the information required by this Item.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that material information required to be disclosed in our periodic reports filed under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission (“SEC”) rules and forms and to ensure that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer as appropriate, to allow timely decisions regarding required disclosure. Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of our disclosure controls and procedures. Based on the foregoing evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of June 30, 2024, our disclosure controls and procedures were effective to provide reasonable assurance that the information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Our management, including our Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer), does not expect that our disclosure controls and procedures will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected. These inherent limitations include, but are not limited to, the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Changes in Internal Controls

There were no changes in the Company’s internal control over financial reporting that occurred during the three months ended June 30, 2024 that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

38

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

From time to time we may be involved in various claims and legal actions arising in the ordinary course of our business. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our company or any of our subsidiaries, threatened against or affecting our company, or any of our subsidiaries in which an adverse decision could have a material adverse effect upon our business, operating results, or financial condition.

Item 1A. Risk Factors

As a smaller reporting company, the Company is not required to include the disclosure required under this Item 1A.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Information required by Item 701 of Regulation S-K as to all unregistered sales of equity securities of the Company during the period covered by this Report have previously been included in Current Reports on Form 8-K filed with the SEC.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

39

Item 6. Exhibits

Exhibit
Number

    

Description

3.1

Certificate of Amendment to the Company’s Certificate of Incorporation, filed with the Secretary of State of the State of Delaware on March 25, 2024 (incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on March 26, 2024).

3.2

Certificate of Amendment to the Company’s Certificate of Incorporation, filed with the Secretary of State of the State of Delaware on April 12, 2024 (incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on April 12, 2024).

4.1

Form of Common Stock Purchase Warrant (incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on April 19, 2024).

4.2

Form of Common Stock Purchase Warrant (incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on April 23, 2024).

4.3

Form of Common Stock Purchase Warrant (incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on April 30, 2024).

4.4

Form of Common Stock Purchase Warrant (incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on May 15, 2024).

4.5

Form of Common Stock Purchase Warrant (incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on May 17, 2024).

10.1

Placement Agency Agreement, dated as of April 17, 2024, by and between the Company and Maxim Group LLC, as placement agent (incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on April 18, 2024).

10.2

Form of Securities Purchase Agreement, by and among the Company and certain purchasers, dated April 17, 2024 (incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on April 18, 2024).

10.3

Placement Agency Agreement, dated as of April 19, 2024, by and between the Company and Maxim Group LLC, as placement agent (incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on April 23, 2024).

10.4

Form of Securities Purchase Agreement, by and among the Company and certain purchasers, dated April 19, 2024 (incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on April 23, 2024).

10.5

Placement Agency Agreement, dated as of April 26, 2024, by and between the Company and Maxim Group LLC, as placement agent (incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on April 30, 2024).

10.6

Form of Securities Purchase Agreement, by and among the Company and certain purchasers, dated April 26, 2024 (incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on April 30, 2024).

10.7

Placement Agency Agreement, dated as of May 13, 2024, by and between the Company and Maxim Group LLC, as placement agent (incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on May 15, 2024).

10.8

Form of Securities Purchase Agreement, by and among the Company and certain purchasers, dated May 13, 2024 (incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on May 15, 2024).

10.9

Placement Agency Agreement, dated as of May 15, 2024, by and between the Company and Maxim Group LLC, as placement agent (incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on May 17, 2024).

10.10

Form of Securities Purchase Agreement, by and among the Company and certain purchasers, dated May 15, 2024 (incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on May 17, 2024).

31.1

Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).

31.2

Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).

32.1

Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).

32.2

Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).

101

Interactive Data Files (embedded within the Inline XBRL document)

104

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

40

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

WISA Technologies, Inc.

Date: August 14, 2024

By:

/s/ Brett Moyer

Brett Moyer

Chief Executive Officer

(Duly Authorized Officer and Principal Executive Officer)

Date: August 14, 2024

By:

/s/ Gary Williams

Gary Williams

Vice President of Finance and Chief Accounting Officer

(Duly Authorized Officer, Principal Financial Officer and Principal Accounting Officer)

41

Exhibit 31.1

CERTIFICATION

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

I, Brett Moyer, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of WiSA Technologies, Inc. (the “registrant”):

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a13a-15(f) and 15d-15(f)) for the registrant and have:

a)Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures; and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 14, 2024

/s/ Brett Moyer

Name:

Brett Moyer

Title:

Chief Executive Officer

(Principal Executive Officer)


Exhibit 31.2

CERTIFICATION

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

I, Gary Williams, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of WiSA Technologies, Inc. (the “registrant”):

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a13a-15(f) and 15d-15(f)) for the registrant and have:

a)Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures; and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 14, 2024

/s/ Gary Williams

Name:

Gary Williams

Title:

Vice President of Finance and Chief Accounting Officer

(Principal Financial Officer and Principal Accounting Officer)


Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of WiSA Technologies, Inc. (the “Company”) for the period ended June 30, 2024 (the “Report”), I, Brett Moyer, Chief Executive Officer of the Company, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that:

1.The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 14, 2024

/s/ Brett Moyer

Name:

Brett Moyer

Title:

Chief Executive Officer

(Principal Executive Officer)

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.


Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of WiSA Technologies, Inc. (the “Company”) for the period ended June 30, 2024 (the “Report”), I, Gary Williams, Vice President of Finance and Chief Accounting Officer of the Company, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that:

1.The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 14, 2024

/s/ Gary Williams

Name:

Gary Williams

Title:

Vice President of Finance and Chief Accounting Officer

(Principal Financial Officer and Principal Accounting Officer)

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.


v3.24.2.u1
Document and Entity Information - shares
6 Months Ended
Jun. 30, 2024
Aug. 13, 2024
Document and Entity Information    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Jun. 30, 2024  
Document Transition Report false  
Entity File Number 001-38608  
Entity Registrant Name WISA Technologies, Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 30-1135279  
Entity Address, Address Line One 15268 NW Greenbrier Pkwy  
Entity Address, City or Town Beaverton  
Entity Address, State or Province OR  
Entity Address, Postal Zip Code 97006  
City Area Code 408  
Local Phone Number 627-4716  
Title of 12(b) Security Common Stock, par value $0.0001 per share  
Trading Symbol WISA  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   5,620,610
Entity Central Index Key 0001682149  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q2  
Amendment Flag false  
v3.24.2.u1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2024
Dec. 31, 2023
Current Assets:    
Cash and cash equivalents $ 6,113 $ 411 [1]
Accounts receivable 117 294 [1]
Inventories 2,330 2,737 [1]
Prepaid expenses and other current assets 1,413 641 [1]
Total current assets 9,973 4,083 [1]
Property and equipment, net 65 93 [1]
Other assets 594 647 [1]
Total assets 10,632 4,823 [1]
Current Liabilities:    
Accounts payable 2,191 2,320 [1]
Accrued liabilities 1,379 1,317 [1]
Total current liabilities 3,570 3,637 [1]
Warrant liabilities 25 5,460 [1]
Other liabilities 607 636 [1]
Total liabilities 4,202 9,733 [1]
Commitments and contingencies (Note 8) [1]
Series B Convertible Redeemable Preferred Stock, par value $0.0001; 375,000 shares authorized; 0 and 38,335 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively [1]   247
Stockholders' Equity / (Deficit):    
Common stock, par value $0.0001; 300,000,000 shares authorized; 4,921,434 and 222,380 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively 1 1 [1]
Additional paid-in capital 293,429 241,884 [1]
Accumulated deficit (287,000) (247,042) [1]
Total stockholders' equity / (deficit) 6,430 (5,157) [1]
Total liabilities, convertible preferred stock and stockholders' equity / (deficit) $ 10,632 $ 4,823 [1]
[1] The condensed consolidated balance sheet as of December 31, 2023 was derived from the audited consolidated balance sheet as of that date.
v3.24.2.u1
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)
Jun. 30, 2024
$ / shares
shares
Dec. 31, 2023
$ / shares
shares
CONDENSED CONSOLIDATED BALANCE SHEETS    
Temporary equity, par or stated value per share | $ / shares $ 0.0001 $ 0.0001
Temporary equity, shares authorized 375,000 375,000
Temporary equity, shares issued 0 38,335
Temporary equity, shares outstanding 0 38,335
Common stock, par value | $ / shares $ 0.0001 $ 0.0001
Common stock, shares authorized 300,000,000 300,000,000
Common stock, shares issued 4,921,434 222,380
Common stock, shares outstanding 4,921,434 222,380
v3.24.2.u1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS        
Revenue, net $ 345,000 $ 425,000 $ 600,000 $ 894,000
Cost of revenue 334,000 626,000 672,000 2,348,000
Gross profit (deficit) 11,000 (201,000) (72,000) (1,454,000)
Operating Expenses:        
Research and development 1,789,000 1,933,000 3,504,000 3,826,000
Sales and marketing 865,000 1,089,000 1,794,000 2,383,000
General and administrative 2,762,000 1,470,000 4,193,000 2,832,000
Total operating expenses 5,416,000 4,492,000 9,491,000 9,041,000
Loss from operations (5,405,000) (4,693,000) (9,563,000) (10,495,000)
Interest expense, net (4,000) (37,000) (1,269,000) (760,000)
Change in fair value of warrant liabilities (37,255,000) 246,000 (29,126,000) 5,850,000
Loss on debt extinguishment   (837,000)   (837,000)
Other expense, net (1,000) (3,000)   (3,000)
Loss before provision for income taxes (42,665,000) (5,324,000) (39,958,000) (6,245,000)
Provision for income taxes 0 2,000 0 2,000
Net loss (42,665,000) (5,326,000) (39,958,000) (6,247,000)
Deemed dividend on conversion of Series B preferred for common stock and repurchase of Series B preferred stock     (5,842,000)  
Net loss attributable to common stockholders $ (42,665,000) $ (5,326,000) $ (45,800,000) $ (6,247,000)
Net loss per common share- basic (in dollars per share) $ (11.89) $ (180.18) $ (21.95) $ (303.28)
Net loss per common share- diluted (in dollars per share) $ (11.89) $ (180.18) $ (21.95) $ (303.28)
Weighted average number of common shares used in computing net loss per common share - Basic (in shares) 3,587,122 29,560 2,086,312 20,598
Weighted average number of common shares used in computing net loss per common share - Diluted (in shares) 3,587,122 29,560 2,086,312 20,598
v3.24.2.u1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)
Apr. 04, 2024
Jan. 24, 2023
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS    
Reverse stock split ratio 0.0067 0.01
v3.24.2.u1
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)
Preferred Stock
Convertible Preferred Stock
Preferred Stock
Series B preferred stock
Common Shares
Series B preferred stock
Common Shares
Convertible Promissory Note
Common Shares
Additional Paid-in Capital
ASC842 adoption adjustment
Additional Paid-in Capital
Series B preferred stock
Additional Paid-in Capital
Convertible Promissory Note
Additional Paid-in Capital
Accumulated Deficit
Series B preferred stock
Convertible Promissory Note
Total
Balance at Dec. 31, 2022         $ 1,000       $ 226,324,000 $ (228,321,000)     $ (1,996,000)
Balance (in shares) at Dec. 31, 2022         4,750                
Stock-based compensation                 499,000       499,000
Restricted stock awards cancelled (in shares)         0                
Issuance of common stock in connection with convertible securities               $ 708,000       $ 708,000  
Issuance of common stock in connection with convertible securities (In shares)       450                  
Issuance of common stock in connection with warrant exercise                 8,202,000       $ 8,202,000
Issuance of common stock in connection with warrant exercise (in shares)         5,723               5,705
Issuance of common stock, pre-funded units and warrants, net of offering costs                 1,271,000       $ 1,271,000
Issuance of common stock, pre-funded units and warrants, net of offering costs (in shares)         9,470                
Net loss                   (921,000)     (921,000)
Balance at Mar. 31, 2023         $ 1,000       237,004,000 (229,242,000)     7,763,000
Balance (in shares) at Mar. 31, 2023         20,393                
Balance at Dec. 31, 2022         $ 1,000       226,324,000 (228,321,000)     (1,996,000)
Balance (in shares) at Dec. 31, 2022         4,750                
Net loss                         (6,247,000)
Balance at Jun. 30, 2023         $ 1,000       240,427,000 (234,568,000)     5,861,000
Balance (in shares) at Jun. 30, 2023         35,341                
Balance at Dec. 31, 2022         $ 1,000       226,324,000 (228,321,000)     (1,996,000)
Balance (in shares) at Dec. 31, 2022         4,750                
Balance at Dec. 31, 2023 $ 247,000       $ 1,000       241,884,000 (247,042,000)     (5,157,000) [1]
Balance (in shares) at Dec. 31, 2023 38,335       222,380                
Balance at Mar. 31, 2023         $ 1,000       237,004,000 (229,242,000)     7,763,000
Balance (in shares) at Mar. 31, 2023         20,393                
Stock-based compensation                 481,000       481,000
Restricted stock awards cancelled (in shares)         (1)                
Release of vested restricted common stock (in shares)         1                
Issuance of common stock in connection with warrant exercise                 1,894,000       $ 1,895,000
Issuance of common stock in connection with warrant exercise (in shares)         9,908               12,856
Issuance of common stock, pre-funded units and warrants, net of offering costs                 1,048,000       $ 1,048,000
Issuance of common stock, pre-funded units and warrants, net of offering costs (in shares)         5,040                
Net loss                   (5,326,000)     (5,326,000)
Balance at Jun. 30, 2023         $ 1,000       240,427,000 (234,568,000)     5,861,000
Balance (in shares) at Jun. 30, 2023         35,341                
Balance at Dec. 31, 2023 $ 247,000       $ 1,000       241,884,000 (247,042,000)     (5,157,000) [1]
Balance (in shares) at Dec. 31, 2023 38,335       222,380                
Stock-based compensation                 380,000       380,000
Stock-based compensation (in shares)         4                
Issuance of Series B preferred stock in connection with warrant exercise, net of discounts   $ 386,000                      
Issuance of Series B preferred stock in connection with warrant exercise, net of discounts (in shares) 29,322                        
Issuance of common stock in connection with conversion of Series B preferred stock   (325,000)                      
Issuance of common stock in connection with conversion of Series B preferred stock (in shares) (5,000)                        
Issuance of common stock in connection with convertible securities             $ 325,000       $ 325,000    
Issuance of common stock in connection with convertible securities (In shares)     8,038                    
Deemed dividend on conversion of Series B preferred for common stock and repurchase of Series B preferred stock   5,842,000         (5,842,000)       (5,842,000)    
Repurchase of Series B preferred stock and Series B preferred stock warrants   $ (6,266,000)         $ 824,000       $ 824,000    
Repurchase of Series B preferred stock and Series B preferred stock warrants (in shares) (62,657)                        
Issuance of common stock and warrants, net of offering costs                 4,210,000       4,210,000
Issuance of common stock and warrants, net of offering costs (in shares)         1,442,518                
Issuance of common stock in connection with reverse split rounding-up for fractional shares, shares         84,255                
Net loss                   2,707,000     2,707,000
Balance (Accounting Standards Update 2020-06) at Mar. 31, 2024 $ 116,000               (116,000)       (116,000)
Balance at Mar. 31, 2024         $ 1,000       241,665,000 (244,335,000)     (2,669,000)
Balance (in shares) at Mar. 31, 2024         1,757,195                
Balance at Dec. 31, 2023 $ 247,000       $ 1,000       241,884,000 (247,042,000)     (5,157,000) [1]
Balance (in shares) at Dec. 31, 2023 38,335       222,380                
Net loss                         (39,958,000)
Balance (Accounting Standards Update 2020-06) at Jun. 30, 2024           $ 116,000              
Balance at Jun. 30, 2024         $ 1,000       293,429,000 (287,000,000)     6,430,000
Balance (in shares) at Jun. 30, 2024         4,921,434                
Balance (Accounting Standards Update 2020-06) at Mar. 31, 2024 $ 116,000               (116,000)       (116,000)
Balance at Mar. 31, 2024         $ 1,000       241,665,000 (244,335,000)     (2,669,000)
Balance (in shares) at Mar. 31, 2024         1,757,195                
Stock-based compensation                 241,000       241,000
Stock-based compensation (in shares)         255,915                
Restricted stock awards cancelled (in shares)         (82)                
Release of vested restricted common stock (in shares)         1                
Conversion of liability warrants to equity warrants                 41,851,000       41,851,000
Issuance of common stock in connection with warrant exercise                 556,000       $ 556,000
Issuance of common stock in connection with warrant exercise (in shares)         441,822               3,211
Issuance of common stock, pre-funded units and warrants, net of offering costs                 8,756,000       $ 8,756,000
Issuance of common stock, pre-funded units and warrants, net of offering costs (in shares)         2,466,583                
Issuance of common stock to vendors                 360,000       360,000
Net loss                   (42,665,000)     (42,665,000)
Balance (Accounting Standards Update 2020-06) at Jun. 30, 2024           $ 116,000              
Balance at Jun. 30, 2024         $ 1,000       $ 293,429,000 $ (287,000,000)     $ 6,430,000
Balance (in shares) at Jun. 30, 2024         4,921,434                
[1] The condensed consolidated balance sheet as of December 31, 2023 was derived from the audited consolidated balance sheet as of that date.
v3.24.2.u1
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)
Apr. 04, 2024
Jan. 24, 2023
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)    
Reverse stock split ratio 0.0067 0.01
v3.24.2.u1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
Cash flows from operating activities:              
Net loss $ (42,665,000) $ 2,707,000 $ (5,326,000) $ (921,000) $ (39,958,000) $ (6,247,000)  
Adjustments to reconcile net loss to net cash used in operating activities:              
Stock-based compensation         777,000 980,000  
Depreciation and amortization 28,000   32,000   48,000 65,000  
Amortization of debt discounts         1,260,000 738,000  
Change in fair value of warrant liability 37,255,000   (246,000)   29,126,000 (5,850,000)  
Loss on extinguishment of convertible note payable     837,000     837,000  
Changes in operating assets and liabilities:              
Accounts receivable         177,000 172,000  
Inventories         407,000 1,595,000  
Prepaid expenses and other current assets         (418,000) 225,000  
Other assets         53,000 47,000  
Accounts payable         (534,000) (1,105,000)  
Accrued liabilities         46,000 (544,000)  
Other liabilities         (29,000) (39,000)  
Net cash used in operating activities         (9,045,000) (9,126,000)  
Cash flows from investing activities:              
Issuance of note receivable         (150,000)    
Purchases of property and equipment         (20,000) (16,000)  
Net cash used in investing activities         (170,000) (16,000)  
Cash flows from financing activities:              
Proceeds from issuance of common stock in connection with warrant exercise         556,000    
Proceeds from issuance of common stock and warrants, net of offering costs         19,980,000 1,927,000  
Proceeds from issuance of short-term loan, net of issuance costs         600,000 7,995,000  
Proceeds from exercise of warrants 556,000   1,895,000   714,000    
Repurchase of Series B preferred stock warrants         (6,266,000)    
Repayment of short-term loan         (667,000)    
Repayment of convertible note payable           (1,657,000)  
Repayment of finance lease           (13,000)  
Net cash provided by financing activities         14,917,000 8,252,000  
Net decrease in cash and cash equivalents         5,702,000 (890,000)  
Cash and cash equivalents as of beginning of period   $ 411,000   $ 2,897,000 411,000 2,897,000 $ 2,897,000
Cash and cash equivalents as of end of period $ 6,113,000   $ 2,007,000   6,113,000 2,007,000 $ 411,000
Supplemental disclosure of cash flow information:              
Cash paid for interest         276,000 20,000  
Cash paid for income taxes           2,000  
Noncash Investing and Financing Activities:              
Conversion of liability warrants to equity warrants         41,851,000    
Issuance of warrant liability in connection with financing         8,701,000    
Deemed dividend on conversion of Series B preferred stock and repurchase of Series B preferred stock         5,842,000    
Unpaid financings issuance costs         421,000    
Cashless exercise of warrants         587,000 8,191,000  
Issuance of common stock to vendors         360,000    
warrant exercise in connection with loan settlement         333,000    
Issuance of common stock in connection with Series B preferred stock         $ 325,000    
Issuance of warrant liability in connection with February 2023 offering           5,600,000  
Issuance of common stock in connection with convertible promissory note           708,000  
Record Right-of-Use Assets obtained in exchange for modified operating lease liabilities           554,000  
Deferred offering costs reclassed from prepaid expenses           $ (97,000)  
v3.24.2.u1
Business and Summary of Significant Accounting Policies
6 Months Ended
Jun. 30, 2024
Business and Summary of Significant Accounting Policies  
Business and Summary of Significant Accounting Policies

1.

Business and Summary of Significant Accounting Policies

WiSA Technologies, Inc. formerly known as Summit Wireless Technologies, Inc. (together with its subsidiaries also referred to herein as “we”, “us”, “our”, or the “Company”), was originally formed as a limited liability company in Delaware on July 23, 2010. Our business is to deliver the best-in-class immersive wireless sound technology for intelligent devices and next generation home entertainment systems through the sale of module components to audio companies as well as audio products to resellers and consumers.

Nasdaq Compliance

The Company is currently in compliance with the listing rules of The Nasdaq Stock Market LLC (“Nasdaq”), subject to the monitorings described below.

On April 29, 2024, Nasdaq notified the Company in a letter that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550 (a)(2) (the “Minimum Bid Price Requirement”) as required by a hearing panel’s decision on April 5, 2024. The Company is subject to monitoring for a period of one year from the date of the letter. If, within that one-year monitoring period, Nasdaq’s Listing Qualifications staff (the “Staff”) finds the Company again out of compliance with the Minimum Bid Price Requirement, the Company will not be permitted to provide the Staff with a plan of compliance with respect to such deficiency and the Staff will not be permitted to grant additional time for the Company to regain compliance with respect to such deficiency, nor will the Company be afforded an applicable cure or compliance period. Instead, the Staff will issue a delist determination letter and the Company will have an opportunity to request a new hearing with a hearings panel. The Company will have the opportunity to respond and present to the panel.    

On July 3, 2024, Nasdaq notified the Company in a letter that the Company has regained compliance with the equity requirement under Nasdaq Listing Rule 5550(b)(1) (the “Equity Rule”) as required by the panel’s April 5, 2024 decision. The Company is subject to monitoring for a period of one year from the date of the letter. If, within that one-year monitoring period, the Staff finds the Company again out of compliance with the Equity Rule, the Company will not be permitted to provide the Staff with a plan of compliance with respect to such deficiency and the Staff will not be permitted to grant additional time for the Company to regain compliance with respect to such deficiency, nor will the Company be afforded an applicable cure or compliance period. Instead, the Staff will issue a delist determination letter and the Company will have an opportunity to request a new hearing with a hearings panel. The Company will have the opportunity to respond and present to the panel.

1.

Business and Summary of Significant Accounting Policies, continued

Reverse Stock Splits

April 2024 Reverse Stock Split

On April 4, 2024, the Board approved a 1-for-150 reverse stock split (the “April 2024 Reverse Stock Split”) of our outstanding shares of common stock and authorized the filing of a certificate of amendment to our certificate of incorporation, as amended, with the Secretary of State of the State of Delaware to effect the April 2024 Reverse Stock Split. On April 12, 2024, the April 2024 Reverse Stock Split was effected and the condensed consolidated financial statements have been retroactively adjusted. All common stock share numbers, warrants to purchase common stock, prices and exercise prices have been retroactively adjusted to reflect the April 2024 Reverse Stock Split. The common stock began trading on a split-adjusted basis at the start of trading on April 15, 2024. Unless otherwise indicated, the information presented in this Quarterly Report on Form 10-Q (this “Report”) gives effect to the April 2024 Reverse Stock Split.

January 2023 Reverse Stock Split

On January 24, 2023, the Board approved a 1-for-100 reverse stock split (the “January 2023 Reverse Stock Split”) of our outstanding shares of common stock and authorized the filing of a certificate of amendment to our certificate of incorporation, as amended, with the Secretary of State of the State of Delaware to effect the January 2023 Reverse Stock Split. On January 26, 2023, the January 2023 Reverse Stock Split was effected and the condensed consolidated financial statements have been retroactively adjusted. All common stock share numbers, warrants to purchase common stock, prices and exercise prices have been retroactively adjusted to reflect the January 2023 Reverse Stock Split. The common stock began trading on a split-adjusted basis at the start of trading on January 27, 2023. Unless otherwise indicated, the information presented in this Report gives effect to the January 2023 Reverse Stock Split.

Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and include all adjustments necessary for the fair presentation of the Company’s financial position, results of operations and cash flows for the periods presented. The condensed consolidated financial statements reflect the accounts of WISA Technologies, Inc. and its wholly-owned subsidiaries, WISA Technologies Korea, LTD, a Korean limited company, which was established in September 2022, and WiSA, LLC, a Delaware limited liability company. All intercompany balances and transactions are eliminated.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

Reclassification

Certain reclassifications have been made to prior periods’ condensed consolidated financial statements to conform to the current period presentation. These reclassifications did not result in any change in previously reported net income (loss), total assets or stockholders’ deficit.

1.Business and Summary of Significant Accounting Policies, continued

Concentration of Credit Risk and Other Risks and Uncertainties

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Cash and cash equivalents are deposited in demand and money market accounts at one financial institution. At times, such deposits may be in excess of insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.

The Company’s accounts receivable are derived from revenue earned from customers located throughout the world. The Company performs credit evaluations of its customers’ financial condition and may, in certain circumstances, require full or partial payment in advance of shipping. As of June 30, 2024 and December 31, 2023, there was no allowance for credit losses. As of June 30, 2024, the Company had four customers accounting for 43%, 33%, 12%and 11% of accounts receivable. As of December 31, 2023, the Company had two customers accounting for 71% and 20% of accounts receivable.

The Company had four customers accounting for 33%, 27%, 20% and 11% of its net revenue for the three months ended June 30, 2024. The Company had four customers accounting for 28%, 27%, 19% and 10% of its net revenue for the six months ended June 30, 2024. The Company had four customers accounting for 35%, 13%, 12% and 11% of its net revenue for the three months ended June 30, 2023. The Company had two customers accounting for 29% and 17% of its net revenue for the six months ended June 30, 2023.

The Company’s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, continued acceptance of the Company’s products, competition from substitute products and larger companies, protection of proprietary technology, strategic relationships and dependence on key individuals.

The Company relies on sole-source suppliers to manufacture some of the components used in its product. The Company’s manufacturers and suppliers may encounter problems during manufacturing due to a variety of reasons, any of which could delay or impede their ability to meet demand. The Company is heavily dependent on a single contractor in China for assembly and testing of its products, a single contractor in Japan for the production of its transmit semiconductor chip and a single contractor in China for the production of its receive semiconductor chip.

Cash and Cash Equivalents

The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents.

Accounts Receivable and Allowance for Credit Losses

Accounts receivable are recorded at the invoice amount and are generally not interest bearing. The Company reviews its trade receivables aging to identify specific customers with known disputes or collection issues. The Company exercises judgment when determining the adequacy of these reserves as it evaluates historical bad debt trends and changes to customers’ financial conditions.

Fair Value of Financial Instruments

Carrying amounts of certain of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities. The carrying value of the Company’s borrowings and capital lease liabilities approximates fair value based upon borrowing rates currently available to the Company for loans and capital leases with similar terms. The Company’s Warrant liabilities are the only financial instrument that is adjusted to fair value on a recurring basis.

1.

Business and Summary of Significant Accounting Policies, continued

Inventories

Inventories, principally purchased components, are stated at the lower of cost or net realizable value. Cost is determined using an average cost, which approximates actual cost on a first-in, first-out basis. Inventory in excess of salable amounts and inventory which is considered obsolete based upon changes in existing technology is written off. At the point of loss recognition, a new lower cost basis for that inventory is established and subsequent changes in facts and circumstances do not result in the restoration or increase in the new cost basis.

Property and Equipment, Net

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over their estimated useful lives of two to five years. Leasehold improvements and assets acquired under capital lease are amortized on a straight-line basis over the shorter of the useful life or term of the lease. Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred.

Convertible Financial Instruments

The Company bifurcates conversion options and warrants from their host instruments and accounts for them as freestanding derivative financial instruments if certain criteria are met. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. An exception to this rule is when the host instrument is deemed to be conventional, as that term is described under applicable U.S. GAAP.

When the Company has determined that the embedded conversion options and warrants should be bifurcated from their host instruments, discounts are recorded for the intrinsic value of conversion options embedded in the instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the instrument.

Debt discounts under these arrangements are amortized to interest expense using the interest method over the earlier of the term of the related debt or their earliest date of redemption.

Warrants for Common Shares, Convertible Redeemable Preferred Shares, and Derivative Financial Instruments

Warrants for our common shares, convertible redeemable preferred shares, and derivative financial instruments are classified as equity if the contracts (1) require physical settlement or net-share settlement or (2) give the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). Contracts which (1) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the control of the Company), (2) give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement), or (3) contain reset provisions that do not qualify for the scope exception are classified as equity or liabilities. The Company assesses classification of its warrants for shares of common stock and other derivatives at each reporting date to determine whether a change in classification between equity and liabilities is required.

1.

Business and Summary of Significant Accounting Policies, continued

Product Warranty

The Company’s products are generally subject to a one-year warranty, which provides for the repair, rework, or replacement of products (at the Company’s option) that fail to perform within the stated specification. The Company has assessed its historical claims and, to date, product warranty claims have not been significant. The Company will continue to assess if there should be a warranty accrual going forward.

Revenue Recognition

The Company generates revenue primarily from two product categories which include the sale of Consumer Audio Products as well as the sale of Components. The Company applies the following five steps: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when a performance obligation is satisfied. The Company considers customer purchase orders to be the contracts with a customer. Revenues, net of expected discounts, are recognized when the performance obligations of the contract with the customer are satisfied and when control of the promised goods are transferred to the customer, typically when products, which have been determined to be the only distinct performance obligations, are shipped to the customer. Expected costs of assurance warranties and claims are recognized as expense.

Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by us from a customer and deposited with the relevant government authority, are excluded from revenue. Our revenue arrangements do not contain significant financing components.

Sales to certain distributors are made under arrangements which provide the distributors with price adjustments, price protection, stock rotation and other allowances under certain circumstances. The Company does not provide its customers with a contractual right of return. However, the Company accepts limited returns on a case-by-case basis. These returns, adjustments and other allowances are accounted for as variable consideration. We estimate these amounts based on the expected amount to be provided to customers and reduce revenue recognized. We believe that there will not be significant changes to our estimates of variable consideration.

If a customer pays consideration, or the Company has a right to an amount of consideration that is unconditional before we transfer a good or service to the customer, those amounts are classified as contract liabilities which are included in other current liabilities when the payment is made or it is due, whichever is earlier.

Practical Expedients and Exemptions

In accordance with Accounting Standards Codification Topic 606, Revenue from Contracts with Customers, we use the following practical expedients: (i) not to adjust the promised amount of consideration for the effects of a significant financing component when we expect, at contract inception, that the period between our transfer of a promised product or service to a customer and when the customer pays for that product or service will be one year or less; (ii) to expense costs as incurred for costs to obtain a contract when the amortization period would have been one year or less; (iii) not to assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract with the customer. In addition, we do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less.

1.

Business and Summary of Significant Accounting Policies, continued

During the three months ended June 30, 2024 and 2023, net revenue consisted of the following:

    

For the Three Months Ended June 30,

    

For the Six Months Ended June 30, 

(in thousands)

2024

    

2023

2024

    

2023

Components

$

314

$

313

$

473

$

640

Consumer Audio Products

 

31

 

112

 

127

 

254

Total

$

345

$

425

$

600

$

894

Contract Balances

The Company receives payments from customers based on a billing schedule as established in our contracts to partially offset prepayments required by our vendors on long lead time materials. Amounts collected prior to the fulfillment of the performance obligation are considered contract liabilities and classified as customer advances within accrued liabilities on the consolidated balance sheets. Contract assets are recorded when the Company has a conditional right to consideration for our completed performance under the contracts. Accounts receivables are recorded when the right to this consideration becomes unconditional. The Company does not have any material contract assets as of June 30, 2024 and December 31, 2023. During the six month ended June 30, 2024, the Company did not recognize any revenue that was included in the contract liabilities balance as of December 31, 2023.

June 30, 

December 31, 

(in thousands)

    

2024

    

2023

Contract Liabilities

$

150

$

19

Revenue by Geographic Area

In general, revenue disaggregated by geography (See Note 10) is aligned according to the nature and economic characteristics of our business and provides meaningful disaggregation of our results of operations. Since we operate in one segment, all financial segment and product line information can be found in the condensed consolidated financial statements.

Stock-Based Compensation

The Company measures and recognizes the compensation expense for restricted stock units and restricted stock awards granted to employees and directors based on the fair value of the award on the grant date.

Restricted stock units give an employee an interest in Company stock but they have no tangible value until vesting is complete. Restricted stock units and restricted stock awards are equity classified and measured at the fair market value of the underlying stock at the grant date and recognized as expense over the related service or performance period. The Company elected to account for forfeitures as they occur. The fair value of stock awards is based on the quoted price of our common stock on the grant date. Compensation cost for restricted stock units and restricted stock awards is recognized using the straight-line method over the requisite service period.

1.

Business and Summary of Significant Accounting Policies, continued

Research and Development

Research and development costs are charged to operations as incurred and includes salaries, consulting expenses and an allocation of facility costs.

Advertising Costs

Advertising costs are charged to sales and marketing expenses as incurred. Advertising costs for the three and six months ended June 30, 2024 were $117,000 and $264,000, respectively. Advertising costs for the three and six months ended June 30,  2023 were $118,000 and $273,000, respectively.

Comprehensive Loss

Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may include certain changes in equity that are excluded from net loss. For the three and six months ended June 30, 2024 and 2023, the Company’s comprehensive loss is the same as its net loss.

Foreign Currency

The financial position and results of operations of the Company’s foreign operations are measured using currencies other than the U.S. dollar as their functional currencies. Accordingly, for these operations all assets and liabilities are translated into U.S. dollars at the current exchange rates as of the respective balance sheet date. Expense items are translated using the weighted average exchange rates prevailing during the period. Cumulative gains and losses from the translation of these operations’ financial statements are reported as a separate component of stockholders’ equity, while foreign currency transaction gains or losses, resulting from re-measuring local currency to the U.S. dollar are recorded in the condensed consolidated statement of operations in other income (expense), net and were not material for the three and six months ended June 30, 2024 and 2023.

Net Loss per Common Share

Basic and diluted net loss per common share is presented in conformity with the two-class method required for participating securities. The Company considers all series of convertible preferred stock to be participating securities. Under the two-class method, the net loss attributable to common stockholders is not allocated to the convertible preferred stock as the holders of the convertible preferred stock do not have a contractual obligation to share in the losses of the Company. Under the two-class method, net income would be attributed to common stockholders and participating securities based on their participation rights.

Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares and potentially dilutive common share equivalents outstanding for the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per common share calculation, Series A 8% Senior Convertible Preferred Stock (“Series A Preferred Stock”), warrants exercisable for common stock, restricted stock units and shares issuable upon the conversion of convertible notes payable are considered to be potentially dilutive securities. Net loss is adjusted for any deemed dividends to preferred stockholders to compute income available to common stockholders.

As of June 30, 2024, warrants to purchase 9,793,531 shares of common stock, 260,441 shares of restricted stock, 16 shares of restricted stock issued under an inducement grant and 14 shares underlying restricted stock units, have been excluded from the calculation of net loss per common share because the inclusion would be antidilutive.

As of June 30, 2023, warrants to purchase 37,572 shares of common stock, 69 shares of restricted stock, 18 shares of restricted stock issued under an inducement grant and 36 shares underlying restricted stock units have been excluded from the calculation of net loss per common share because the inclusion would be antidilutive.

1.Business and Summary of Significant Accounting Policies, continued

Income Taxes

Deferred taxes are provided on the liability method whereby deferred tax assets are recognized for deductible temporary differences, and operating loss and tax credit carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is “more-likely-than-not” that some portion or all of the deferred tax assets will not be realized. The Company has recognized valuation allowances against its deferred tax assets as of June 30, 2024 and December 31, 2023. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

The Company uses a comprehensive model for recognizing, measuring, presenting, and disclosing in the condensed consolidated financial statements tax positions taken or expected to be taken on a tax return. A tax position is recognized as a benefit only if it is “more-likely-than-not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more-likely-than-not” test, no tax benefit is recorded. The Company recognizes interest accrued and penalties related to unrecognized tax benefits in tax expense. As of June 30, 2024 and December 31, 2023, the Company recognized no interest and penalties.

Recently Adopted Accounting Pronouncements

In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06 “Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity.” This ASU simplifies accounting for convertible instruments by removing major separation models required under current U.S. GAAP. The Company adopted this standard on January 1, 2024 using the modified retrospective method by applying the ASU to financial instruments outstanding as of January 1, 2024, with the cumulative effect of adoption recognized at that date through an adjustment to the opening balance of retained earnings. As such, the Company adopted the standard by eliminating any unamortized discount to the Series B Preferred Stock for the beneficial conversion feature. The cumulative effect of ASU 2020-06 adoption adjusted against additional paid-in-capital due to the absence of retained earnings on January 1, 2024 amounted to $116,000.

Recently Issued and Not Yet Adopted Accounting Pronouncements

In December 2023, the FASB issued ASU 2023-09 – Income Taxes (Topic 740): Improvements to Income Tax Disclosures” to help investors better understand an entity’s exposure to potential changes in jurisdictional tax legislation and the ensuing risks and opportunities. Furthermore, the Update improves disclosures used to assess income tax information that affects cash flow forecasts and capital allocation decisions. The Update is effective for public business entities for annual periods beginning after December 15, 2024, on a prospective basis. The Company is currently evaluating the impact of the adoption of this standard on our condensed consolidated financial statements.

In November 2023, the FASB issued ASU 2023-07 “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,” aiming to enhance the transparency and relevance of segment information provided in financial statements. The amendments in this Update require that a public entity disclose significant segment expenses, profit or loss and assets, etc. for each reportable segment, on an annual and interim basis. The Update is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact of the adoption of this standard on our condensed consolidated financial statements.

We have reviewed other recent accounting pronouncements and concluded they are either not applicable to the business, or no material effect is expected on the condensed consolidated financial statements as a result of future adoption.

v3.24.2.u1
Going Concern
6 Months Ended
Jun. 30, 2024
Going Concern  
Going Concern

2.

Going Concern

The condensed consolidated financial statements of the Company have been prepared on a going concern basis, which contemplates the realization of assets and the discharge of liabilities in the normal course of business. As of June 30, 2024, the Company had cash and cash equivalents of $6.1 million and reported net cash used in operations of $9.0 million during the six months ended June 30, 2024. The Company expects operating losses to continue in the foreseeable future because of additional costs and expenses related to research and development activities, plans to expand its product portfolio, and increase its market share. The Company’s ability to attain profitable operations is dependent upon achieving a level of revenues adequate to support its cost structure.

Based on current operating levels, the Company will need to raise additional funds in the next 12 months by selling additional equity or incurring debt. To date, the Company has funded its operations primarily through sales of its securities in public and private markets, proceeds from the exercise of warrants to purchase common stock and the sale of convertible notes. Additionally, future capital requirements will depend on many factors, including the rate of revenue growth, the selling price of the Company’s products, the expansion of sales and marketing activities, the timing and extent of spending on research and development efforts and the continuing market acceptance of the Company’s products. These factors raise substantial doubt about the Company’s ability to continue as a going concern for the twelve months from the date of this Report.

Management of the Company intends to raise additional funds through the issuance of equity securities or debt. There can be no assurance that, in the event the Company requires additional financing, such financing will be available at terms acceptable to the Company, if at all. Failure to generate sufficient cash flows from operations, raise additional capital and reduce discretionary spending could have a material adverse effect on the Company’s ability to achieve its intended business objectives. As a result, the substantial doubt about the Company’s ability to continue as a going concern has not been alleviated. The accompanying condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

v3.24.2.u1
Balance Sheet Components
6 Months Ended
Jun. 30, 2024
Balance Sheet Components  
Balance Sheet Components

3.

Balance Sheet Components

Inventories (in thousands):

June 30, 

December 31, 

    

2024

    

2023

Raw materials

$

648

$

621

Work in progress

22

Finished goods

 

1,660

 

2,116

Total inventories

$

2,330

$

2,737

Note receivable:

On June 13, 2024, the Company entered into a Senior Secured Promissory Note and Security Agreement (“Promissory Note and Security Agreement”) with an unaffiliated third-party company (“the Borrower”). Pursuant to the Promissory Note and Security Agreement, the Company agreed to provide the Borrower with a term loan in the principal amount of $150,000 (“June 2024 Note”). The June 2024 Note matures on October 11, 2024. Borrowings under the June 2024 Note bear interest at a rate per annum equal to 5.12%. On the maturity date, subject to any extension, the Borrower will be obligated to make a payment equal to all unpaid principal and accrued interest. Note receivable is included in other assets on the condensed consolidated balance sheets. There was no note receivable at December 31, 2023.

3.Balance Sheet Components, continued

Property and equipment, net (in thousands):

June 30, 

December 31, 

    

2024

    

2023

Machinery and equipment

$

758

$

741

Tooling

 

14

 

11

 

772

 

752

Less: Accumulated depreciation and amortization

 

(707)

 

(659)

Property and equipment, net

$

65

$

93

Depreciation and amortization expense for the three months ended June 30, 2024 and 2023 were approximately of $28,000 and $32,000, respectively. Depreciation and amortization expense for the six months ended June 30, 2024 and 2023 were approximately  $48,000 and $65,000, respectively.

Accrued liabilities (in thousands):

June 30, 

December 31, 

    

2024

    

2023

Accrued vacation

$

448

$

418

Accrued audit fees

161

211

Accrued legal fees

158

Accrued rebate

151

215

Customer advance

150

19

Accrued compensation

 

130

 

127

Accrued lease liability, current portion

67

Accrued other

114

327

Total accrued liabilities

$

1,379

$

1,317

v3.24.2.u1
Borrowings
6 Months Ended
Jun. 30, 2024
Borrowings  
Borrowings

4.

Borrowings

Convertible Promissory Note

On August 15, 2022, the Company entered into a Securities Purchase Agreement (the “August Purchase Agreement”), by and between the Company and an institutional investor (the “Convertible Note Investor”), pursuant to which the Company agreed to issue to the Investor a senior secured convertible note in the principal amount of $3,600,000 (the “Convertible Note”) and a warrant to purchase up to 140 shares of the Company’s common stock, at an initial exercise price of $14,955.00 per share, in consideration for $3,000,000. Pursuant to the August Purchase Agreement, upon the closing of the private placement, pursuant to which Maxim Group LLC (“Maxim”) acted as placement agent (the “Private Placement”), the Company received gross proceeds of $3,000,000. After the deduction of banker fees, commitment fees and other expenses associated with the transaction, the Company received net proceeds of $2,483,000. The Company used the net proceeds primarily for working capital and general corporate purposes.

4.

Borrowings, continued

The Convertible Note matured on August 15, 2024, does not bear interest and ranks senior to the Company’s existing and future indebtedness and is secured to the extent and as provided in the Security Agreements. The Convertible Note is convertible in whole or in part at the option of the Convertible Note Investor into shares of Common stock (the “Conversion Shares”) at the Conversion Price (as defined below) at any time following the date of issuance of the Convertible Note. The Convertible Note defines “Conversion Price” as equal to the lesser of (a) 90% of the average of the five lowest daily VWAPs (as defined in the Convertible Note) during the previous twenty trading days prior to delivery to the Company of the Convertible Note Investor’s applicable notice of conversion and (b) $13,890.00 (the “Base Conversion Price”). The Base Conversion Price is subject to full ratchet antidilution protection, subject to a floor conversion price of $75.00 per share (the “Floor Price”).

In connection with the Private Placement, the Company issued warrants to the Convertible Note Investor and Maxim to purchase common shares of 140 and 13, respectively (see Note 5 – Fair Value Measurements). The sum of the fair value of the warrants, the original issue discount for interest, issuance costs and the derivative liability for the embedded conversion feature for the Convertible Note were recorded as debt discounts totaling $2,509,000 to be amortized to interest expense over the respective term using the effective interest method. During the year ended December 31, 2023, the Company recognized $737,000 of interest expense from the amortization of debt discounts and repayment of the convertible note payable in April 2023.

In connection with the Private Placement, the Company entered into a placement agency agreement with Maxim (the “Placement Agency Agreement”), and agreed to issue to Maxim, a warrant to purchase up to an aggregate of 13 shares of Common Stock (the “Maxim Warrant”) at an initial exercise price of $14,955.00 per share, which is exercisable at any time on or after the six-month anniversary of the closing date of the Private Placement and will expire on the fifth (5th) anniversary of its date of issuance.

Effective August 24, 2022, the Company and the Investor agreed to amend Section 3.1(b) of the Convertible Note to provide that the Conversion Price could not be lower than the Floor Price until stockholder approval has been obtained, after which stockholder approval the Floor Price may be reduced to no lower than $37.50, subject to adjustment pursuant to the terms of the Convertible Note. The changes were effected by cancellation of the Convertible Note and the issuance of a replacement senior secured convertible note (the “New Convertible Note”) to the Investor. The New Convertible Note contains identical terms as the Convertible Note, except for the amendment to the Section 3.1(b).

On November 21, 2022, the Company and Maxim entered into an agreement to amend the Maxim Warrant (the “Maxim Warrant Amendment”). Specifically, the Maxim Warrant Amendment sets forth certain circumstances in which the lock up restrictions to which the Maxim Warrant is subject would not apply. The Maxim Warrant Amendment also clarifies certain limitations with respect to demand registration rights and provides that Maxim’s piggy-back registration rights expire on the fifth (5th) anniversary of the Maxim Warrant’s date of issuance.

The New Convertible Note contained several embedded conversion features. The Company concluded that those conversion features require bifurcation from the New Convertible Note and subsequent accounting in the same manner as a freestanding derivative. The Company recognized a derivative liability of $286,000 upon execution of the note agreement and such amount was included in the $2,509,000 of debt discounts noted above. Subsequent changes in the fair value of these conversion features are measured at each reporting period and recognized in the consolidated statement of operations.

On November 28, 2022, the Company entered into a waiver of rights (the “Waiver”) with the New Convertible Note Investor, pursuant to which the New Convertible Note Investor agreed to waive certain prohibitions under the August Purchase Agreement with respect to the offering of units in December 2022 in exchange for the issuance by the Company, on the closing date of such offering, of an additional number of Series A warrants to purchase shares of Common Stock (“Series A Warrants”) and an additional number of Series B warrants to purchase shares of Common Stock (“Series B Warrants”) equal to the quotient obtained by dividing $750,000 by the public offering price for the units sold in the offering (such Warrants, the “Waiver Warrants”).

4.

Borrowings, continued

In connection with the public offering the Company consummated on December 1, 2022 (the “December 2022 Offering”), the Company issued 357 Series A Warrants and 357 Series B Warrants to the New Convertible Note Investor (See Note 6). The Company’s obligation to issue shares of common stock underlying the Waiver Warrants is expressly conditioned upon stockholder approval of all of the transactions contemplated by the August Purchase Agreement. At a Special Meeting of Stockholders held on January 24, 2023, the Company received stockholder approval of the transactions contemplated by the August Purchase Agreement. Additionally, as a result of the December 2022 Offering, the Base Conversion Price was adjusted to the Floor Price.

On February 1, 2023, the holder of the New Convertible Note converted approximately $708,000, a portion of the outstanding principal amount into 450 shares of the Company’s common stock.

On April 11, 2023, the Company paid $1,656,744 to the holder of the New Convertible Note which repaid the entirety of the outstanding balance and included the unpaid principal, interest through the payoff date, and a pre-payment premium of $276,000 which was recorded as a component of loss on debt extinguishment.

September 2023 Short-Term Loan Agreement

On September 8, 2023, the Company entered into that certain Loan and Security Agreement with the Meriwether Group Capital Hero Fund LP (“Meriwether Hero Fund”). Pursuant to the Loan and Security Agreement, the Meriwether Hero Fund agreed to provide the Company with bridge financing in the form of a term loan in the original principal amount of $650,000, which term loan will be senior in priority to the Company’s present and future indebtedness (“Meriwether Loan”). The Meriwether Loan was to mature on November 7, 2023, subject to further extension. In addition, the Company had the right to request additional funding under the Loan and Security Agreement.

Borrowings under the Meriwether Loan bore interest at a rate per annum equal to 18%. On the maturity date, subject to any extension, the Company was obligated to make a payment equal to all unpaid principal and accrued interest. Pursuant to Meriwether Loan, the Company was required to pay to the Meriwether Hero Fund a fully earned, non-refundable, origination fee in the amount of$50,000. The Company was also required to pay to the Meriwether Hero Fund a fully earned, non-refundable, exit fee in the amount of $50,000 due and payable on the maturity date.

The Meriwether Loan also provided that all present and future indebtedness and the obligations of the Company to the Meriwether Hero Fund shall be secured by a first priority security interest in all real and personal property collateral of the Company.

The Meriwether Loan contained customary representations, warranties and affirmative and negative covenants. In addition, the Meriwether Loan contained customary events of default that entitle the Meriwether Hero Fund to cause the Company’s indebtedness under the Meriwether Loan to become immediately due and payable, and to exercise remedies against the Company and the collateral securing the term loan.

On October 10, 2023, the Meriwether Hero Fund, agreed to extend the Meriwether Loan maturity date from November 7, 2023 to December 7, 2023, for a fee of $20,000.

On December 7, 2023, the Company repaid the full amount of the Meriwether Loan, including all fees and accrued interest.

January 2024 Short-Term Loan Agreement

On January 19, 2024, the Company issued promissory notes in the aggregate principal amount of $1,000,000 (the “January 2024 Promissory Notes”) and common stock purchase warrants to purchase up to an aggregate of 66,665 shares (the “January 2024 Warrant Shares”) of the Company’s common stock, at an initial exercise price of $22.23 per share with four accredited investors (each an “Investor” and together the “Investors”). In connection with the January 2024 Promissory Notes, the Company received gross proceeds of $600,000, before fees and other expenses associated with the transaction. 

4.

Borrowings, continued

The January 2024 Promissory Note was to mature on the earlier to occur of: (i) July 17, 2024 and (ii) the full or partial exercise of certain Series B Preferred Stock purchase warrants currently held by the Investor, issuable for at least 9,322 shares of the Company’s Series B Convertible Preferred Stock, par value $0.0001 per share (“Series B Preferred Stock”), upon such full or partial exercise. The January 2024 Promissory Notes did not bear interest except upon the occurrence of an Event of Default (as defined in the January 2024 Promissory Notes). The January 2024 Promissory Notes were not convertible into shares of Common Stock or Series B Preferred Stock.  

Between the dates of January 26, 2024 and February 2, 2024, the January 2024 Promissory Notes were repaid in full following the exercise of certain of the Company’s Series B Preferred Stock purchase warrants for a total of 29,322 shares of Series B Preferred Stock. The 2024 Promissory Notes were settled via the payment of $667,000 in cash and a $333,000 offset to the amount due by one of the investors from the exercise of 9,322 Series B Preferred Stock purchase warrants.

In connection with the issuance of the January 2024 Warrant Shares (see Note 5 – Fair Value Measurements), the fair value of the warrants and the original issue discount for interest were recorded as debt discounts totaling $1,260,000. The debt discounts were to be amortized to interest expense over the respective term using the effective interest method. In connection with the full repayment of the January 2024 Promissory Notes, the Company recognized $1,260,000 of interest expense in the six months ended June 30, 2024.

v3.24.2.u1
Fair Value Measurements
6 Months Ended
Jun. 30, 2024
Fair Value Measurements  
Fair Value Measurements

5.

Fair Value Measurements

The Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. Each level of input has different levels of subjectivity and difficulty involved in determining fair value.

Level 1 – Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date. Therefore, determining fair value for Level 1 investments generally does not require significant judgment, and the estimation is not difficult.
Level 2 – Pricing is provided by third-party sources of market information obtained through investment advisors. The Company does not adjust for or apply any additional assumptions or estimates to the pricing information received from its advisors.
Level 3 – Inputs used to measure fair value are unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions. The determination of fair value for Level 3 instruments involves the most management judgment and subjectivity. The Company’s financial assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2024 and December 31, 2023 by level within the fair value hierarchy, are as follows:

(in thousands)

June 30, 2024

Significant

Quoted prices

other

Significant

in active

observable

unobservable

markets

inputs

inputs

    

(Level 1)

    

(Level 2)

    

(Level 3)

Liabilities:

  

  

  

Warrant liabilities

$

$

$

25

5.Fair Value Measurements, continued

(in thousands)

December 31, 2023

Significant

Quoted prices

other

Significant

in active

observable

unobservable

markets

inputs

inputs

    

(Level 1)

    

(Level 2)

    

(Level 3)

Liabilities:

Warrant liabilities

$

$

$

5,460

There were no transfers between Level 1, 2 or 3 during the three and six months ended June 30, 2024 or 2023.

Warrant Liabilities

The following table includes a summary of changes in fair value of the Company’s warrant liabilities measured at fair value using significant unobservable inputs (Level 3) as of June 30, 2024 and 2023. For June 30, 2024, the fair value of the common warrants was determined using the Black-Scholes Model based on the following key inputs and assumptions: common stock price of $2.57; exercise prices between $3.196 and $1,574.00; expected yield of 0.0%; expected volatility of 143%; risk-free interest rate of 4.52% and expected life between 3.1 and 3.6 years.

During the three months ended June 30, 2024, the Company amended the terms of certain warrant agreements to remove certain exercise price reset, right to reprice and/or share adjustment provisions (“Reset Provisions”) following a reverse split, in addition to other revisions to the warrants. In April 2024, the Company effected the April 2024 Reverse Stock Split thereby removing the Reset Provisions (“Reset Amendment Effective Date”) and in accordance with provisions in certain of the warrants issued warrants to purchase an additional 5,602,693 shares of common stock. Accordingly, the Company remeasured the warrant liability for each of the amended warrants following the Reset Amendment Effective Date and recorded that amount to change in fair value of warrant liabilities with a corresponding increase to warrant liabilities. Following the Reset Amendment Effective Date, such warrants were no longer deemed to be liability warrants but were now classified as equity warrants. In connection with this reclassification the Company reclassed approximately $41.9 million from warrant liabilities to additional paid in capital.

For the six months ended June 30,

(in thousands)

    

2024

2023

Beginning balance

$

5,460

    

$

8,945

Additions

 

8,701

 

5,600

Change in fair value

 

29,126

 

(5,850)

Exercise of warrant liabilities

 

(587)

 

(8,191)

Repurchase

(824)

Conversion of liability warrants to equity warrants

(41,851)

Ending balance

$

25

$

504

The changes in fair value of the warrant liabilities are recorded in change in fair value of warrant liabilities in the condensed consolidated statements of operations.

v3.24.2.u1
Convertible Redeemable Preferred Stock and Stockholders' Equity
6 Months Ended
Jun. 30, 2024
Convertible Redeemable Preferred Stock and Stockholders' Equity  
Convertible Redeemable Preferred Stock and Stockholders' Equity

6.

Convertible Redeemable Preferred Stock and Stockholders’ Equity

Series B Preferred Stock, Series B Preferred Stock Warrants

On October 16, 2023, the Company consummated a public offering for an aggregate of 87,000 Series B Units (“Series B Units”). Each Series B Unit consists of one share of the Company’s Series B Preferred Stock and two warrants, each to purchase one share of Series B Preferred Stock (“Series B Preferred Stock Warrant”). Each share of Series B Preferred Stock is convertible at the holder’s option at any time, through a two-year period, into the number of shares of the Company’s common stock determined by dividing the $100 stated value per share of the Series B Preferred Stock by a conversion price of $62.205 per share. Each share of Series B Preferred Stock is convertible into 1 share of common stock, and each Series B Preferred Stock Warrant entitles the holder to purchase one share of Series B Preferred Stock at an initial exercise price of $55 per share. Dividends are paid in additional fully paid and nonassessable Series B Preferred Stock, at a 20% dividend rate, non-cumulative. If any shares of Series B Preferred Stock are outstanding at the end of the two-year period, the holder would be entitled to a cash redemption value equal to the $100 stated value per share. The gross proceeds from the sale of Series B Units were $4,785,000, before broker fees and related expenses of approximately $830,000.

Exercise of Series B Preferred Stock Warrants

On December 5, 2023, the Company executed an Inducement Agreement (the “Inducement Agreement”) with the holders of Series B Preferred Stock Warrants, reducing the exercise price to $35.72 per share of Series B Preferred Stock. Any holder that exercised Series B Preferred Stock Warrants under the Inducement Agreement received a new Common Stock Warrant (“New Common Stock Warrants”) for each Series B Preferred Stock Warrant exercised. Each New Common Stock Warrant entitles the holder to purchase 2 shares of common stock at an initial exercise price of $22.23 per share.

Due to certain price protections included with the New Common Stock Warrants, the warrants did not meet the criteria for equity classification and thus are subject to liability treatment. Total proceeds from the exercise of 61,613 Series B Preferred Stock Warrants of $2,264,000 through December 31, 2023, and the remaining fair value of the Series B Preferred Stock Warrant liability immediately prior to the exercise of $1,628,000 resulted in a total of $3,892,000 recorded for the new 61,613 shares of Series B Preferred Stock, of which $3,322,000 was allocated to the Common Stock Warrants liability based on their fair value and $569,000 was allocated to the Series B Preferred Stock using the residual method of allocation. In connection with this new issuance, the Company has recorded additional discounts to the Series B Preferred Stock for a beneficial conversion feature of $196,000, the Common Stock Warrants of $3,322,000 and issuance costs of $146,000. The Company also accretes to Series B Preferred Stock, against additional paid in capital as a deemed dividend, for the difference between the total proceeds of $35.72 per share of Series B Preferred Stock and the full redemption price of $100 per share. The Company uses the effective interest method to calculate the accretion amount for each period. All 61,613 New Common Stock Warrants issued as a result of the exercise of Series B Preferred Stock Warrants were outstanding as of December 31, 2023.

Issuance costs of $429,000 and $125,000 were expensed on the date of issuance of the Series B Preferred Stock Warrants and the New Common Stock Warrants, respectively as such warrants were recorded at fair value. Total issuance costs expensed from the issuances were charged to Change in fair value of warrant liabilities and amounted to $554,000.

6.

Convertible Redeemable Preferred Stock and Stockholders’ Equity, continued

Through various dates from issuance to December 31, 2023, the holders of 110,278 shares of Series B Preferred Stock converted their shares into 177,282 shares of Common Stock. Unamortized discounts to the Series B Preferred Stock of $6,063,000 were immediately recorded as a deemed dividend as of conversion date. Amortization and accretion of discounts from issuance date through December 31, 2023 amounted to $297,000, which were also recorded as a deemed dividend to the holders of Series B Preferred Stock. The total such deemed dividends amounted to $6,360,000 for the year ended December 31, 2023 and was recorded as a net loss available to common stockholders on the Company’s consolidated statement of operations.

The 38,335 shares of Series B Preferred Stock outstanding as of December 31, 2023, were to become mandatorily redeemable on October 15, 2025 in the amount of $3,833,500.

Through various dates during the six months ended June 30, 2024, holders of Series B Preferred Stock Warrants exercised their warrants into 29,332 shares of Series B Preferred Stock at an exercise price of $35.72 per share. For each exercised Series B Preferred Stock Warrant, the holder received one share of Series B Preferred Stock and one New Common Stock Warrant. Each New Common Stock Warrant entitles the holder to purchase 2 shares of Common Stock at an initial exercise price of $22.23 per share. Due to certain price protections included with the New Common Stock Warrants, the warrants did not meet the criteria for equity classification and thus are subject to liability treatment. Total proceeds from the exercise of the 29,332 Series B Preferred Stock Warrants amounted to $1,047,000, and the remaining fair value of the Series B Preferred Stock Warrant Liability immediately prior to the exercise of $587,000 resulted in a total of $1,634,000 recorded for the new 29,332 shares of Series B Preferred Stock, of which $1,188,000 was allocated to the New Common Stock Warrants liability based on their fair value and $446,000 was allocated to the Series B Preferred Stock using the residual method of allocation. In connection with this new issuance, the Company recorded additional discounts to the Series B Preferred Stock for the New Common Stock Warrants of $1,188,000 and issuance costs of $61,000. The Company also accretes to Series B Preferred Stock, against additional paid-in-capital as a deemed dividend, for the difference between the total proceeds of $35.72 per share of Series B Preferred Stock and the full redemption price of $100 per share. The Company uses the effective interest method to calculate the accretion amount for each period.

Issuance costs of $44,000 were expensed on the date of issuance of the New Common Stock Warrants, as such warrants were recorded at fair value.

Conversion of Series B Preferred Stock

Through various dates during the six months ended June 30, 2024, the holders of 5,000 shares of Series B Preferred Stock converted their shares into 8,038 shares of Common Stock. Unamortized discounts to the Series B Preferred Stock of $269,000 were immediately recorded as a deemed dividend as of conversion date.

February 2024 Series B Preferred Stock and Series B Preferred Stock Warrants Repurchase

On February 13, 2024, the Company and its Series B Preferred Stock and Series B Preferred Stock Warrants holders entered into an arrangement where the Company agreed to repurchase 62,657 Series B Preferred Stock shares and 81,315 Series B Preferred Stock warrants for a total of $6,266,000. Unamortized discounts to the Series B Preferred Stock of $5,381,000 were immediately recorded as a deemed dividend as of repurchase date. The remaining fair value of the Series B Preferred Stock Warrant Liability of $824,000 was adjusted against additional paid-in-capital on repurchase date.

Other Deemed Dividends

Amortization and accretion of discounts for all Series B Preferred Stock during the six months ended June 30, 2024 amounted to $192,000, which were also recorded as a deemed dividend to the holders of Series B Preferred Stock.

The total of deemed dividends (as discussed in this section, the Conversion of Series B Preferred Stock and February 2024 Series B Preferred Stock and Series B Preferred Stock Warrants Repurchase sections above) amounted to $5,842,000 for the six months ended June 30, 2024 and was recorded as an adjustment to net loss available to common stockholders on the Company’s condensed consolidated statement of operations.

6.

Convertible Redeemable Preferred Stock and Stockholders’ Equity, continued

Common Stock

2018 Long Term Stock Incentive Plan

On January 30, 2018, the Company’s board of directors approved the establishment of the Company’s 2018 Long-Term Stock Incentive Plan (the “LTIP”) and termination of its Carve-Out Plan. Under the LTIP, the aggregate maximum number of shares of common stock (including shares underlying options) that may be issued under the LTIP pursuant to awards of Restricted Shares or Options will be limited to 15% of the outstanding shares of common stock, which calculation shall be made on the first trading day of each new fiscal year; provided that, in any year no more than 8% of the common stock or derivative securitization with common stock underlying 8% of the common stock may be issued in any fiscal year. At a Special Meeting of Stockholders on January 24, 2023, the Company’s stockholders approved certain amendments to the LTIP to: (i) increase the annual share limit of Common Stock that may be issued in any single fiscal year only for the 2023 fiscal year under the LTIP from 8% of the shares of Common Stock outstanding to 15% of the shares of Common Stock outstanding (which amount equates to the maximum amount that may be issued in the aggregate under the LTIP), and (ii) permit immediately quarterly calculations based on the number of shares of Common Stock outstanding as of the first trading day of each fiscal quarter, rather than solely as of the first trading day of the fiscal year. At a Special Meeting of Stockholders on March 15, 2024, the Company’s stockholders further approved an amendment to the LTIP to increase the annual share limit of Common Stock that may be issued only for the 2024 fiscal year under the LTIP from 8% of the shares of Common Stock outstanding to 15% of the shares of Common Stock outstanding (which amount equates to the maximum amount that may be issued in the aggregate under the LTIP). As of June 30, 2024, up to 477,774 shares of common stock are available for grants to participants under the LTIP.

A summary of activity related to restricted stock awards for the six months ended June 30, 2024 is presented below:

    

    

Weighted-Average 

Stock Awards

Shares

Grant Date Fair Value

Non-vested as of January 1, 2024

5,382

$

374.00

Granted

 

255,915

$

2.64

Vested

 

(774)

$

674.09

Forfeited

 

(82)

$

681.69

Non-vested as of June 30, 2024

 

260,441

$

9.22

As of June 30, 2024, the unamortized compensation costs related to the unvested restricted stock awards was approximately $1,620,000 which is to be amortized on a straight-line basis over a weighted-average period of approximately 2 years.

For the six months ended June 30, 2024, 774 shares of common stock were issued upon vesting of outstanding restricted stock, pursuant to the LTIP with an intrinsic value of less than $2,000. For the six months ended June 30, 2023, 24 shares of common stock were issued upon vesting of outstanding restricted stock, pursuant to the LTIP with an intrinsic value of less than $5,000.

6.

Convertible Redeemable Preferred Stock and Stockholders’ Equity, continued

2020 Stock Incentive Plan

A summary June 30, 2024 is presented below:

Weighted-Average 

Stock Units

    

Shares

    

Grant Date Fair Value

Non-vested as of January 1, 2024

 

1

$

56,430.00

Granted

 

$

Vested

 

(1)

$

56,430.00

Forfeited

 

$

Non-vested as of June 30, 2024

 

$

As of June 30, 2024, there was no unamortized compensation costs.

For the six months ended June 30, 2024, 1 share of common stock was issued upon vesting of outstanding restricted stock units pursuant to the 2020 Stock Incentive Plan with an intrinsic value of less than $1,000. For the six months ended June 30, 2023, no shares of common stock, issued under the 2020 Stock Incentive Plan, were released.

Inducement Grant

On September 13, 2021, the Company issued 21 shares of restricted common stock to Eric Almgren, the Company’s Chief Strategist, as an inducement grant (“September 2021 Inducement Grant”). As of June 30, 2024, the unamortized compensation cost related to the unvested September 2021 Inducement Grant was approximately $57,000 which is being amortized on a straight-line basis over a period of approximately 0.2 years. The Company recorded stock-based compensation of $64,000 and $128,000 related to this grant for three and six months ended June 30, 2024. As of June 30, 2024, 16 shares are unvested.

For the six months ended June 30, 2024, no shares of restricted stock were released under the September 2021 Inducement Grant.

2022 Plan

A summary of activity related to restricted stock units under the Company’s Technical Team Retention Plan of 2022 (the “2022 Plan”) for the six months ended June 30, 2024 is presented below:

Weighted-Average

Stock Units

    

Shares

    

Grant Date Fair Value

Non-vested as of January 1, 2024

 

17

$

7,800.00

Granted

 

$

Vested

 

(3)

$

7,800.00

Forfeited

 

$

Non-vested as of June 30, 2024

 

14

$

7,800.00

As of June 30, 2024, the unamortized compensation cost related to the unvested restricted stock units was approximately $94,000 which is to be amortized on a straight-line basis over a weighted-average period of approximately 2 years.

For the six months ended June 30, 2024, 3 shares of common stock were issued upon vesting of outstanding restricted stock units pursuant to the 2022 Plan with an intrinsic value of less than $1,000. For the six months ended June 30, 2023, no shares of common stock, issued under the 2022 Plan, were released.

6.

Convertible Redeemable Preferred Stock and Stockholders’ Equity, continued

February 2023 Offering

On January 31, 2023, the Company entered into a securities purchase agreement with certain institutional investors, pursuant to which the Company agreed to issue and sell to such investors (i) in a registered direct offering, 1,344 shares of common stock and pre-funded warrants (the “February 2023 Pre-Funded Warrants”) to purchase up to 2,545 shares of common stock, at an exercise price of $0.015 per share of common stock, and (ii) in a concurrent private placement, common stock purchase warrants, exercisable for an aggregate of up to 5,833 shares of common stock, at an initial exercise price of $1,573.50 per share of common stock (the “February 2023 Offering”). In February and March of 2023, all the February 2023 Pre-Funded Warrants were exercised for cash.

On February 3, 2023, the Company closed the February 2023 Offering, and received net proceeds of approximately $5.3 million after deducting placement agent fees and other offering expenses payable by the Company.

Also, in connection with the February 2023 Offering, on January 31, 2023, the Company entered into a placement agency agreement with Maxim, pursuant to which Maxim agreed to act as placement agent on a “best efforts” basis in connection with the offering and (ii) the Company agreed to pay Maxim an aggregate fee equal to 8.0% of the gross proceeds raised in the offering.

March 2023 Offering

On March 27, 2023, the Company entered into a securities purchase agreement with certain institutional investors, pursuant to which the Company agreed to issue and sell to such investors (i) in a registered direct offering, 5,581 shares of common stock of the Company and (ii) in a concurrent private placement, common stock purchase warrants, exercisable for an aggregate of up to 11,163 shares of common stock, at an initial exercise price of $286.50 per share (the “March 2023 Offering”).

On March 29, 2023, the Company closed the March 2023 Offering and received net proceeds of approximately $1.6 million, after deducting fees payable to the financial advisor and other offering expenses.

April 2023 Offering

On April 7, 2023, the Company entered into a securities purchase agreement with certain institutional investors, pursuant to which the Company issued and sold to such investors (i) in a registered direct offering, 4,954 shares of common stock of the Company and (ii) in a concurrent private placement, common stock purchase warrants exercisable for an aggregate of up to 9,908 shares of Common Stock, at an initial exercise price of $211.50 per share of Common Stock (the “April 2023 Offering”).

On April 12, 2023, the Company closed the April 2023 Offering and received net proceeds of approximately $1.0 million, after deducting fees payable to the financial advisor and other offering expenses.

October 2023 Warrant Repurchase

On October 16, 2023, the Company and certain of its common stock warrants holders entered into an arrangement where the Company agreed to repurchase outstanding common stock purchase warrants exercisable for an aggregate of up to 30,978 shares of Common Stock, at an exercise prices ranging from $193.50 to $286.50 per share of Common Stock for a total of $2,323,000. The repurchased warrants were previously classified as equity warrants and at the date of repurchase a charge was recorded to additional paid-in capital.

6.

Convertible Redeemable Preferred Stock and Stockholders’ Equity, continued

February 2024 Issuance of Common Stock and Pre-Funded Common Stock Warrants

On February 13, 2024, the Company consummated a public offering (the “February Public Offering”) of 158,227 units (the “February Units”) and 867,373 pre-funded units (the “February Pre-Funded Units”). Each February Unit was issued at $9.75 per unit and included one share of common stock and one common stock warrant (the “February Common Warrants”) exercisable for one share of common stock at a $9.75 exercise price. Each February Pre-Funded Unit was issued at $9.735 per unit and included one pre-funded common stock warrant (the “February Pre-Funded Warrants”), exercisable for one share of common stock at an initial exercise price of $0.015 and one February Common Warrant. The gross proceeds from the issuance of the February Units and the February Pre-Funded Units were $1,543,000 and $8,444,000, respectively, for total aggregate proceeds of $9,987,000 before broker fees and related expenses of approximately $998,000. As a result of certain price protection clauses, the February Common Warrants did not meet the criteria for equity classification and thus are subject to liability treatment. Accordingly, of the $9,987,000 gross proceeds from the February public offering, an amount of $6,308,000, representing the fair value of the February Common Warrants as of the issuance date was allocated to the February Common Warrants liability, with the residual proceeds of $3,679,000 allocated to the Common Stock and February Pre-Funded Warrants, which met the criteria for equity classification.

Of the gross broker fees and related expenses of approximately $998,000, the Company allocated $368,000 to the issued Common Stock and February Pre-Funded Warrants, which were recorded as a reduction of additional paid-in-capital. The remaining issuance cost of $630,000 was allocated to the February Common Warrants and was expensed on the date of issuance as such warrants were recorded at fair value.

March 2024 Issuance of Common Stock, Prefunded Common Stock Warrants and Common Stock Warrants

On March 26, 2024, the Company entered into a Securities Purchase Agreement with certain purchasers where the Company issued 417,833 shares of common stock, 93,342 pre-funded common stock warrants (the “March Pre-Funded Warrants”) and common stock warrants (the “March Common Warrants”) to purchase up to 511,175 shares of common stock at an initial exercise price of $6.00 per share (known in aggregate as the “March 2024 Offering”). Total proceeds per the Securities Purchase Agreement amounted to $2,299,000 before broker fees and other related expenses of approximately $388,000. As a result of certain price protection clauses, the March Common Warrants did not meet the criteria for equity classification and thus are subject to liability treatment. Accordingly, of the $2,299,000 gross proceeds from the March public offering, an amount of $1,227,000, representing the fair value of the March Common Warrants as of the issuance date was allocated to the March Common Warrants liability, with the residual proceeds of $1,072,000 allocated to the Common Stock and March Pre-Funded Warrants, which met the criteria for equity classification.

Of the gross broker fees and related expenses of approximately $388,000, the Company allocated $181,000 to the issued Common Stock and the March Pre-Funded Warrants, which were recorded as a reduction of additional paid-in-capital. The remaining issuance cost of $207,000 was allocated to the March Common Warrants and was expensed on the date of issuance as such warrants were recorded at fair value.

April 2024 Issuances of Common Stock and Common Stock Warrants

On April 17, 2024, the Company entered into a securities purchase agreement with certain accredited investors, pursuant to which the Company agreed to issue and sell to such investors (i) in a registered direct offering, 225,834 shares of common stock at $3.321 per share, and (ii) in a concurrent private placement, common stock purchase warrants exercisable for an aggregate of up to 225,834 shares of common stock, at an initial exercise price of $3.196 per share (the “Initial April 2024 Registered Direct Offering and Concurrent Private Placement”). The Initial 2024 Registered Direct Offering and Concurrent Private Placement closed on April 19, 2024 and the Company received gross proceeds of approximately $750,000 before deducting placement agent fees and other offering expenses of approximately $159,000.

6.

Convertible Redeemable Preferred Stock and Stockholders’ Equity, continued

On April 19, 2024, the Company entered into a securities purchase agreement with certain accredited investors, pursuant to which the Company agreed to issue and sell to such investors (i) in a registered direct offering, 361,904 shares of common stock at $5.25 per share, and (ii) in a concurrent private placement, common stock purchase warrants exercisable for an aggregate of up to 542,856 shares of common stock, at an initial exercise price of $5.06 per share (the “Second April 2024 Registered Direct Offering and Concurrent Private Placement”). The Second 2024 Registered Direct Offering and Concurrent Private Placement closed on April 23, 2024 and the Company received gross proceeds of approximately $1.9 million before deducting placement agent fees and other offering expenses of approximately $268,000.

On April 26, 2024, the Company entered into a securities purchase agreement with certain accredited investors, pursuant to which the Company agreed to issue and sell to such investors (i) in a registered direct offering, 418,845 shares of common stock at $5.73 per share, and (ii) in a concurrent private placement, common stock purchase warrants exercisable for an aggregate of up to 418,845 shares of common stock, at an initial exercise price of $5.60 per share (the “Third April 2024 Registered Direct Offering and Concurrent Private Placement”). The Third 2024 Registered Direct Offering and Concurrent Private Placement closed on April 30, 2024 and the Company received gross proceeds of approximately $2.4 million before deducting placement agent fees and other offering expenses of approximately $298,000.

May 2024 Issuances of Common Stock and Common Stock Warrants

On May 13, 2024, the Company entered into a securities purchase agreement with certain accredited investors, pursuant to which the Company agreed to issue and sell to such investors (i) in a registered direct offering, 785,000 shares of common stock at $3.31 per share, and (ii) in a concurrent private placement, common stock purchase warrants exercisable for an aggregate of up to 785,000 shares of common stock, at an initial exercise price of $3.18 per share (the “Initial May 2024 Registered Direct Offering and Concurrent Private Placement”). The Initial May 2024 Registered Direct Offering and Concurrent Private Placement closed on May 15, 2024 and the Company received gross proceeds of approximately $2.6 million before deducting placement agent fees and other offering expenses of approximately $314,000.

On May 15, 2024, the Company entered into a securities purchase agreement with certain accredited investors, pursuant to which the Company agreed to issue and sell to such investors (i) in a registered direct offering, 675,000 shares of common stock at $3.61 per share, and (ii) in a concurrent private placement, common stock purchase warrants exercisable for an aggregate of up to 675,000 shares of common stock, at an initial exercise price of $3.48 per share (the “Second May 2024 Registered Direct Offering and Concurrent Private Placement”). The Second May 2024 Registered Direct Offering and Concurrent Private Placement closed on May 17, 2024 and the Company received gross proceeds of approximately $2.4 million before deducting placement agent fees and other offering expenses of approximately $290,000.

For the three months ended June 30, 2024, the Company’s board of directors approved the issuance of a total of 136,203 shares of common stock to two vendors for investor relations services. The fair value of such common shares was calculated to be $360,000 and was recorded to other assets and additional paid in capital. The fair value of such shares will be amortized over the service period of each agreement which ranged from 6 months to 12 months. The shares of common stock will be issued in July 2024.

Warrants for Shares of Common Stock

A summary of the warrant activity and related information for the six months ended June 30, 2024 and the year ended 2023 is provided as follows.

In connection with February 2023 Offering, the Company issued common stock purchase warrants to investors to purchase up to 5,833 shares of the Company’s common stock, at an initial exercise price of $1,573.50 per share. The grant date fair value of such warrants was $5,600,000, which was recorded as a liability with the offset recorded to additional paid-in capital on the condensed consolidated balance sheets. The fair value of such warrants was determined using the Black-Scholes Model based on the following weighted average assumption: common stock price on the date of grant of $1,335.00; expected yield of 0.0%; expected volatility of 96%; risk-free interest rate of 3.67% and expected life of 5 years.

6.

Convertible Redeemable Preferred Stock and Stockholders’ Equity, continued

In connection with March 2023 Offering, the Company issued common stock purchase warrants to investors to purchase up to 11,163 shares of the Company’s common stock, at an initial exercise price of $286.50 per share. The grant date fair value of such warrant was $2,113,000, which was recorded as equity. The fair value of such warrants was determined using the Black-Scholes Model based on the following weighted average assumption: common stock price on the date of grant of $249.00; expected yield of 0.0%; expected volatility of 104%; risk-free interest rate of 3.67% and expected life of 5 years.

May 2023 Warrant Inducement

On May 15, 2023, the Company entered into warrant exercise inducement offer letters with the holders of common stock purchase warrants exercisable for an aggregate of up to 9,907 shares of common stock at an initial exercise price of $211.50 per share issued on April 12, 2023 (the “April Warrants”). The April Warrant holders agreed to exercise for cash April Warrants to purchase up to 9,907 shares of common stock in exchange for the Company’s agreement to issue 19,815 new warrants (the “May Inducement Warrants”) on substantially the same terms as the April Warrants. The Company received net proceeds of approximately $1.9 million from the exercise of the April Warrants. Each May Inducement Warrant is exercisable at a price per share of common stock of $199.50, which was equal to the Minimum Price (as defined by the Nasdaq Listing Rules).

Each May Inducement Warrant is immediately exercisable upon issuance and will expire on the fifth anniversary of its issuance. The exercise price of the May Inducement Warrants is subject to appropriate adjustment in the event of recapitalization events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting the Company’s common stock. The May Inducement Warrants are callable by the Company at a redemption price of $75.00 per May Inducement Warrant, provided that the resale of the shares of common stock underlying the May Inducement Warrants are then registered or may be resold under Rule 144 under the Securities Act.

July 2023 Warrant Inducement

On July 26, 2023, the Company entered into warrant exercise inducement offer letters (the “July Inducement Letters”) with holders of the May Inducement Warrants pursuant to which the Company agreed to issue new inducement warrants (the “July Inducement Warrants”) to purchase a number of shares of Common Stock equal to 100% of the number of shares of Common Stock received upon exercise of the May Inducement Warrants during the period provided for in the July Inducement Letters, with such July Inducement Warrants to be issued on substantially the same terms as the May Inducement Warrants. The holders exercised 3,400 May Inducement Warrants pursuant to certain of the July Inducement Letters, and the Company received aggregate gross proceeds of approximately $678,000 from such exercises. In exchange for the exercises of the May Inducement Warrants, the Company issued July Inducement Warrants exercisable for an aggregate of up to 3,400 shares of common stock at an initial exercise price of $193.50 per share. The inducement offering period closed at 5:00 p.m. EDT on August 8, 2023.

6.

Convertible Redeemable Preferred Stock and Stockholders’ Equity, continued

Each July Inducement Warrant was immediately exercisable upon issuance and will expire on the fifth anniversary of its issuance. The exercise price of the July Inducement Warrants is subject to appropriate adjustment in the event of recapitalization events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting the Company’s common stock. The July Inducement Warrants are callable by the Company at a redemption price of $75.00 per July Inducement Warrant, provided that the resale of the shares of common stock underlying the July Inducement Warrants are then registered or may be resold under Rule 144 under the Securities Act.

During the three months ended March 31, 2023, 18 warrants to purchase common stock were exercised for cash, resulting in proceeds of approximately $32,000. In addition, during the three months ended March 31, 2023, 7,454 warrants were exercised using an alternative cashless exercise provision, resulting in the issuance 5,705 shares of common stock.

In connection with the January 2024 Promissory Notes, the Company issued common stock purchase warrants to investors to purchase up to 66,665 shares of the Company’s common stock, at an initial exercise price of $22.23 per share. The grant date fair value of such warrant was $860,000, which was recorded as a liability with the offset recorded to additional paid-in capital on the condensed consolidated balance sheets. The fair value of such warrants was determined using the Black-Scholes Model based on the following weighted average assumption: common stock price on the date of grant of $15.99; expected yield of 0.0%; expected volatility of 119%; risk-free interest rate of 4.31% and expected life of 5 years.

In connection with February Public Offering, the Company issued common stock purchase warrants to investors to purchase up to 1,025,600 shares of the Company’s common stock, at an initial exercise price of $9.75 per share. The grant date fair value of such warrant was $6,308,000, which was recorded as a liability with the offset recorded to additional paid-in capital on the condensed consolidated balance sheets. The fair value of such warrants was determined using the Black-Scholes Model based on the following weighted average assumption: common stock price on the date of grant of $7.62; expected yield of 0.0%; expected volatility of 119%; risk-free interest rate of 4.31% and expected life of 5 years.

In connection with March 2024 Offering, the Company issued common stock purchase warrants to investors to purchase up to 511,175 shares of the Company’s common stock, at an initial exercise price of $6.00 per share. The grant date fair value of such warrant was $1,227,000, which was recorded as a liability with the offset recorded to additional paid-in capital on the condensed consolidated balance sheets. The fair value of such warrants was determined using the Black-Scholes Model based on the following weighted average assumption: common stock price on the date of grant of $3.18; expected yield of 0.0%; expected volatility of 119%; risk-free interest rate of 4.21% and expected life of 5 years.

On March 26, 2024, the Company entered into a warrant amendment agreement (the “Warrant Amendment Agreement”) with certain holders of (i) the New Common Stock Warrants, (ii) the common stock purchase warrants dated January 23, 2024 (the “January 2024 Warrants”), and (iii) the February Common Warrants (together with the New Common Stock Warrants and the January 2024 Warrants, the “Original Warrants”), whereby the holders agreed to (i) amend the New Common Stock Warrants and the January 2024 Warrants so such warrants shall not be exercisable until one or more certificates of amendment to the Company’s certificate of incorporation, as amended, are filed with the Secretary of State of the State of Delaware to effectuate an increase in authorized shares of capital stock of the Company and a reverse stock split of the Company’s outstanding shares of common stock; and (ii) remove certain exercise price reset, right to reprice and/or share adjustment provisions in the Original Warrants, to be effective following the first adjustments following the April 2024 Reverse Stock Split.

In connection with the Initial April 2024 Registered Direct Offering and Concurrent Private Placement, the Company issued Common Stock Purchase Warrants to investors to purchase up to 225,834 shares of the Company’s common stock, at an initial exercise price of $3.196 per share. The grant date fair value of such warrant was $1,255,000, which was recorded as equity. The fair value of such warrants was determined using the Black-Scholes Model based on the following weighted average assumption: common stock price on the date of grant of $6.06; expected yield of 0.0%; expected volatility of 135%; risk-free interest rate of 4.63% and expected life of 5 years.

6.

Convertible Redeemable Preferred Stock and Stockholders’ Equity, continued

In connection with the Second April 2024 Registered Direct Offering and Concurrent Private Placement, the Company issued Common Stock Purchase Warrants to investors to purchase up to 542,856 shares of the Company’s common stock, at an initial exercise price of $5.06 per share. The grant date fair value of such warrant was $2,595,000, which was recorded as equity. The fair value of such warrants was determined using the Black-Scholes Model based on the following weighted average assumption: common stock price on the date of grant of $5.39; expected yield of 0.0%; expected volatility of 135%; risk-free interest rate of 4.63% and expected life of 5 years.

In connection with the Third April 2024 Registered Direct Offering and Concurrent Private Placement, the Company issued Common Stock Purchase Warrants to investors to purchase up to 418,845 shares of the Company’s common stock, at an initial exercise price of $5.60 per share. The grant date fair value of such warrant was $2,048,000, which was recorded as equity. The fair value of such warrants was determined using the Black-Scholes Model based on the following weighted average assumption: common stock price on the date of grant of $5.54; expected yield of 0.0%; expected volatility of 135%; risk-free interest rate of 4.63% and expected life of 5 years.

In connection with the Initial May 2024 Registered Direct Offering and Concurrent Private Placement, the Company issued Common Stock Purchase Warrants to investors to purchase up to 785,000 shares of the Company’s common stock, at an initial exercise price of $3.18 per share. The grant date fair value of such warrant was $2,453,000, which was recorded as equity. The fair value of such warrants was determined using the Black-Scholes Model based on the following weighted average assumption: common stock price on the date of grant of $3.50; expected yield of 0.0%; expected volatility of 137%; risk-free interest rate of 4.35% and expected life of 5 years.

In connection with the Second May 2024 Registered Direct Offering and Concurrent Private Placement, the Company issued Common Stock Purchase Warrants to investors to purchase up to 675,000 shares of the Company’s common stock, at an initial exercise price of $3.48 per share. The grant date fair value of such warrant was $1,944,000, which was recorded as equity. The fair value of such warrants was determined using the Black-Scholes Model based on the following weighted average assumption: common stock price on the date of grant of $3.26; expected yield of 0%; expected volatility of 137%; risk-free interest rate of 4.35% and expected life of 5 years.

During the three months ended June 30, 2024, 438,611 warrants, including pre-funded warrants, to purchase common stock were exercised for cash, resulting in net proceeds of approximately $556,000. In addition, during the three months ended June 30, 2024, 3,225 warrants were exercised using an alternative cashless exercise provision, resulting in the issuance 3,211 shares of common stock. During the three months ended June 30, 2023, 1,486,132 warrants to purchase common stock were exercised for cash, resulting in net proceeds of approximately $1,895,000. In addition, during the three months ended June 30, 2023, 17,143 warrants were exercised using an alternative cashless exercise provision, resulting in the issuance 12,856 shares of common stock.

Information regarding warrants for common stock outstanding and exercisable as of June 30, 2024 is as follows:

Warrants

Weighted Average

Warrants

Exercise

Outstanding as of

Remaining

Exercisable as of

Price

    

June 30, 2024

    

Life (years)

    

June 30, 2024

$0.015 - $3.48

 

8,832,641

 

4.9

 

1,693,173

$5.06 - $6.00

 

954,827

 

4.8

 

954,827

$1,574.00

 

5,831

 

3.6

 

5,831

$14,995.00

 

12

 

3.1

 

12

$22,800 - $393,000

 

220

 

1.1

 

219

$4.45 *

 

9,793,531

 

4.9

 

2,654,062

*Weighted average

6.Convertible Redeemable Preferred Stock and Stockholders’ Equity, continued

Warrants exercisable as of June 30, 2024 exclude warrants to purchase 7,139,469 shares of common stock issued to investors that participated in the February Public Offering and March 2024 Offering that require shareholder approval prior to the warrants being exercisable.

Information regarding warrants for common stock outstanding and exercisable as of December 31, 2023 is as follows:

    

Warrants

    

Weighted Average

    

Warrants

Exercise

Outstanding as of

Remaining

Exercisable as of

Price

December 31, 2023

Life (years)

December 31, 2023

$22.50

 

188,025

 

4.9

 

467

$1,573.50

 

5,833

 

4.1

 

5,833

$14,955.00

 

13

 

3.6

 

13

$22,800.00

 

3

 

3.0

 

3

$30,000- $654,000

 

239

 

1.6

 

239

$135.00 *

 

194,113

 

4.9

 

6,555

*Weighted Average

Warrants exercisable as of December 31, 2023 exclude warrants to purchase 1 shares of common stock issued to a marketing firm, which vest upon the achievement of certain milestones and warrants to purchase 187,557 shares of common stock issued to investors that participated in the Inducement Agreement that requires shareholder approval prior to the warrants being exercisable.

v3.24.2.u1
Income Taxes
6 Months Ended
Jun. 30, 2024
Income Taxes  
Income Taxes

7.

Income Taxes

The Company recorded no provision for income taxes for the three and six months ended June 30, 2024. The Company recorded a provision for income taxes of $2,000 and $2,000 for the three and six months ended June 30, 2023, respectively.

The Company’s effective tax rate was 0.0% for the three and six months ended June 30, 2024 and 2023. The difference between the effective tax rate and the federal statutory tax rate for the three and six months ended June 30, 2024 and 2023 primarily relates to the valuation allowance on the Company’s deferred tax assets.

For interim periods, the Company estimates its annual effective income tax rate and applies the estimated rate to the year-to-date income or loss before income taxes. The Company also computes the tax provision or benefit related to items reported separately and recognizes the items net of their related tax effect in the interim periods in which they occur. The Company also recognizes the effect of changes in enacted tax laws or rates in the interim periods in which the changes occur.

As of June 30, 2024 and December 31, 2023, the Company retains a full valuation allowance on its deferred tax assets. The realization of the Company’s deferred tax assets depends primarily on its ability to generate taxable income in future periods. The amount of deferred tax assets considered realizable in future periods may change as management continues to reassess the underlying factors it uses in estimating future taxable income.

The provision for income taxes for the three and six months ended June 30, 2024 and 2023 was calculated on a jurisdiction basis.

v3.24.2.u1
Commitments and Contingencies
6 Months Ended
Jun. 30, 2024
Commitments and Contingencies  
Commitments and Contingencies

8.

Commitments and Contingencies

Operating Leases

The Company leases office space under a non-cancellable operating lease that expires in January 2024 and has an option to renew this lease, with renewal rates to be negotiated. Operating lease rentals are expensed on a straight-line basis over the life of the lease beginning on the date we take possession of the property. At lease inception, we determine the lease term by assuming the exercise of those renewal options that are reasonably assured. The exercise of lease renewal options is at our sole discretion. The lease term is used to determine whether a lease is financing or operating and is used to calculate straight-line rent expense. Additionally, the depreciable life of leasehold improvements is limited by the expected lease term. Leases with an initial term of 12 months or less are not recorded on the condensed consolidated balance sheet; we recognize lease expense for these leases on a straight-line basis over the lease term.

The following table reflects our lease assets and our lease liabilities at June 30, 2024 and December 31, 2023 (in thousands):

    

June 30, 

    

December 31,

2024

2023

Assets:

Operating lease right-of-use assets

$

575

$

616

Liabilities:

 

  

 

  

Operating lease liabilities, current

$

67

$

Operating lease liabilities, non-current

$

607

$

636

Operating lease right-of-use assets are included in other assets. Operating lease liabilities, current, are included in accrued liabilities and Operating lease liabilities, non-current, are include in other liabilities on the condensed consolidated balance sheets.

Lease Costs:

The components of lease costs were as follows (in thousands):

    

Three Months Ended

    

Six Months Ended

June 30, 2024

June 30, 2024

Operating lease cost

$

42

$

95

Short term lease cost

$

7

15

Total lease cost

$

49

$

110

As of June 30, 2024, the maturity of operating lease liabilities was as follows (in thousands):

Payments due in:

 

Year ending December 31, 2024 (6 months remaining)

 

$

59

Year ending December 31, 2025

 

185

Year ending December 31, 2026

191

Year ending December 31, 2027

197

Year ending December 31, 2028

203

Thereafter

93

Total minimum lease payments

928

Less: Amounts representing interest

 

(254)

Present value of capital lease obligations

$

674

8.

Commitments and Contingencies, continued

Lease Term and Discount Rate:

    

June 30, 2024

Weighted-average remaining lease term (in years)

 

5.00

Weighted-average discount rate

 

13.0

%

The discount rate was calculated by using the Company’s estimated incremental borrowing rate.

Other Information:

Supplemental cash flow information related to leases was as follows (in thousands):

    

Three Months Ended

    

Six Months Ended

June 30, 2024

June 30, 2024

Operating cash outflows from operating leases

$

$

3

Contingencies

In the normal course of business, the Company may become involved in legal proceedings. The Company will accrue a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When only a range of a possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. The accrual for a litigation loss contingency might include, for example, estimates of potential damages, outside legal fees and other directly related costs expected to be incurred.

The Company’s management does not believe that any such matters, individually or in the aggregate, will have a materially adverse effect on the Company’s condensed consolidated financial statements.

v3.24.2.u1
Related Parties
6 Months Ended
Jun. 30, 2024
Related Parties  
Related Parties

9.

Related Parties

Helge Kristensen

Mr. Kristensen has served as a member of the Company’s board of directors since 2010. Mr. Kristensen serves as vice president of Hansong Technology, an original device manufacturer of audio products based in China, president of Platin Gate Aps, a company with focus on service-branding in lifestyle products as well as pro line products based in Denmark and co-founder and director of Inizio Capital, an investment company based in the Cayman Islands.

For the three months ended June 30, 2024 and 2023, Hansong Technology purchased modules from the Company of approximately $10,000 and $24,000, respectively, and made payments to the Company of approximately $0 and $189,000, respectively. At June 30, 2024 and 2023, Hansong Technology owed the Company approximately $39,000 and $29,000, respectively. For the three months ended June 30, 2024 and 2023, Hansong Technology sold speaker products to the Company of approximately $1,000 and $21,000, respectively, and the Company made payments to Hansong Technology of approximately $63,000 and $794,000 respectively. At June 30, 2024 and 2023, the Company owed Hansong Technology approximately $163,000 and $350,000, respectively.

For the six months ended June 30, 2024 and 2023, Hansong Technology purchased modules from the Company of approximately $35,000 and $48,000, respectively, and made payments to the Company of approximately $0 and $189,000, respectively. For the six months ended June 30, 2024 and 2023, Hansong Technology sold speaker products to the Company of approximately $1,000 and $59,000, respectively, and the Company made payments to Hansong Technology of approximately $88,000 and $1,053,000, respectively.

9.

Related Parties, continued

As of June 30, 2024 and December 31, 2023, Mr. Kristensen owned less than 1.0% of the outstanding shares of the Company’s common stock.

David Howitt

Mr. Howitt has served as a member of the Company’s board of directors since December 2021. Mr. Howitt is founder and CEO of Meriwether Group LLC, (“Meriwether”), a strategic consulting firm that works with disruptive consumer brands by integrating their visions, developing growth strategies, scaling their brands, and increasing revenue in order to build enterprise value. Meriwether is the manager of Meriwether Accelerators LLC. Meriwether which is also majority-owned by Mr. Howitt, owns a 25% general partner interest in Meriwether Hero Fund.

On September 8, 2023, the Company entered into a Loan and Security Agreement with Meriwether Hero Fund. Pursuant to the Loan and Security Agreement, Meriwether Hero Fund provided the Company with a term loan in the principal amount of $650,000 that was scheduled to mature on November 7, 2023, subject to further extension. The Company repaid the loan in full on December 7, 2023. See Note 4 Short-Term Loan for additional information.

As of June 30, 2024 and December 31, 2023, Mr. Howitt owned less than 1.0% of the outstanding shares of the Company’s common stock.

v3.24.2.u1
Segment Information
6 Months Ended
Jun. 30, 2024
Segment Information  
Segment Information

10.

Segment Information

The Company operates in one business segment. Our chief decision-maker, the President and Chief Executive Officer, evaluates our performance based on company-wide consolidated results.

Net revenue from customers is designated based on the geographic region to which the product is delivered. Net revenue by geographic region for the three and six months ended June 30, 2024 and 2023 was as follows:

For the Three Months Ended

For the Six Months Ended

June 30, 

June 30, 

(in thousands)

    

2024

    

2023

    

2024

    

2023

Asia Pacific

$

264

$

301

$

351

$

598

North America

26

112

115

265

Europe

 

55

 

12

 

134

 

31

Total

$

345

$

425

$

600

$

894

Substantially all of our long-lived assets are located in the United States.

v3.24.2.u1
Pay vs Performance Disclosure - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2024
Jun. 30, 2023
Pay vs Performance Disclosure            
Net Income (Loss) $ (42,665) $ 2,707 $ (5,326) $ (921) $ (39,958) $ (6,247)
v3.24.2.u1
Insider Trading Arrangements
3 Months Ended
Jun. 30, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
v3.24.2.u1
Business and Summary of Significant Accounting Policies (Policies)
6 Months Ended
Jun. 30, 2024
Business and Summary of Significant Accounting Policies  
Nasdaq Compliance

Nasdaq Compliance

The Company is currently in compliance with the listing rules of The Nasdaq Stock Market LLC (“Nasdaq”), subject to the monitorings described below.

On April 29, 2024, Nasdaq notified the Company in a letter that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550 (a)(2) (the “Minimum Bid Price Requirement”) as required by a hearing panel’s decision on April 5, 2024. The Company is subject to monitoring for a period of one year from the date of the letter. If, within that one-year monitoring period, Nasdaq’s Listing Qualifications staff (the “Staff”) finds the Company again out of compliance with the Minimum Bid Price Requirement, the Company will not be permitted to provide the Staff with a plan of compliance with respect to such deficiency and the Staff will not be permitted to grant additional time for the Company to regain compliance with respect to such deficiency, nor will the Company be afforded an applicable cure or compliance period. Instead, the Staff will issue a delist determination letter and the Company will have an opportunity to request a new hearing with a hearings panel. The Company will have the opportunity to respond and present to the panel.    

On July 3, 2024, Nasdaq notified the Company in a letter that the Company has regained compliance with the equity requirement under Nasdaq Listing Rule 5550(b)(1) (the “Equity Rule”) as required by the panel’s April 5, 2024 decision. The Company is subject to monitoring for a period of one year from the date of the letter. If, within that one-year monitoring period, the Staff finds the Company again out of compliance with the Equity Rule, the Company will not be permitted to provide the Staff with a plan of compliance with respect to such deficiency and the Staff will not be permitted to grant additional time for the Company to regain compliance with respect to such deficiency, nor will the Company be afforded an applicable cure or compliance period. Instead, the Staff will issue a delist determination letter and the Company will have an opportunity to request a new hearing with a hearings panel. The Company will have the opportunity to respond and present to the panel.

Reverse Stock Splits

Reverse Stock Splits

April 2024 Reverse Stock Split

On April 4, 2024, the Board approved a 1-for-150 reverse stock split (the “April 2024 Reverse Stock Split”) of our outstanding shares of common stock and authorized the filing of a certificate of amendment to our certificate of incorporation, as amended, with the Secretary of State of the State of Delaware to effect the April 2024 Reverse Stock Split. On April 12, 2024, the April 2024 Reverse Stock Split was effected and the condensed consolidated financial statements have been retroactively adjusted. All common stock share numbers, warrants to purchase common stock, prices and exercise prices have been retroactively adjusted to reflect the April 2024 Reverse Stock Split. The common stock began trading on a split-adjusted basis at the start of trading on April 15, 2024. Unless otherwise indicated, the information presented in this Quarterly Report on Form 10-Q (this “Report”) gives effect to the April 2024 Reverse Stock Split.

January 2023 Reverse Stock Split

On January 24, 2023, the Board approved a 1-for-100 reverse stock split (the “January 2023 Reverse Stock Split”) of our outstanding shares of common stock and authorized the filing of a certificate of amendment to our certificate of incorporation, as amended, with the Secretary of State of the State of Delaware to effect the January 2023 Reverse Stock Split. On January 26, 2023, the January 2023 Reverse Stock Split was effected and the condensed consolidated financial statements have been retroactively adjusted. All common stock share numbers, warrants to purchase common stock, prices and exercise prices have been retroactively adjusted to reflect the January 2023 Reverse Stock Split. The common stock began trading on a split-adjusted basis at the start of trading on January 27, 2023. Unless otherwise indicated, the information presented in this Report gives effect to the January 2023 Reverse Stock Split.

Basis of Presentation

Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and include all adjustments necessary for the fair presentation of the Company’s financial position, results of operations and cash flows for the periods presented. The condensed consolidated financial statements reflect the accounts of WISA Technologies, Inc. and its wholly-owned subsidiaries, WISA Technologies Korea, LTD, a Korean limited company, which was established in September 2022, and WiSA, LLC, a Delaware limited liability company. All intercompany balances and transactions are eliminated.

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

Reclassification

Reclassification

Certain reclassifications have been made to prior periods’ condensed consolidated financial statements to conform to the current period presentation. These reclassifications did not result in any change in previously reported net income (loss), total assets or stockholders’ deficit.

Concentration of Credit Risk and Other Risks and Uncertainties

Concentration of Credit Risk and Other Risks and Uncertainties

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Cash and cash equivalents are deposited in demand and money market accounts at one financial institution. At times, such deposits may be in excess of insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.

The Company’s accounts receivable are derived from revenue earned from customers located throughout the world. The Company performs credit evaluations of its customers’ financial condition and may, in certain circumstances, require full or partial payment in advance of shipping. As of June 30, 2024 and December 31, 2023, there was no allowance for credit losses. As of June 30, 2024, the Company had four customers accounting for 43%, 33%, 12%and 11% of accounts receivable. As of December 31, 2023, the Company had two customers accounting for 71% and 20% of accounts receivable.

The Company had four customers accounting for 33%, 27%, 20% and 11% of its net revenue for the three months ended June 30, 2024. The Company had four customers accounting for 28%, 27%, 19% and 10% of its net revenue for the six months ended June 30, 2024. The Company had four customers accounting for 35%, 13%, 12% and 11% of its net revenue for the three months ended June 30, 2023. The Company had two customers accounting for 29% and 17% of its net revenue for the six months ended June 30, 2023.

The Company’s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, continued acceptance of the Company’s products, competition from substitute products and larger companies, protection of proprietary technology, strategic relationships and dependence on key individuals.

The Company relies on sole-source suppliers to manufacture some of the components used in its product. The Company’s manufacturers and suppliers may encounter problems during manufacturing due to a variety of reasons, any of which could delay or impede their ability to meet demand. The Company is heavily dependent on a single contractor in China for assembly and testing of its products, a single contractor in Japan for the production of its transmit semiconductor chip and a single contractor in China for the production of its receive semiconductor chip.

Cash and Cash Equivalents

Cash and Cash Equivalents

The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents.

Accounts Receivable and Allowance for Credit Losses

Accounts Receivable and Allowance for Credit Losses

Accounts receivable are recorded at the invoice amount and are generally not interest bearing. The Company reviews its trade receivables aging to identify specific customers with known disputes or collection issues. The Company exercises judgment when determining the adequacy of these reserves as it evaluates historical bad debt trends and changes to customers’ financial conditions.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Carrying amounts of certain of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities. The carrying value of the Company’s borrowings and capital lease liabilities approximates fair value based upon borrowing rates currently available to the Company for loans and capital leases with similar terms. The Company’s Warrant liabilities are the only financial instrument that is adjusted to fair value on a recurring basis.

Inventories

Inventories

Inventories, principally purchased components, are stated at the lower of cost or net realizable value. Cost is determined using an average cost, which approximates actual cost on a first-in, first-out basis. Inventory in excess of salable amounts and inventory which is considered obsolete based upon changes in existing technology is written off. At the point of loss recognition, a new lower cost basis for that inventory is established and subsequent changes in facts and circumstances do not result in the restoration or increase in the new cost basis.

Property and Equipment, Net

Property and Equipment, Net

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over their estimated useful lives of two to five years. Leasehold improvements and assets acquired under capital lease are amortized on a straight-line basis over the shorter of the useful life or term of the lease. Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred.

Convertible Financial Instruments

Convertible Financial Instruments

The Company bifurcates conversion options and warrants from their host instruments and accounts for them as freestanding derivative financial instruments if certain criteria are met. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. An exception to this rule is when the host instrument is deemed to be conventional, as that term is described under applicable U.S. GAAP.

When the Company has determined that the embedded conversion options and warrants should be bifurcated from their host instruments, discounts are recorded for the intrinsic value of conversion options embedded in the instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the instrument.

Debt discounts under these arrangements are amortized to interest expense using the interest method over the earlier of the term of the related debt or their earliest date of redemption.

Warrants for Common Shares, Convertible Redeemable Preferred Shares, and Derivative Financial Instruments

Warrants for Common Shares, Convertible Redeemable Preferred Shares, and Derivative Financial Instruments

Warrants for our common shares, convertible redeemable preferred shares, and derivative financial instruments are classified as equity if the contracts (1) require physical settlement or net-share settlement or (2) give the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). Contracts which (1) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the control of the Company), (2) give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement), or (3) contain reset provisions that do not qualify for the scope exception are classified as equity or liabilities. The Company assesses classification of its warrants for shares of common stock and other derivatives at each reporting date to determine whether a change in classification between equity and liabilities is required.

Product Warranty

Product Warranty

The Company’s products are generally subject to a one-year warranty, which provides for the repair, rework, or replacement of products (at the Company’s option) that fail to perform within the stated specification. The Company has assessed its historical claims and, to date, product warranty claims have not been significant. The Company will continue to assess if there should be a warranty accrual going forward.

Revenue Recognition

Revenue Recognition

The Company generates revenue primarily from two product categories which include the sale of Consumer Audio Products as well as the sale of Components. The Company applies the following five steps: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when a performance obligation is satisfied. The Company considers customer purchase orders to be the contracts with a customer. Revenues, net of expected discounts, are recognized when the performance obligations of the contract with the customer are satisfied and when control of the promised goods are transferred to the customer, typically when products, which have been determined to be the only distinct performance obligations, are shipped to the customer. Expected costs of assurance warranties and claims are recognized as expense.

Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by us from a customer and deposited with the relevant government authority, are excluded from revenue. Our revenue arrangements do not contain significant financing components.

Sales to certain distributors are made under arrangements which provide the distributors with price adjustments, price protection, stock rotation and other allowances under certain circumstances. The Company does not provide its customers with a contractual right of return. However, the Company accepts limited returns on a case-by-case basis. These returns, adjustments and other allowances are accounted for as variable consideration. We estimate these amounts based on the expected amount to be provided to customers and reduce revenue recognized. We believe that there will not be significant changes to our estimates of variable consideration.

If a customer pays consideration, or the Company has a right to an amount of consideration that is unconditional before we transfer a good or service to the customer, those amounts are classified as contract liabilities which are included in other current liabilities when the payment is made or it is due, whichever is earlier.

Practical Expedients and Exemptions

Practical Expedients and Exemptions

In accordance with Accounting Standards Codification Topic 606, Revenue from Contracts with Customers, we use the following practical expedients: (i) not to adjust the promised amount of consideration for the effects of a significant financing component when we expect, at contract inception, that the period between our transfer of a promised product or service to a customer and when the customer pays for that product or service will be one year or less; (ii) to expense costs as incurred for costs to obtain a contract when the amortization period would have been one year or less; (iii) not to assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract with the customer. In addition, we do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less.

During the three months ended June 30, 2024 and 2023, net revenue consisted of the following:

    

For the Three Months Ended June 30,

    

For the Six Months Ended June 30, 

(in thousands)

2024

    

2023

2024

    

2023

Components

$

314

$

313

$

473

$

640

Consumer Audio Products

 

31

 

112

 

127

 

254

Total

$

345

$

425

$

600

$

894

Contract Balances

Contract Balances

The Company receives payments from customers based on a billing schedule as established in our contracts to partially offset prepayments required by our vendors on long lead time materials. Amounts collected prior to the fulfillment of the performance obligation are considered contract liabilities and classified as customer advances within accrued liabilities on the consolidated balance sheets. Contract assets are recorded when the Company has a conditional right to consideration for our completed performance under the contracts. Accounts receivables are recorded when the right to this consideration becomes unconditional. The Company does not have any material contract assets as of June 30, 2024 and December 31, 2023. During the six month ended June 30, 2024, the Company did not recognize any revenue that was included in the contract liabilities balance as of December 31, 2023.

June 30, 

December 31, 

(in thousands)

    

2024

    

2023

Contract Liabilities

$

150

$

19

Revenue by Geographic Area

Revenue by Geographic Area

In general, revenue disaggregated by geography (See Note 10) is aligned according to the nature and economic characteristics of our business and provides meaningful disaggregation of our results of operations. Since we operate in one segment, all financial segment and product line information can be found in the condensed consolidated financial statements.

Stock-Based Compensation

Stock-Based Compensation

The Company measures and recognizes the compensation expense for restricted stock units and restricted stock awards granted to employees and directors based on the fair value of the award on the grant date.

Restricted stock units give an employee an interest in Company stock but they have no tangible value until vesting is complete. Restricted stock units and restricted stock awards are equity classified and measured at the fair market value of the underlying stock at the grant date and recognized as expense over the related service or performance period. The Company elected to account for forfeitures as they occur. The fair value of stock awards is based on the quoted price of our common stock on the grant date. Compensation cost for restricted stock units and restricted stock awards is recognized using the straight-line method over the requisite service period.

Research and Development

Research and Development

Research and development costs are charged to operations as incurred and includes salaries, consulting expenses and an allocation of facility costs.

Advertising Costs

Advertising Costs

Advertising costs are charged to sales and marketing expenses as incurred. Advertising costs for the three and six months ended June 30, 2024 were $117,000 and $264,000, respectively. Advertising costs for the three and six months ended June 30,  2023 were $118,000 and $273,000, respectively.

Comprehensive Loss

Comprehensive Loss

Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may include certain changes in equity that are excluded from net loss. For the three and six months ended June 30, 2024 and 2023, the Company’s comprehensive loss is the same as its net loss.

Foreign Currency

Foreign Currency

The financial position and results of operations of the Company’s foreign operations are measured using currencies other than the U.S. dollar as their functional currencies. Accordingly, for these operations all assets and liabilities are translated into U.S. dollars at the current exchange rates as of the respective balance sheet date. Expense items are translated using the weighted average exchange rates prevailing during the period. Cumulative gains and losses from the translation of these operations’ financial statements are reported as a separate component of stockholders’ equity, while foreign currency transaction gains or losses, resulting from re-measuring local currency to the U.S. dollar are recorded in the condensed consolidated statement of operations in other income (expense), net and were not material for the three and six months ended June 30, 2024 and 2023.

Net Loss per Common Share

Net Loss per Common Share

Basic and diluted net loss per common share is presented in conformity with the two-class method required for participating securities. The Company considers all series of convertible preferred stock to be participating securities. Under the two-class method, the net loss attributable to common stockholders is not allocated to the convertible preferred stock as the holders of the convertible preferred stock do not have a contractual obligation to share in the losses of the Company. Under the two-class method, net income would be attributed to common stockholders and participating securities based on their participation rights.

Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares and potentially dilutive common share equivalents outstanding for the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per common share calculation, Series A 8% Senior Convertible Preferred Stock (“Series A Preferred Stock”), warrants exercisable for common stock, restricted stock units and shares issuable upon the conversion of convertible notes payable are considered to be potentially dilutive securities. Net loss is adjusted for any deemed dividends to preferred stockholders to compute income available to common stockholders.

As of June 30, 2024, warrants to purchase 9,793,531 shares of common stock, 260,441 shares of restricted stock, 16 shares of restricted stock issued under an inducement grant and 14 shares underlying restricted stock units, have been excluded from the calculation of net loss per common share because the inclusion would be antidilutive.

As of June 30, 2023, warrants to purchase 37,572 shares of common stock, 69 shares of restricted stock, 18 shares of restricted stock issued under an inducement grant and 36 shares underlying restricted stock units have been excluded from the calculation of net loss per common share because the inclusion would be antidilutive.

Income Taxes

Income Taxes

Deferred taxes are provided on the liability method whereby deferred tax assets are recognized for deductible temporary differences, and operating loss and tax credit carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is “more-likely-than-not” that some portion or all of the deferred tax assets will not be realized. The Company has recognized valuation allowances against its deferred tax assets as of June 30, 2024 and December 31, 2023. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

The Company uses a comprehensive model for recognizing, measuring, presenting, and disclosing in the condensed consolidated financial statements tax positions taken or expected to be taken on a tax return. A tax position is recognized as a benefit only if it is “more-likely-than-not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more-likely-than-not” test, no tax benefit is recorded. The Company recognizes interest accrued and penalties related to unrecognized tax benefits in tax expense. As of June 30, 2024 and December 31, 2023, the Company recognized no interest and penalties.

Recently Adopted Accounting Pronouncements

Recently Adopted Accounting Pronouncements

In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06 “Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity.” This ASU simplifies accounting for convertible instruments by removing major separation models required under current U.S. GAAP. The Company adopted this standard on January 1, 2024 using the modified retrospective method by applying the ASU to financial instruments outstanding as of January 1, 2024, with the cumulative effect of adoption recognized at that date through an adjustment to the opening balance of retained earnings. As such, the Company adopted the standard by eliminating any unamortized discount to the Series B Preferred Stock for the beneficial conversion feature. The cumulative effect of ASU 2020-06 adoption adjusted against additional paid-in-capital due to the absence of retained earnings on January 1, 2024 amounted to $116,000.

Recently Issued and Not Yet Adopted Accounting Pronouncements

Recently Issued and Not Yet Adopted Accounting Pronouncements

In December 2023, the FASB issued ASU 2023-09 – Income Taxes (Topic 740): Improvements to Income Tax Disclosures” to help investors better understand an entity’s exposure to potential changes in jurisdictional tax legislation and the ensuing risks and opportunities. Furthermore, the Update improves disclosures used to assess income tax information that affects cash flow forecasts and capital allocation decisions. The Update is effective for public business entities for annual periods beginning after December 15, 2024, on a prospective basis. The Company is currently evaluating the impact of the adoption of this standard on our condensed consolidated financial statements.

In November 2023, the FASB issued ASU 2023-07 “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,” aiming to enhance the transparency and relevance of segment information provided in financial statements. The amendments in this Update require that a public entity disclose significant segment expenses, profit or loss and assets, etc. for each reportable segment, on an annual and interim basis. The Update is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact of the adoption of this standard on our condensed consolidated financial statements.

We have reviewed other recent accounting pronouncements and concluded they are either not applicable to the business, or no material effect is expected on the condensed consolidated financial statements as a result of future adoption.

v3.24.2.u1
Business and Summary of Significant Accounting Policies (Tables)
6 Months Ended
Jun. 30, 2024
Business and Summary of Significant Accounting Policies  
Schedule of net revenue

    

For the Three Months Ended June 30,

    

For the Six Months Ended June 30, 

(in thousands)

2024

    

2023

2024

    

2023

Components

$

314

$

313

$

473

$

640

Consumer Audio Products

 

31

 

112

 

127

 

254

Total

$

345

$

425

$

600

$

894

Schedule of contract balances

June 30, 

December 31, 

(in thousands)

    

2024

    

2023

Contract Liabilities

$

150

$

19

v3.24.2.u1
Balance Sheet Components (Tables)
6 Months Ended
Jun. 30, 2024
Balance Sheet Components  
Schedule of inventories

Inventories (in thousands):

June 30, 

December 31, 

    

2024

    

2023

Raw materials

$

648

$

621

Work in progress

22

Finished goods

 

1,660

 

2,116

Total inventories

$

2,330

$

2,737

Schedule of property and equipment, net

Property and equipment, net (in thousands):

June 30, 

December 31, 

    

2024

    

2023

Machinery and equipment

$

758

$

741

Tooling

 

14

 

11

 

772

 

752

Less: Accumulated depreciation and amortization

 

(707)

 

(659)

Property and equipment, net

$

65

$

93

Schedule of accrued liabilities

Accrued liabilities (in thousands):

June 30, 

December 31, 

    

2024

    

2023

Accrued vacation

$

448

$

418

Accrued audit fees

161

211

Accrued legal fees

158

Accrued rebate

151

215

Customer advance

150

19

Accrued compensation

 

130

 

127

Accrued lease liability, current portion

67

Accrued other

114

327

Total accrued liabilities

$

1,379

$

1,317

v3.24.2.u1
Fair Value Measurements (Tables)
6 Months Ended
Jun. 30, 2024
Fair Value Measurements  
Schedule of company's financial assets and liabilities that are measured at fair value on a recurring basis

(in thousands)

June 30, 2024

Significant

Quoted prices

other

Significant

in active

observable

unobservable

markets

inputs

inputs

    

(Level 1)

    

(Level 2)

    

(Level 3)

Liabilities:

  

  

  

Warrant liabilities

$

$

$

25

(in thousands)

December 31, 2023

Significant

Quoted prices

other

Significant

in active

observable

unobservable

markets

inputs

inputs

    

(Level 1)

    

(Level 2)

    

(Level 3)

Liabilities:

Warrant liabilities

$

$

$

5,460

Warrant Liabilities  
Fair Value Measurements  
Schedule of changes in the fair value of the warrant liability and derivative liability

For the six months ended June 30,

(in thousands)

    

2024

2023

Beginning balance

$

5,460

    

$

8,945

Additions

 

8,701

 

5,600

Change in fair value

 

29,126

 

(5,850)

Exercise of warrant liabilities

 

(587)

 

(8,191)

Repurchase

(824)

Conversion of liability warrants to equity warrants

(41,851)

Ending balance

$

25

$

504

v3.24.2.u1
Convertible Redeemable Preferred Stock and Stockholders' Equity (Tables)
6 Months Ended
Jun. 30, 2024
Convertible Redeemable Preferred Stock and Stockholders' Equity  
Summary of activity related to restricted stock awards/units

    

    

Weighted-Average 

Stock Awards

Shares

Grant Date Fair Value

Non-vested as of January 1, 2024

5,382

$

374.00

Granted

 

255,915

$

2.64

Vested

 

(774)

$

674.09

Forfeited

 

(82)

$

681.69

Non-vested as of June 30, 2024

 

260,441

$

9.22

Summary of Information regarding warrants for common stock outstanding and exercisable

Information regarding warrants for common stock outstanding and exercisable as of June 30, 2024 is as follows:

Warrants

Weighted Average

Warrants

Exercise

Outstanding as of

Remaining

Exercisable as of

Price

    

June 30, 2024

    

Life (years)

    

June 30, 2024

$0.015 - $3.48

 

8,832,641

 

4.9

 

1,693,173

$5.06 - $6.00

 

954,827

 

4.8

 

954,827

$1,574.00

 

5,831

 

3.6

 

5,831

$14,995.00

 

12

 

3.1

 

12

$22,800 - $393,000

 

220

 

1.1

 

219

$4.45 *

 

9,793,531

 

4.9

 

2,654,062

*Weighted average

Information regarding warrants for common stock outstanding and exercisable as of December 31, 2023 is as follows:

    

Warrants

    

Weighted Average

    

Warrants

Exercise

Outstanding as of

Remaining

Exercisable as of

Price

December 31, 2023

Life (years)

December 31, 2023

$22.50

 

188,025

 

4.9

 

467

$1,573.50

 

5,833

 

4.1

 

5,833

$14,955.00

 

13

 

3.6

 

13

$22,800.00

 

3

 

3.0

 

3

$30,000- $654,000

 

239

 

1.6

 

239

$135.00 *

 

194,113

 

4.9

 

6,555

*Weighted Average
2020 Stock Incentive Plan  
Convertible Redeemable Preferred Stock and Stockholders' Equity  
Summary of activity related to restricted stock awards/units

Weighted-Average 

Stock Units

    

Shares

    

Grant Date Fair Value

Non-vested as of January 1, 2024

 

1

$

56,430.00

Granted

 

$

Vested

 

(1)

$

56,430.00

Forfeited

 

$

Non-vested as of June 30, 2024

 

$

2022 Stock Incentive Plan  
Convertible Redeemable Preferred Stock and Stockholders' Equity  
Summary of activity related to restricted stock awards/units

Weighted-Average

Stock Units

    

Shares

    

Grant Date Fair Value

Non-vested as of January 1, 2024

 

17

$

7,800.00

Granted

 

$

Vested

 

(3)

$

7,800.00

Forfeited

 

$

Non-vested as of June 30, 2024

 

14

$

7,800.00

v3.24.2.u1
Commitments and Contingencies (Tables)
6 Months Ended
Jun. 30, 2024
Commitments and Contingencies  
Schedule of our lease assets and our lease liabilities

The following table reflects our lease assets and our lease liabilities at June 30, 2024 and December 31, 2023 (in thousands):

    

June 30, 

    

December 31,

2024

2023

Assets:

Operating lease right-of-use assets

$

575

$

616

Liabilities:

 

  

 

  

Operating lease liabilities, current

$

67

$

Operating lease liabilities, non-current

$

607

$

636

Schedule of components of lease costs

The components of lease costs were as follows (in thousands):

    

Three Months Ended

    

Six Months Ended

June 30, 2024

June 30, 2024

Operating lease cost

$

42

$

95

Short term lease cost

$

7

15

Total lease cost

$

49

$

110

Schedule of maturity of operating lease liabilities

As of June 30, 2024, the maturity of operating lease liabilities was as follows (in thousands):

Payments due in:

 

Year ending December 31, 2024 (6 months remaining)

 

$

59

Year ending December 31, 2025

 

185

Year ending December 31, 2026

191

Year ending December 31, 2027

197

Year ending December 31, 2028

203

Thereafter

93

Total minimum lease payments

928

Less: Amounts representing interest

 

(254)

Present value of capital lease obligations

$

674

Schedule of lease term and discount rate

    

June 30, 2024

Weighted-average remaining lease term (in years)

 

5.00

Weighted-average discount rate

 

13.0

%

Schedule of supplemental cash flow information related to leases

Supplemental cash flow information related to leases was as follows (in thousands):

    

Three Months Ended

    

Six Months Ended

June 30, 2024

June 30, 2024

Operating cash outflows from operating leases

$

$

3

v3.24.2.u1
Segment Information (Tables)
6 Months Ended
Jun. 30, 2024
Segment Information  
Schedule of net revenue by geographic region

For the Three Months Ended

For the Six Months Ended

June 30, 

June 30, 

(in thousands)

    

2024

    

2023

    

2024

    

2023

Asia Pacific

$

264

$

301

$

351

$

598

North America

26

112

115

265

Europe

 

55

 

12

 

134

 

31

Total

$

345

$

425

$

600

$

894

v3.24.2.u1
Business and Summary of Significant Accounting Policies - Schedule of net revenue (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Business and Summary of Significant Accounting Policies        
Net revenue $ 345 $ 425 $ 600 $ 894
Components        
Business and Summary of Significant Accounting Policies        
Net revenue 314 313 473 640
Consumer Audio Products        
Business and Summary of Significant Accounting Policies        
Net revenue $ 31 $ 112 $ 127 $ 254
v3.24.2.u1
Business and Summary of Significant Accounting Policies - Schedule of Contract Balances (Details) - USD ($)
$ in Thousands
Jun. 30, 2024
Dec. 31, 2023
Business and Summary of Significant Accounting Policies    
Contract Liabilities $ 150 $ 19
v3.24.2.u1
Business and Summary of Significant Accounting Policies - Narratives (Details)
3 Months Ended 6 Months Ended 12 Months Ended
Apr. 04, 2024
Jan. 24, 2023
Jun. 30, 2024
USD ($)
customer
Jun. 30, 2023
USD ($)
customer
Jun. 30, 2024
USD ($)
customer
segment
shares
Jun. 30, 2023
USD ($)
customer
shares
Dec. 31, 2023
USD ($)
customer
Mar. 31, 2024
USD ($)
Mar. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Business and Summary of Significant Accounting Policies                    
Number of operating segments | segment         1          
Reverse stock split ratio 0.0067 0.01                
Allowance for credit losses             $ 0 $ 0    
Practical expedient applied for remaining performance obligation         false          
Advertising costs     $ 117,000 $ 118,000 $ 264,000 $ 273,000        
Interest and penalties         $ 0   0      
Warranty period of company products (in years)         1 year          
Stockholders' equity     $ 6,430,000 5,861,000 $ 6,430,000 $ 5,861,000 (5,157,000) [1] (2,669,000) $ 7,763,000 $ (1,996,000)
Maximum                    
Business and Summary of Significant Accounting Policies                    
Estimated useful life of property and equipment (in years)     5 years   5 years          
Minimum                    
Business and Summary of Significant Accounting Policies                    
Estimated useful life of property and equipment (in years)     2 years   2 years          
Warrant                    
Business and Summary of Significant Accounting Policies                    
Antidilutive securities excluded from computation of earnings per share (in shares) | shares         9,793,531 37,572        
Restricted stock                    
Business and Summary of Significant Accounting Policies                    
Antidilutive securities excluded from computation of earnings per share (in shares) | shares         260,441 69        
Restricted stock units                    
Business and Summary of Significant Accounting Policies                    
Antidilutive securities excluded from computation of earnings per share (in shares) | shares         16 18        
Convertible Preferred Stock                    
Business and Summary of Significant Accounting Policies                    
Antidilutive securities excluded from computation of earnings per share (in shares) | shares         14 36        
Series A Preferred Stock                    
Business and Summary of Significant Accounting Policies                    
Dividend rate (in %)         8.00%          
Additional Paid-in Capital                    
Business and Summary of Significant Accounting Policies                    
Stockholders' equity     $ 293,429,000 $ 240,427,000 $ 293,429,000 $ 240,427,000 $ 241,884,000 241,665,000 $ 237,004,000 $ 226,324,000
Accounting Standards Update 2020-06                    
Business and Summary of Significant Accounting Policies                    
Stockholders' equity               (116,000)    
Accounting Standards Update 2020-06 | Additional Paid-in Capital                    
Business and Summary of Significant Accounting Policies                    
Stockholders' equity               $ (116,000)    
Cumulative effect, period of adoption, adjustment | Accounting Standards Update 2020-06 | Additional Paid-in Capital                    
Business and Summary of Significant Accounting Policies                    
Stockholders' equity     $ 116,000   $ 116,000          
Accounts Receivable | Customer Concentration Risk                    
Business and Summary of Significant Accounting Policies                    
Number of customers | customer         4   2      
Accounts Receivable | Customer Concentration Risk | Customer 1                    
Business and Summary of Significant Accounting Policies                    
Concentration Risk Percentage (in %)         43.00%   71.00%      
Accounts Receivable | Customer Concentration Risk | Customer 2                    
Business and Summary of Significant Accounting Policies                    
Concentration Risk Percentage (in %)         33.00%   20.00%      
Accounts Receivable | Customer Concentration Risk | Customer 3                    
Business and Summary of Significant Accounting Policies                    
Concentration Risk Percentage (in %)         12.00%          
Accounts Receivable | Customer Concentration Risk | Customer 4                    
Business and Summary of Significant Accounting Policies                    
Concentration Risk Percentage (in %)         11.00%          
Net Revenue | Customer Concentration Risk                    
Business and Summary of Significant Accounting Policies                    
Number of customers | customer     4 4 4 2        
Net Revenue | Customer Concentration Risk | Customer 1                    
Business and Summary of Significant Accounting Policies                    
Concentration Risk Percentage (in %)     33.00% 35.00% 28.00% 29.00%        
Net Revenue | Customer Concentration Risk | Customer 2                    
Business and Summary of Significant Accounting Policies                    
Concentration Risk Percentage (in %)     27.00% 13.00% 27.00% 17.00%        
Net Revenue | Customer Concentration Risk | Customer 3                    
Business and Summary of Significant Accounting Policies                    
Concentration Risk Percentage (in %)     20.00% 12.00% 19.00%          
Net Revenue | Customer Concentration Risk | Customer 4                    
Business and Summary of Significant Accounting Policies                    
Concentration Risk Percentage (in %)     11.00% 11.00% 10.00%          
[1] The condensed consolidated balance sheet as of December 31, 2023 was derived from the audited consolidated balance sheet as of that date.
v3.24.2.u1
Going Concern (Details) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
[1]
Going Concern      
Cash and cash equivalents $ 6,113   $ 411
Net cash used in operations $ (9,045) $ (9,126)  
[1] The condensed consolidated balance sheet as of December 31, 2023 was derived from the audited consolidated balance sheet as of that date.
v3.24.2.u1
Balance Sheet Components - Inventories (Details) - USD ($)
$ in Thousands
Jun. 30, 2024
Dec. 31, 2023
Balance Sheet Components    
Raw materials $ 648 $ 621
Work in progress 22  
Finished goods 1,660 2,116
Total inventories $ 2,330 $ 2,737 [1]
[1] The condensed consolidated balance sheet as of December 31, 2023 was derived from the audited consolidated balance sheet as of that date.
v3.24.2.u1
Balance Sheet Components - Narratives (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Jun. 13, 2024
Dec. 31, 2023
Balance Sheet Components            
Note receivable         $ 150,000  
Annual interest rate         5.12%  
Depreciation and amortization expense $ 28,000 $ 32,000 $ 48,000 $ 65,000    
Other noncurrent assets            
Balance Sheet Components            
Note receivable           $ 0
v3.24.2.u1
Balance Sheet Components - Property and equipment, net (Details) - USD ($)
$ in Thousands
Jun. 30, 2024
Dec. 31, 2023
Balance Sheet Components    
Property and equipment, gross $ 772 $ 752
Less: Accumulated depreciation and amortization (707) (659)
Property and equipment, net 65 93 [1]
Machinery and equipment    
Balance Sheet Components    
Property and equipment, gross 758 741
Tooling    
Balance Sheet Components    
Property and equipment, gross $ 14 $ 11
[1] The condensed consolidated balance sheet as of December 31, 2023 was derived from the audited consolidated balance sheet as of that date.
v3.24.2.u1
Balance Sheet Components - Accrued liabilities (Details) - USD ($)
$ in Thousands
Jun. 30, 2024
Dec. 31, 2023
Balance Sheet Components    
Accrued vacation $ 448 $ 418
Accrued audit fees 161 211
Accrued legal fees 158  
Accrued rebate 151 215
Customer advance 150 19
Accrued compensation 130 127
Accrued lease liability, current portion 67  
Accrued other 114 327
Total accrued liabilities $ 1,379 $ 1,317 [1]
[1] The condensed consolidated balance sheet as of December 31, 2023 was derived from the audited consolidated balance sheet as of that date.
v3.24.2.u1
Borrowings - Convertible Promissory Note - Narratives (Details)
3 Months Ended 6 Months Ended 12 Months Ended
Sep. 08, 2023
USD ($)
Apr. 11, 2023
USD ($)
Feb. 01, 2023
USD ($)
shares
Nov. 28, 2022
USD ($)
Nov. 21, 2022
Aug. 15, 2022
USD ($)
item
D
$ / shares
shares
Jun. 30, 2023
USD ($)
shares
Jun. 30, 2024
USD ($)
shares
Jun. 30, 2023
USD ($)
shares
Dec. 31, 2023
USD ($)
Jan. 19, 2024
USD ($)
Mar. 31, 2023
shares
Dec. 01, 2022
shares
Aug. 24, 2022
$ / shares
Borrowings                            
Aggregate shares issued upon exercise of warrants (in shares) | shares             17,143 3,225 17,143     7,454    
Amortization of debt discounts               $ 1,260,000 $ 738,000          
Loss on extinguishment of convertible note payable $ 650,000           $ 837,000   $ 837,000          
Convertible Note                            
Borrowings                            
Repayment of debt   $ 1,656,744                        
Convertible Note                            
Borrowings                            
Net proceeds           $ 2,483,000                
Floor price (in $ per share) | $ / shares           $ 75.00                
Debt discount               2,509,000            
Loss on extinguishment of convertible note payable   $ 276,000                        
Maxim Group LLC                            
Borrowings                            
Aggregate shares issued upon exercise of warrants (in shares) | shares           13                
Warrants exercise price (in $ per share) | $ / shares           $ 14,955.00                
Exercise period of warrants (in months)           6 months                
Expiration period of warrants (in years)         5 years 5 years                
Maxim Group LLC | Convertible Note                            
Borrowings                            
Gross proceeds           $ 3,000,000                
Investor                            
Borrowings                            
Value used for calculation of warrants to be issued       $ 750,000                    
Investor | Series A warrants                            
Borrowings                            
Number of warrants issued (in shares) | shares                         357  
Investor | Series B warrants                            
Borrowings                            
Number of warrants issued (in shares) | shares                         357  
Investor | Convertible Note                            
Borrowings                            
Aggregate shares issued upon exercise of warrants (in shares) | shares           140                
Warrants exercise price (in $ per share) | $ / shares           $ 14,955.00                
Floor price (in $ per share) | $ / shares                           $ 37.50
Maxim Group LLC                            
Borrowings                            
Aggregate shares issued upon exercise of warrants (in shares) | shares           13                
Convertible Note                            
Borrowings                            
Conversion price, percentage of average VWAPs considered (in %)           90.00%                
Conversion price, Number of lowest daily VWAPs considered | item           5                
Conversion price, Number of trading days (in days) | D           20                
Base conversion price (in $ per share) | $ / shares           $ 13,890.00                
Debt discount           $ 2,509,000         $ 1,260,000      
Amortization of debt discounts               1,260,000   $ 737,000        
Derivative liability               $ 286,000            
Outstanding principal converted     $ 708,000                      
Number of shares issued upon conversion (in shares) | shares     450                      
Convertible Note | Investor                            
Borrowings                            
Principal amount           $ 3,600,000                
January 2024 Promissory notes | January 2024 Short-Term Loan Agreement                            
Borrowings                            
Principal amount                     $ 1,000,000      
v3.24.2.u1
Borrowings - Convertible Promissory Note - Maxim (Details)
Jun. 30, 2024
USD ($)
Convertible Promissory Note  
Borrowings  
Debt discount $ (2,509,000)
v3.24.2.u1
Borrowings - Short-term Loan Agreement - Meriwether (Details)
1 Months Ended 6 Months Ended
Jan. 19, 2024
USD ($)
item
$ / shares
shares
Oct. 10, 2023
USD ($)
Sep. 08, 2023
USD ($)
Feb. 29, 2024
USD ($)
shares
Jun. 30, 2024
USD ($)
$ / shares
shares
Jun. 30, 2023
USD ($)
shares
Feb. 02, 2024
shares
Jan. 26, 2024
shares
Dec. 31, 2023
$ / shares
Mar. 31, 2023
shares
Borrowings                    
Amortization of debt discounts         $ 1,260,000 $ 738,000        
Aggregate shares issued upon exercise of warrants (in shares) | shares         3,225 17,143       7,454
Agreement Entered With Number of Investors | item 4                  
Temporary equity, par or stated value per share | $ / shares         $ 0.0001       $ 0.0001  
Series B preferred stock | Series B Preferred Stock                    
Borrowings                    
Warrants exercise price (in $ per share) | $ / shares         $ 35.72          
Short-term loan | Meriwether                    
Borrowings                    
Debt instrument, interest rate (in %)     18.00%              
Loan fee   $ 20,000 $ 50,000              
Exit fee amount     $ 50,000              
January 2024 Short-Term Loan Agreement | January 2024 Promissory notes                    
Borrowings                    
Principal amount $ 1,000,000                  
Repayment of of Debt in Cash       $ 667,000            
Repayment of Debt in Shares       $ 333,000            
Proceeds from Notes Payable $ 600,000                  
January 2024 Short-Term Loan Agreement | Series B Preferred Stock                    
Borrowings                    
Temporary equity, par or stated value per share | $ / shares $ 0.0001                  
January 2024 Short-Term Loan Agreement | January 2024 Warrant Shares                    
Borrowings                    
Aggregate shares issued upon exercise of warrants (in shares) | shares 66,665                  
Warrants exercise price (in $ per share) | $ / shares $ 22.23                  
January 2024 Short-Term Loan Agreement | Series B preferred stock | Series B Preferred Stock | January 2024 Promissory notes                    
Borrowings                    
Aggregate shares issued upon exercise of warrants (in shares) | shares 9,322           29,322 29,322    
Shares, Exercise of Warrants for Repayment Of Debt | shares       9,322            
v3.24.2.u1
Fair Value Measurements - Financial assets and liabilities measured at fair value on recurring basis (Details) - Recurring - USD ($)
$ in Thousands
Jun. 30, 2024
Dec. 31, 2023
Quoted prices in active markets (Level 1)    
Liabilities:    
Warrant liabilities $ 0 $ 0
Significant other observable inputs (Level 2)    
Liabilities:    
Warrant liabilities 0 0
Significant unobservable inputs (Level 3)    
Liabilities:    
Warrant liabilities $ 25 $ 5,460
v3.24.2.u1
Fair Value Measurements - Transfers between levels (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Fair Value Measurements        
Transfers from level 1 to 2 $ 0 $ 0 $ 0 $ 0
Transfers from level 2 to 1 0 0 0 0
Transfers into level 3 0 0 0 0
Transfers out of level 3 $ 0 $ 0 $ 0 $ 0
v3.24.2.u1
Fair Value Measurements - Significant unobservable inputs of warrant liabilities fair value (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Apr. 30, 2024
USD ($)
shares
Jun. 30, 2024
USD ($)
$ / shares
shares
Jun. 30, 2024
$ / shares
shares
Dec. 31, 2023
shares
Jun. 30, 2023
shares
Mar. 31, 2023
shares
Aggregate shares issued upon exercise of warrants | shares   3,225 3,225   17,143 7,454
Reclassification of warrant liabilities to additional paid in capital | $ $ 41,900 $ 41,851        
Warrant            
Aggregate shares issued upon exercise of warrants | shares       1    
Equity warrants            
Aggregate shares issued upon exercise of warrants | shares 5,602,693          
Significant unobservable inputs (Level 3) | Warrant            
Common stock price (in $ per share) | $ / shares   $ 2.57 $ 2.57      
Significant unobservable inputs (Level 3) | Warrant | Exercise price (in $ per share)            
Warrant, Exercise Price, Decrease | $ / shares     3.196      
Warrant, Exercise Price, Increase | $ / shares     $ 1,574.00      
Significant unobservable inputs (Level 3) | Warrant | Expected yield (in %)            
Measurement input   0.0 0.0      
Significant unobservable inputs (Level 3) | Warrant | Expected volatility (in %)            
Measurement input   143 143      
Significant unobservable inputs (Level 3) | Warrant | Risk-free interest rate (in %) | Minimum            
Measurement input   4.52 4.52      
Significant unobservable inputs (Level 3) | Warrant | Expected life (in years) | Minimum            
Warrant term   3 years 1 month 6 days 3 years 1 month 6 days      
Significant unobservable inputs (Level 3) | Warrant | Expected life (in years) | Maximum            
Warrant term   3 years 7 months 6 days 3 years 7 months 6 days      
v3.24.2.u1
Fair Value Measurements - Summary of changes in fair value of the Company's warrant liability and derivative liability (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Apr. 30, 2024
Jun. 30, 2024
Jun. 30, 2024
Jun. 30, 2023
Summary of changes in fair value of the Company's liabilities        
Conversion of liability warrants to equity warrants $ 41,900 $ 41,851    
Warrant Liabilities        
Summary of changes in fair value of the Company's liabilities        
Beginning balance     $ 5,460 $ 8,945
Additions     8,701 5,600
Change in fair value     29,126 (5,850)
Exercise of warrant liabilities     (587) (8,191)
Repurchase     (824)  
Conversion of liability warrants to equity warrants     (41,851)  
Ending balance   $ 25 $ 25 $ 504
v3.24.2.u1
Convertible Redeemable Preferred Stock and Stockholders' Equity (Details) - USD ($)
Oct. 16, 2023
Jun. 30, 2024
Dec. 31, 2023
October Public Offering      
Convertible Preferred Stock and Stockholders' Equity      
Number of shares called by each warrant 2    
October Public Offering | Series B preferred stock      
Convertible Preferred Stock and Stockholders' Equity      
Number of shares called by each warrant 1    
Series B Units | October Public Offering      
Convertible Preferred Stock and Stockholders' Equity      
Issuance of common stock, pre-funded units and warrants, net of offering costs (in shares) 87,000    
Proceeds from issuance of Series B preferred stock, net of issuance costs $ 4,785,000    
Cash fees paid $ 830,000    
Series B Preferred Stock      
Convertible Preferred Stock and Stockholders' Equity      
Number of shares issued upon conversion     177,282
Price per share   $ 35.72  
Series B Preferred Stock | October Public Offering      
Convertible Preferred Stock and Stockholders' Equity      
Number of common shares per unit 1    
Term of conversion of temporary equity 2 years    
Stated value per share $ 100    
Conversion price $ 62.205    
Number of shares issued upon conversion 1    
Series B Preferred Stock | October Public Offering | Series B preferred stock      
Convertible Preferred Stock and Stockholders' Equity      
Number of common shares per unit 1    
Price per share $ 55    
Dividend rate 20.00%    
v3.24.2.u1
Convertible Redeemable Preferred Stock and Stockholders' Equity - Exercise of Series B Preferred Stock Warrants (Details) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Feb. 13, 2024
Dec. 05, 2023
Jun. 30, 2024
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
Oct. 16, 2023
Convertible Preferred Stock and Stockholders' Equity                  
Proceeds from the exercise of prefunded warrants and common stock warrants     $ 556,000 $ 1,895,000   $ 714,000      
Additional proceeds         $ 32,000        
Change in fair value of warrant liability     $ 37,255,000 $ (246,000)   $ 29,126,000 $ (5,850,000)    
Number of shares outstanding     0     0   38,335  
Issuance of common stock in connection with warrant exercise (in shares)     3,211 12,856 5,705        
Proceeds from exercise of warrants     $ 556,000 $ 1,895,000   $ 714,000      
Issuance of common stock in connection with warrant exercise     556,000 $ 1,895,000 $ 8,202,000        
Repurchase price $ 6,266,000                
Series B preferred stock                  
Convertible Preferred Stock and Stockholders' Equity                  
Convertible note warrant     587,000     587,000      
Warrant liabilities     $ 587,000     587,000      
Issuance of common stock in connection with warrant exercise           $ 1,634,000      
Number of warrants repurchased 81,315                
Remaining fair value of warrant liability adjusted against additional paid-in-capital $ 824,000                
New Common Stock Warrants                  
Convertible Preferred Stock and Stockholders' Equity                  
Warrants exercise price     $ 22.23     $ 22.23      
Number of shares called by each warrant     2     2      
Issuance costs           $ 44,000      
Issuance of common stock in connection with warrant exercise           $ 1,188,000      
October Public Offering                  
Convertible Preferred Stock and Stockholders' Equity                  
Number of shares called by each warrant                 2
October Public Offering | Series B preferred stock                  
Convertible Preferred Stock and Stockholders' Equity                  
Number of shares called by each warrant                 1
Series B Preferred Stock                  
Convertible Preferred Stock and Stockholders' Equity                  
Redemption price per share     $ 100     $ 100      
Change in fair value of warrant liability           $ 554,000      
Number of Shares Converted     5,000     5,000   110,278  
Number of shares issued upon conversion               177,282  
Unamortized discount           $ 269,000   $ 6,063,000  
Amortization and accretion of discounts           192,000   297,000  
Deemed dividends               $ 6,360,000  
Number of shares outstanding               38,335  
Aggregate amount of redemption     $ 5,842,000     $ 5,842,000   $ 3,833,500  
Number of preferred share received per warrant exercised           1      
Number of common share warrant received per warrant exercised           1      
Issuance of common stock in connection with warrant exercise           $ 446,000      
Price per share     $ 35.72     $ 35.72      
Issuance of common stock in connection with notes payable (in shares)           8,038      
Number of shares repurchased 62,657                
Unamortized discounts on warrants repurchase $ 5,381,000                
Series B Preferred Stock | Common Stock Warrants liability                  
Convertible Preferred Stock and Stockholders' Equity                  
Convertible note warrant               3,322,000  
Warrant liabilities               3,322,000  
Series B Preferred Stock | Preferred Stock Warrants liability                  
Convertible Preferred Stock and Stockholders' Equity                  
Convertible note warrant               1,628,000  
Warrant liabilities               $ 1,628,000  
Series B Preferred Stock | Series B preferred stock                  
Convertible Preferred Stock and Stockholders' Equity                  
Warrants exercise price     $ 35.72     $ 35.72      
Proceeds from the exercise of prefunded warrants and common stock warrants           $ 1,047,000      
Issuance costs           $ 61,000      
Issuance of common stock in connection with warrant exercise (in shares)           29,332      
Proceeds from exercise of warrants           $ 1,047,000      
Additional discounts in connection with the issuance           $ 1,188,000      
Series B Preferred Stock | October Public Offering                  
Convertible Preferred Stock and Stockholders' Equity                  
Redemption price per share               $ 100 $ 100
Number of shares issued upon conversion                 1
Series B Preferred Stock | October Public Offering | Series B preferred stock                  
Convertible Preferred Stock and Stockholders' Equity                  
Issuance costs               $ 429,000  
Price per share                 $ 55
Series B Preferred Stock | Inducement Agreement                  
Convertible Preferred Stock and Stockholders' Equity                  
Additional proceeds               569,000  
Beneficial conversion feature               196,000  
Issuance costs               $ 146,000  
Series B Preferred Stock | Inducement Agreement | Series B preferred stock                  
Convertible Preferred Stock and Stockholders' Equity                  
Warrants exercise price   $ 35.72           $ 35.72  
Proceeds from the exercise of prefunded warrants and common stock warrants               $ 2,264,000  
Additional proceeds               $ 3,892,000  
Number of Warrants Exercised               61,613  
Proceeds from exercise of warrants               $ 2,264,000  
Series B Preferred Stock | Inducement Agreement | New Common Stock Warrants                  
Convertible Preferred Stock and Stockholders' Equity                  
Warrants exercise price   $ 22.23              
Number of shares called by each warrant   2              
Remaining warrants outstanding               61,613  
Issuance costs   $ 125,000              
v3.24.2.u1
Convertible Redeemable Preferred Stock and Stockholders' Equity - Common Stock Plan (Details)
3 Months Ended 6 Months Ended
Sep. 13, 2021
shares
Jun. 30, 2024
USD ($)
shares
Jun. 30, 2024
USD ($)
shares
Jun. 30, 2023
USD ($)
shares
Mar. 15, 2024
Mar. 14, 2024
Dec. 31, 2023
shares
Jan. 24, 2023
Jan. 23, 2023
Convertible Preferred Stock and Stockholders' Equity                  
Stock-based compensation | $   $ 64,000 $ 128,000            
Shares unvested   16 16            
Restricted stock                  
Convertible Preferred Stock and Stockholders' Equity                  
Unamortized compensation costs | $   $ 1,620,000 $ 1,620,000            
Weighted-average period     2 years            
Number of stock released     774            
Shares unvested   260,441 260,441       5,382    
Number of restricted shares granted     255,915            
LTSI                  
Convertible Preferred Stock and Stockholders' Equity                  
Maximum shares authorized to issue, percentage   15.00% 15.00%   15.00% 8.00%      
Percentage of maximum shares issued in a year   8 8         15 8
Number of shares available for grant   477,774 477,774            
LTSI | Restricted stock units                  
Convertible Preferred Stock and Stockholders' Equity                  
Number of stock released     774 24          
Aggregate intrinsic value | $     $ 2,000 $ 5,000          
2020 Stock Incentive Plan | Restricted stock                  
Convertible Preferred Stock and Stockholders' Equity                  
Unamortized compensation costs | $   $ 0 $ 0            
Number of stock released     1 0          
Aggregate intrinsic value | $     $ 1,000            
2020 Stock Incentive Plan | Restricted stock units                  
Convertible Preferred Stock and Stockholders' Equity                  
Number of stock released     1            
Shares unvested             1    
September 2021 Inducement Grant                  
Convertible Preferred Stock and Stockholders' Equity                  
Unrecognized tax benefits, interest on income taxes expense | $     $ 57,000            
Vesting term     2 months 12 days            
September 2021 Inducement Grant | Restricted stock                  
Convertible Preferred Stock and Stockholders' Equity                  
Number of restricted shares granted     0            
September 2021 Inducement Grant | Restricted stock units                  
Convertible Preferred Stock and Stockholders' Equity                  
Number of units issued 21                
2022 Plan | Restricted stock                  
Convertible Preferred Stock and Stockholders' Equity                  
Number of restricted shares granted     3            
2022 Plan | Restricted stock units                  
Convertible Preferred Stock and Stockholders' Equity                  
Unamortized compensation costs | $   $ 94,000 $ 94,000            
Weighted-average period     2 years            
2022 | Restricted stock units                  
Convertible Preferred Stock and Stockholders' Equity                  
Number of stock released     3 0          
Aggregate intrinsic value | $     $ 1,000            
Shares unvested   14 14       17    
v3.24.2.u1
Convertible Redeemable Preferred Stock and Stockholders' Equity - Activity related to restricted stock awards (Details) - $ / shares
6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Shares    
Non-vested Ending Balance 16  
Restricted stock    
Shares    
Non-vested Beginning Balance 5,382  
Granted 255,915  
Vested (774)  
Forfeited (82)  
Non-vested Ending Balance 260,441  
Weighted-Average Grant Date Fair Value    
Non-vested Beginning Balance $ 374.00  
Granted 2.64  
Vested 674.09  
Forfeited 681.69  
Non-vested Ending Balance $ 9.22  
Restricted stock | 2020 Stock Incentive Plan    
Shares    
Vested (1) 0
Restricted stock units | 2020 Stock Incentive Plan    
Shares    
Non-vested Beginning Balance 1  
Vested (1)  
Weighted-Average Grant Date Fair Value    
Non-vested Beginning Balance $ 56,430.00  
Vested $ 56,430.00  
Restricted stock units | 2022    
Shares    
Non-vested Beginning Balance 17  
Vested (3) 0
Non-vested Ending Balance 14  
Weighted-Average Grant Date Fair Value    
Non-vested Beginning Balance $ 7,800.00  
Vested 7,800.00  
Non-vested Ending Balance $ 7,800.00  
v3.24.2.u1
Convertible Redeemable Preferred Stock and Stockholders' Equity - 2023 Offering (Details) - USD ($)
$ / shares in Units, $ in Millions
Apr. 12, 2023
Apr. 07, 2023
Mar. 29, 2023
Mar. 27, 2023
Feb. 03, 2023
Jan. 31, 2023
Jun. 30, 2024
Jun. 30, 2023
Mar. 31, 2023
Convertible Preferred Stock and Stockholders' Equity                  
Aggregate shares issued upon exercise of warrants             3,225 17,143 7,454
February 2023,Registered direct offering                  
Convertible Preferred Stock and Stockholders' Equity                  
Aggregate share issued           1,344      
Net proceeds         $ 5.3        
Maxim an aggregate fee of the gross proceeds           8.00%      
February 2023,Registered direct offering | Pre-Funded Warrants                  
Convertible Preferred Stock and Stockholders' Equity                  
Aggregate shares issued upon exercise of warrants           2,545      
Warrants exercise price           $ 0.015      
February 2023,Registered direct offering | Private Placement Warrants                  
Convertible Preferred Stock and Stockholders' Equity                  
Aggregate shares issued upon exercise of warrants           5,833      
Warrants exercise price           $ 1,573.50      
March 2023,Registered direct offering                  
Convertible Preferred Stock and Stockholders' Equity                  
Net proceeds     $ 1.6            
Number of shares issued and sold       5,581          
March 2023,Registered direct offering | Private Placement Warrants                  
Convertible Preferred Stock and Stockholders' Equity                  
Aggregate shares issued upon exercise of warrants       11,163          
Warrants exercise price       $ 286.50          
April 2023,Registered direct offering                  
Convertible Preferred Stock and Stockholders' Equity                  
Aggregate share issued   4,954              
Warrants exercise price   $ 211.50              
Net proceeds $ 1.0                
April 2023,Registered direct offering | Private Placement Warrants                  
Convertible Preferred Stock and Stockholders' Equity                  
Aggregate shares issued upon exercise of warrants   9,908              
v3.24.2.u1
Convertible Redeemable Preferred Stock and Stockholders' Equity - Warrant Repurchase (Details) - USD ($)
Jun. 30, 2024
Oct. 16, 2023
Jun. 30, 2023
Mar. 31, 2023
Convertible Redeemable Preferred Stock and Stockholders' Equity        
Warrants exercisable 3,225   17,143 7,454
Common stock purchase warrants        
Convertible Redeemable Preferred Stock and Stockholders' Equity        
Warrants exercisable   30,978    
Warrant   $ 2,323,000    
Common stock purchase warrants | Maximum        
Convertible Redeemable Preferred Stock and Stockholders' Equity        
Warrants exercise price   $ 286.50    
Common stock purchase warrants | Minimum        
Convertible Redeemable Preferred Stock and Stockholders' Equity        
Warrants exercise price   $ 193.50    
v3.24.2.u1
Convertible Redeemable Preferred Stock and Stockholders' Equity - February 2024 Issuance of Common Stock and Pre-Funded Common Stock Warrants (Details)
Feb. 13, 2024
USD ($)
$ / shares
shares
February 2024 public offering  
Convertible Preferred Stock and Stockholders' Equity  
Aggregate purchase price $ 9,987,000
Cash fees paid $ 998,000
Common stock purchase warrants | February 2024 public offering  
Convertible Preferred Stock and Stockholders' Equity  
Number of shares called by each warrant | shares 1
Cash fees paid $ 630,000
Fair value of warrant $ 6,308,000
Prefunded common stock warrants | February 2024 public offering  
Convertible Preferred Stock and Stockholders' Equity  
Number of shares called by each warrant | shares 1
Units | February 2024 public offering  
Convertible Preferred Stock and Stockholders' Equity  
Aggregate share issued | shares 158,227
Price per share | $ / shares $ 9.75
Number of common shares per unit | shares 1
Shares Issued, Price Per Share | $ / shares $ 9.75
Proceeds from issuance of units $ 1,543,000
Units | Common stock purchase warrants  
Convertible Preferred Stock and Stockholders' Equity  
Number of common shares per unit | shares 1
Units | Common stock purchase warrants | February 2024 public offering  
Convertible Preferred Stock and Stockholders' Equity  
Warrants exercise price | $ / shares $ 9.75
Pre-Funded Units | February 2024 public offering  
Convertible Preferred Stock and Stockholders' Equity  
Aggregate share issued | shares 867,373
Price per share | $ / shares $ 9.735
Number of common shares per unit | shares 1
Warrants exercise price | $ / shares $ 0.015
Shares Issued, Price Per Share | $ / shares $ 9.735
Proceeds from issuance of units $ 8,444,000
Common Shares | Pre-Funded Warrants | February 2024 public offering  
Convertible Preferred Stock and Stockholders' Equity  
Cash fees paid 368,000
Fair value of warrant $ 3,679,000
v3.24.2.u1
Convertible Redeemable Preferred Stock and Stockholders' Equity - March 2024 Issuance of Common Stock, Prefunded Common Stock Warrants and Common Stock Warrants (Details) - USD ($)
Mar. 26, 2024
Jun. 30, 2024
Dec. 31, 2023
Oct. 16, 2023
Jun. 30, 2023
Mar. 31, 2023
Convertible Preferred Stock and Stockholders' Equity            
Aggregate shares issued upon exercise of warrants (in shares)   3,225     17,143 7,454
March 2024 Offering            
Convertible Preferred Stock and Stockholders' Equity            
Aggregate purchase price $ 2,299,000          
Cash fees paid $ 388,000          
Common stock | March 2024 Offering            
Convertible Preferred Stock and Stockholders' Equity            
Aggregate share issued 417,833          
Warrant            
Convertible Preferred Stock and Stockholders' Equity            
Aggregate shares issued upon exercise of warrants (in shares)     1      
Warrant | March 2024 Offering            
Convertible Preferred Stock and Stockholders' Equity            
Aggregate shares issued upon exercise of warrants (in shares) 511,175          
Warrants exercise price (in $ per share) $ 6.00          
Fair value of warrant $ 1,227,000          
Pre-Funded Warrants | March 2024 Offering            
Convertible Preferred Stock and Stockholders' Equity            
Aggregate share issued 93,342          
Pre-Funded Warrants | Common stock | March 2024 Offering            
Convertible Preferred Stock and Stockholders' Equity            
Cash fees paid $ 181,000          
Fair value of warrant 1,072,000          
Common Warrants            
Convertible Preferred Stock and Stockholders' Equity            
Aggregate shares issued upon exercise of warrants (in shares)       30,978    
Common Warrants | March 2024 Offering            
Convertible Preferred Stock and Stockholders' Equity            
Cash fees paid 207,000          
Fair value of warrant $ 1,227,000          
v3.24.2.u1
Convertible Redeemable Preferred Stock and Stockholders' Equity - April 2024 Issuances of Common Stock and Common Stock Warrants (Details) - USD ($)
Apr. 30, 2024
Apr. 26, 2024
Apr. 23, 2024
Apr. 19, 2024
Apr. 17, 2024
Jun. 30, 2024
Jun. 30, 2023
Mar. 31, 2023
Convertible Preferred Stock and Stockholders' Equity                
Aggregate shares issued upon exercise of warrants           3,225 17,143 7,454
Initial April 2024 Registered Direct Offering and Concurrent Private Placement                
Convertible Preferred Stock and Stockholders' Equity                
Gross proceeds       $ 750,000        
Placement agent fees and other offering expenses       $ 159,000        
Initial April 2024 Registered Direct Offering                
Convertible Preferred Stock and Stockholders' Equity                
Aggregate share issued         225,834      
Price per share         $ 3.321      
Initial April 2024 Concurrent Private Placement                
Convertible Preferred Stock and Stockholders' Equity                
Aggregate shares issued upon exercise of warrants         225,834      
Warrants exercise price (in $ per share)         $ 3.196      
Second April 2024 Registered Direct Offering and Concurrent Private Placement                
Convertible Preferred Stock and Stockholders' Equity                
Gross proceeds     $ 1,900,000          
Placement agent fees and other offering expenses     $ 268,000          
Second April 2024 Registered Direct Offering                
Convertible Preferred Stock and Stockholders' Equity                
Aggregate share issued       361,904        
Price per share       $ 5.25        
Second April 2024 Concurrent Private Placement                
Convertible Preferred Stock and Stockholders' Equity                
Aggregate shares issued upon exercise of warrants       542,856        
Warrants exercise price (in $ per share)       $ 5.06        
Third April 2024 Registered Direct Offering and Concurrent Private Placement                
Convertible Preferred Stock and Stockholders' Equity                
Gross proceeds $ 2,400,000              
Placement agent fees and other offering expenses $ 298,000              
Third April 2024 Registered Direct Offering                
Convertible Preferred Stock and Stockholders' Equity                
Aggregate share issued   418,845            
Price per share   $ 5.73            
Third April 2024 Concurrent Private Placement                
Convertible Preferred Stock and Stockholders' Equity                
Aggregate shares issued upon exercise of warrants   418,845            
Warrants exercise price (in $ per share)   $ 5.60            
v3.24.2.u1
Convertible Redeemable Preferred Stock and Stockholders' Equity - May 2024 Issuances of Common Stock and Common Stock Warrants (Details)
3 Months Ended
May 17, 2024
USD ($)
May 15, 2024
USD ($)
$ / shares
shares
May 13, 2024
$ / shares
shares
Jun. 30, 2024
USD ($)
item
shares
Jun. 30, 2023
shares
Mar. 31, 2023
shares
Convertible Preferred Stock and Stockholders' Equity            
Aggregate shares issued upon exercise of warrants       3,225 17,143 7,454
Issuance of common stock to vendor (in shares)       136,203    
Number of vendors | item       2    
Issuance of common stock to vendor | $       $ 360,000    
Maximum            
Convertible Preferred Stock and Stockholders' Equity            
Service period of the shares       12 months    
Minimum            
Convertible Preferred Stock and Stockholders' Equity            
Service period of the shares       6 months    
Initial May 2024 Registered Direct Offering and Concurrent Private Placement            
Convertible Preferred Stock and Stockholders' Equity            
Gross proceeds | $   $ 2,600,000        
Placement agent fees and other offering expenses | $   $ 314,000        
Initial May 2024 Registered Direct Offering            
Convertible Preferred Stock and Stockholders' Equity            
Aggregate share issued     785,000      
Price per share | $ / shares     $ 3.31      
Initial May 2024 Concurrent Private Placement            
Convertible Preferred Stock and Stockholders' Equity            
Aggregate shares issued upon exercise of warrants     785,000      
Warrants exercise price (in $ per share) | $ / shares     $ 3.18      
Second May 2024 Registered Direct Offering and Concurrent Private Placement            
Convertible Preferred Stock and Stockholders' Equity            
Gross proceeds | $ $ 2,400,000          
Placement agent fees and other offering expenses | $ $ 290,000          
Second May 2024 Registered Direct Offering            
Convertible Preferred Stock and Stockholders' Equity            
Aggregate share issued   675,000        
Price per share | $ / shares   $ 3.61        
Second May 2024 Concurrent Private Placement            
Convertible Preferred Stock and Stockholders' Equity            
Aggregate shares issued upon exercise of warrants   675,000        
Warrants exercise price (in $ per share) | $ / shares   $ 3.48        
v3.24.2.u1
Convertible Redeemable Preferred Stock and Stockholders' Equity - Warrants for Shares of Common Shares (Details)
3 Months Ended 6 Months Ended 12 Months Ended
May 17, 2024
USD ($)
May 15, 2024
USD ($)
$ / shares
Y
shares
Apr. 30, 2024
USD ($)
Apr. 23, 2024
USD ($)
Apr. 19, 2024
USD ($)
$ / shares
Y
shares
Jul. 26, 2023
USD ($)
$ / shares
shares
May 15, 2023
USD ($)
$ / shares
shares
Jun. 30, 2024
USD ($)
shares
Jun. 30, 2023
USD ($)
shares
Mar. 31, 2023
USD ($)
shares
Jun. 30, 2024
USD ($)
shares
Dec. 31, 2023
shares
May 13, 2024
USD ($)
Y
$ / shares
shares
Apr. 26, 2024
USD ($)
Y
$ / shares
shares
Apr. 17, 2024
USD ($)
$ / shares
Y
shares
Mar. 26, 2024
USD ($)
$ / shares
Y
shares
Feb. 13, 2024
USD ($)
$ / shares
Y
shares
Jan. 19, 2024
USD ($)
$ / shares
Y
shares
Mar. 27, 2023
USD ($)
$ / shares
Y
shares
Jan. 31, 2023
USD ($)
$ / shares
Y
shares
Convertible Preferred Stock and Stockholders' Equity                                        
Warrants to purchase shares of common stock for cash | shares               438,611 1,486,132 18                    
Proceeds from exercise of warrants | $               $ 556,000 $ 1,895,000   $ 714,000                  
Proceeds from issuance of warrants, net of issuance costs | $                   $ 32,000                    
Aggregate shares issued upon exercise of warrants (in shares) | shares               3,225 17,143 7,454 3,225                  
Issuance of common stock upon warrant exchanged | shares               3,211 12,856 5,705                    
Common stock                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Issuance of common stock upon warrant exchanged | shares               441,822 9,908 5,723                    
Initial April 2024 Registered Direct Offering and Concurrent Private Placement                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Net proceeds | $         $ 750,000                              
Second April 2024 Registered Direct Offering and Concurrent Private Placement                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Net proceeds | $       $ 1,900,000                                
Third April 2024 Registered Direct Offering and Concurrent Private Placement                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Net proceeds | $     $ 2,400,000                                  
Initial May 2024 Registered Direct Offering and Concurrent Private Placement                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Net proceeds | $   $ 2,600,000                                    
Second May 2024 Registered Direct Offering and Concurrent Private Placement                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Net proceeds | $ $ 2,400,000                                      
Warrant                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Aggregate shares issued upon exercise of warrants (in shares) | shares                       1                
Issuance of common stock upon warrant exchanged | shares                     7,139,469 187,557                
Warrant | February 2023 Offering                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Aggregate shares issued upon exercise of warrants (in shares) | shares                                       5,833
Warrants exercise price (in $ per share)                                       $ 1,573.50
Fair value of warrant | $                                       $ 5,600,000
Warrant | March 2023 Offering                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Aggregate shares issued upon exercise of warrants (in shares) | shares                                     11,163  
Warrants exercise price (in $ per share)                                     $ 286.50  
Fair value of warrant | $                                     $ 2,113,000  
Warrant | January 2024 Promissory notes                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Aggregate shares issued upon exercise of warrants (in shares) | shares                                   66,665    
Warrants exercise price (in $ per share)                                   $ 22.23    
Fair value of warrant | $                                   $ 860,000    
Warrant | February Public Offering                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Aggregate shares issued upon exercise of warrants (in shares) | shares                                 1,025,600      
Warrants exercise price (in $ per share)                                 $ 9.75      
Fair value of warrant | $                                 $ 6,308,000      
Warrant | March 2024 Offering                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Aggregate shares issued upon exercise of warrants (in shares) | shares                               511,175        
Warrants exercise price (in $ per share)                               $ 6.00        
Fair value of warrant | $                               $ 1,227,000        
Exercise price                               $ 6.00        
Warrant | Initial April 2024 Registered Direct Offering and Concurrent Private Placement                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Aggregate shares issued upon exercise of warrants (in shares) | shares                             225,834          
Warrants exercise price (in $ per share)                             $ 3.196          
Fair value of warrant | $                             $ 1,255,000          
Warrant | Second April 2024 Registered Direct Offering and Concurrent Private Placement                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Aggregate shares issued upon exercise of warrants (in shares) | shares         542,856                              
Warrants exercise price (in $ per share)         $ 5.06                              
Fair value of warrant | $         $ 2,595,000                              
Warrant | Third April 2024 Registered Direct Offering and Concurrent Private Placement                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Aggregate shares issued upon exercise of warrants (in shares) | shares                           418,845            
Warrants exercise price (in $ per share)                           $ 5.60            
Fair value of warrant | $                           $ 2,048,000            
Warrant | Initial May 2024 Registered Direct Offering and Concurrent Private Placement                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Aggregate shares issued upon exercise of warrants (in shares) | shares                         785,000              
Warrants exercise price (in $ per share)                         $ 3.18              
Fair value of warrant | $                         $ 2,453,000              
Warrant | Second May 2024 Registered Direct Offering and Concurrent Private Placement                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Aggregate shares issued upon exercise of warrants (in shares) | shares   675,000                                    
Warrants exercise price (in $ per share)   $ 3.48                                    
Fair value of warrant | $   $ 1,944,000                                    
May 2023 Inducement Warrants                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Warrants to purchase shares of common stock for cash | shares             19,815                          
Aggregate shares issued upon exercise of warrants (in shares) | shares             9,907                          
Warrants exercise price (in $ per share)             $ 211.50                          
Net proceeds | $             $ 1,900,000                          
Exercise price             $ 199.50                          
Redemption price per warrant             $ 75.00                          
July 2023 Inducement Warrants                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Aggregate shares issued upon exercise of warrants (in shares) | shares           3,400                            
Net proceeds | $           $ 678,000                            
Warrants exercise price (in $ per share)           $ 193.50                            
Redemption price per warrant           $ 75.00                            
Stock price (in dollar per share) | Warrant | February 2023 Offering                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input                                       1,335.00
Stock price (in dollar per share) | Warrant | March 2023 Offering                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input                                     249.00  
Stock price (in dollar per share) | Warrant | January 2024 Promissory notes                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input                                   15.99    
Stock price (in dollar per share) | Warrant | February Public Offering                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input                                 7.62      
Stock price (in dollar per share) | Warrant | March 2024 Offering                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input                               3.18        
Stock price (in dollar per share) | Warrant | Initial April 2024 Registered Direct Offering and Concurrent Private Placement                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input                             6.06          
Stock price (in dollar per share) | Warrant | Second April 2024 Registered Direct Offering and Concurrent Private Placement                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input         5.39                              
Stock price (in dollar per share) | Warrant | Third April 2024 Registered Direct Offering and Concurrent Private Placement                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input                           5.54            
Stock price (in dollar per share) | Warrant | Initial May 2024 Registered Direct Offering and Concurrent Private Placement                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input                         3.50              
Stock price (in dollar per share) | Warrant | Second May 2024 Registered Direct Offering and Concurrent Private Placement                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input   3.26                                    
Expected yield (in %) | Warrant | February 2023 Offering                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input                                       0.000
Expected yield (in %) | Warrant | March 2023 Offering                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input                                     0.000  
Expected yield (in %) | Warrant | January 2024 Promissory notes                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input                                   0.000    
Expected yield (in %) | Warrant | February Public Offering                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input                                 0.000      
Expected yield (in %) | Warrant | March 2024 Offering                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input                               0.000        
Expected yield (in %) | Warrant | Initial April 2024 Registered Direct Offering and Concurrent Private Placement                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input                             0.000          
Expected yield (in %) | Warrant | Second April 2024 Registered Direct Offering and Concurrent Private Placement                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input         0.000                              
Expected yield (in %) | Warrant | Third April 2024 Registered Direct Offering and Concurrent Private Placement                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input                           0.000            
Expected yield (in %) | Warrant | Initial May 2024 Registered Direct Offering and Concurrent Private Placement                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input                         0.000              
Expected yield (in %) | Warrant | Second May 2024 Registered Direct Offering and Concurrent Private Placement                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input   0                                    
Expected volatility (in %) | Warrant | February 2023 Offering                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input                                       0.96
Expected volatility (in %) | Warrant | March 2023 Offering                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input                                     1.04  
Expected volatility (in %) | Warrant | January 2024 Promissory notes                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input                                   1.19    
Expected volatility (in %) | Warrant | February Public Offering                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input                                 1.19      
Expected volatility (in %) | Warrant | March 2024 Offering                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input                               1.19        
Expected volatility (in %) | Warrant | Initial April 2024 Registered Direct Offering and Concurrent Private Placement                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input                             1.35          
Expected volatility (in %) | Warrant | Second April 2024 Registered Direct Offering and Concurrent Private Placement                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input         1.35                              
Expected volatility (in %) | Warrant | Third April 2024 Registered Direct Offering and Concurrent Private Placement                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input                           1.35            
Expected volatility (in %) | Warrant | Initial May 2024 Registered Direct Offering and Concurrent Private Placement                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input                         1.37              
Expected volatility (in %) | Warrant | Second May 2024 Registered Direct Offering and Concurrent Private Placement                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input   1.37                                    
Risk-free interest rate (in %) | Warrant | February 2023 Offering                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input                                       0.0367
Risk-free interest rate (in %) | Warrant | March 2023 Offering                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input                                     0.0367  
Risk-free interest rate (in %) | Warrant | January 2024 Promissory notes                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input                                   0.0431    
Risk-free interest rate (in %) | Warrant | February Public Offering                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input                                 0.0431      
Risk-free interest rate (in %) | Warrant | March 2024 Offering                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input                               0.0421        
Risk-free interest rate (in %) | Warrant | Initial April 2024 Registered Direct Offering and Concurrent Private Placement                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input                             0.0463          
Risk-free interest rate (in %) | Warrant | Second April 2024 Registered Direct Offering and Concurrent Private Placement                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input         0.0463                              
Risk-free interest rate (in %) | Warrant | Third April 2024 Registered Direct Offering and Concurrent Private Placement                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input                           0.0463            
Risk-free interest rate (in %) | Warrant | Initial May 2024 Registered Direct Offering and Concurrent Private Placement                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input                         0.0435              
Risk-free interest rate (in %) | Warrant | Second May 2024 Registered Direct Offering and Concurrent Private Placement                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input   0.0435                                    
Expected life (in years) | Warrant | February 2023 Offering                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input | Y                                       5
Expected life (in years) | Warrant | March 2023 Offering                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input | Y                                     5  
Expected life (in years) | Warrant | January 2024 Promissory notes                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input | Y                                   5    
Expected life (in years) | Warrant | February Public Offering                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input | Y                                 5      
Expected life (in years) | Warrant | March 2024 Offering                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input | Y                               5        
Expected life (in years) | Warrant | Initial April 2024 Registered Direct Offering and Concurrent Private Placement                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input | Y                             5          
Expected life (in years) | Warrant | Second April 2024 Registered Direct Offering and Concurrent Private Placement                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input | Y         5                              
Expected life (in years) | Warrant | Third April 2024 Registered Direct Offering and Concurrent Private Placement                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input | Y                           5            
Expected life (in years) | Warrant | Initial May 2024 Registered Direct Offering and Concurrent Private Placement                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input | Y                         5              
Expected life (in years) | Warrant | Second May 2024 Registered Direct Offering and Concurrent Private Placement                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Measurement input | Y   5                                    
Common stock | July 2023 Inducement Warrants                                        
Convertible Preferred Stock and Stockholders' Equity                                        
Percentage of exercise of warrants issued           100.00%                            
v3.24.2.u1
Convertible Redeemable Preferred Stock and Stockholders' Equity - Warrants for common stock outstanding and exercisable (Details) - Warrant - $ / shares
6 Months Ended 12 Months Ended
Jun. 30, 2024
Dec. 31, 2023
Convertible Preferred Stock and Stockholders' Equity    
Exercise Price $ 4.45 $ 135.00
Warrants Outstanding 9,793,531 194,113
Weighted Average Remaining Life (years) 4 years 10 months 24 days 4 years 10 months 24 days
Warrants Exercisable 2,654,062 6,555
Exercise price range one    
Convertible Preferred Stock and Stockholders' Equity    
Exercise Price   $ 22.50
Warrants Outstanding 8,832,641 188,025
Weighted Average Remaining Life (years) 4 years 10 months 24 days 4 years 10 months 24 days
Warrants Exercisable 1,693,173 467
Exercise price range one | Minimum    
Convertible Preferred Stock and Stockholders' Equity    
Exercise Price $ 0.015  
Exercise price range one | Maximum    
Convertible Preferred Stock and Stockholders' Equity    
Exercise Price $ 3.48  
Exercise price range two    
Convertible Preferred Stock and Stockholders' Equity    
Exercise Price   $ 1,573.50
Warrants Outstanding 954,827 5,833
Weighted Average Remaining Life (years) 4 years 9 months 18 days 4 years 1 month 6 days
Warrants Exercisable 954,827 5,833
Exercise price range two | Minimum    
Convertible Preferred Stock and Stockholders' Equity    
Exercise Price $ 5.06  
Exercise price range two | Maximum    
Convertible Preferred Stock and Stockholders' Equity    
Exercise Price 6.00  
Exercise price range three    
Convertible Preferred Stock and Stockholders' Equity    
Exercise Price $ 1,574.00 $ 14,955.00
Warrants Outstanding 5,831 13
Weighted Average Remaining Life (years) 3 years 7 months 6 days 3 years 7 months 6 days
Warrants Exercisable 5,831 13
Exercise price range four    
Convertible Preferred Stock and Stockholders' Equity    
Exercise Price $ 14,995.00 $ 22,800.00
Warrants Outstanding 12 3
Weighted Average Remaining Life (years) 3 years 1 month 6 days 3 years
Warrants Exercisable 12 3
Exercise price range five    
Convertible Preferred Stock and Stockholders' Equity    
Warrants Outstanding 220 239
Weighted Average Remaining Life (years) 1 year 1 month 6 days 1 year 7 months 6 days
Warrants Exercisable 219 239
Exercise price range five | Minimum    
Convertible Preferred Stock and Stockholders' Equity    
Exercise Price $ 22,800 $ 30,000
Exercise price range five | Maximum    
Convertible Preferred Stock and Stockholders' Equity    
Exercise Price $ 393,000 $ 654,000
v3.24.2.u1
Income Taxes (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Income Taxes        
Provision for income taxes $ 0 $ 2,000 $ 0 $ 2,000
Effective tax rate 0.00% 0.00% 0.00% 0.00%
v3.24.2.u1
Commitments and Contingencies (Details)
6 Months Ended
Jun. 30, 2024
Commitments and Contingencies  
Lease expiration date Jan. 01, 2024
Initial lease term 12 months
v3.24.2.u1
Commitments and Contingencies - Schedule of lease assets and lease liabilities (Details) - USD ($)
$ in Thousands
Jun. 30, 2024
Dec. 31, 2023
Commitments and Contingencies    
Operating lease right-of-use assets $ 575 $ 616
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Other Assets, Noncurrent Other Assets, Noncurrent
Operating lease liabilities, current $ 67  
Operating lease liabilities, non-current $ 607 $ 636
Office space under a non-cancellable operating lease    
Commitments and Contingencies    
Operating lease liabilities, current [Extensible Enumeration] Accrued Liabilities, Current Accrued Liabilities, Current
Operating lease liabilities, non-current [Extensible Enumeration] Other liabilities Other liabilities
v3.24.2.u1
Commitments and Contingencies - Schedule of components of lease costs (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2024
Commitments and Contingencies    
Operating lease cost $ 42 $ 95
Short term lease cost 7 15
Total lease cost $ 49 $ 110
v3.24.2.u1
Commitments and Contingencies - Schedule of maturity of operating lease liabilities (Details)
$ in Thousands
Jun. 30, 2024
USD ($)
Commitments and Contingencies  
Present value of lease liabilities [Extensible Enumeration] us-gaap:OtherLiabilities
Year ending December 31, 2024 (6 months remaining) $ 59
Year ending December 31, 2025 185
Year ending December 31, 2026 191
Year ending December 31, 2027 197
Year ending December 31, 2028 203
Thereafter 93
Total minimum lease payments 928
Less: Amounts representing interest (254)
Present value of capital lease obligations $ 674
v3.24.2.u1
Commitments and Contingencies - Schedule of lease term and discount rate (Details)
Jun. 30, 2024
Commitments and Contingencies  
Weighted-average remaining lease term (in years) 5 years
Weighted-average discount rate 13.00%
v3.24.2.u1
Commitments and Contingencies - Schedule of supplemental cash flow information (Details)
$ in Thousands
6 Months Ended
Jun. 30, 2024
USD ($)
Commitments and Contingencies  
Operating cash outflows from operating leases $ 3
v3.24.2.u1
Related Parties (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
Sep. 08, 2023
Related Parties            
Net revenue $ 345,000 $ 425,000 $ 600,000 $ 894,000    
Ownership percentage 1.00%   1.00%   1.00%  
Loan and Security Agreement | Meriwether | Short-term loan            
Related Parties            
Principal amount           $ 650,000
Mr. Howitt | Meriwether | Meriwether            
Related Parties            
Ownership interest percentage     25.00%      
Helge Kristensen | Warrant            
Related Parties            
Ownership percentage 1.00%   1.00%   1.00%  
Hansong Technology | Sales of Modules To Related Party            
Related Parties            
Net revenue $ 10,000 24,000 $ 35,000 48,000    
Payments for purchases 0 189,000 0 189,000    
Amount due from related parties 39,000 29,000 39,000 29,000    
Hansong Technology | Purchase of speaker products from related party            
Related Parties            
Payments for purchases 63,000 794,000 88,000 1,053,000    
Amount due from related parties 163,000 350,000 163,000 350,000    
Purchase of wireless audio speaker systems from related party $ 1,000 $ 21,000 $ 1,000 $ 59,000    
v3.24.2.u1
Segment Information (Details)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2024
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2024
USD ($)
segment
Jun. 30, 2023
USD ($)
Segment Information        
Number of operating segments | segment     1  
Net revenue $ 345 $ 425 $ 600 $ 894
Asia Pacific        
Segment Information        
Net revenue 264 301 351 598
North America        
Segment Information        
Net revenue 26 112 115 265
Europe        
Segment Information        
Net revenue $ 55 $ 12 $ 134 $ 31

WiSA Technologies (NASDAQ:WISA)
過去 株価チャート
から 11 2024 まで 12 2024 WiSA Technologiesのチャートをもっと見るにはこちらをクリック
WiSA Technologies (NASDAQ:WISA)
過去 株価チャート
から 12 2023 まで 12 2024 WiSA Technologiesのチャートをもっと見るにはこちらをクリック